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Testimonial
This thesis started with the following patient.
“It was in September 2007 that I was diagnosed with a carcinoma in the ascending part 
of the colon. In October, a hemicolectomy was performed, and a few months later 
chemotherapy with oxaliplatin was started because metastasis was suspected in two of 
the twenty lymph nodes. After six successive cycles, I noticed progressive pain in my 
hands and feet. Together with the oncologist,  I decided to stop the chemotherapeutic 
administrations since the indication for it was weak. However, in the following months 
after cessation, the pain continued to increase and became chronically invalidating. I 
could no longer walk or stand for more than 10 minutes because of the pain, and if I kept 
standing or walking I almost fainted, which forced me to sit down. I felt a burning 
sensation, especially my feet, although my legs halfway up to the calves were numb on 
testing. Lifting my feet to avoid pressure on the soles minimized the pain. Being a 
physician myself, I tried several analgesics and vitamin B12 without much success; at 
night I frequently woke up from the pain in my legs. After only a few minutes, typing on 
my computer became impossible because of the pain. Buttoning up my shirt became 
difficult. Therefore I consulted our pain clinic, where once again amitriptyline was 
started without any noticeable effect. At last we tried an infusion with lidocaine under 
continuous ECG and blood pressure monitoring; this had a short-lasting effect until its 
plasma concentration decreased below its effective concentration. The neuropathic 
syndrome is still progressing, now giving myoclonic movements in various muscles and 
tremors in my hands. My history is only one of a large number of patients who have 
received oxaliplatin therapy for cancer. Its invalidating effect demands more research to 
prevent or diminish such effects.”
 
Prof. L.H.D.J. Booij
Head of department of Anesthesiology, Pain and Palliative Medicine, 
Radboudumc Nijmegen from 1989-2010
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In recent decades, there has been a remarkable increase in long-term survival in cancer 
patients due to improvements in early detection, precise subtype characterization, 
and new treatment options. An emerging issue in cancer treatment is dealing with 
long-term sequelae that impair quality of life (QOL) in cancer patients and cancer 
survivors. Besides fatigue and emotional distress, pain is one of the most commonly 
reported problems in cancer survivors. Cancer-related pain can be due to either the 
disease process itself or from its treatment. During active treatment or after treatment, 
pain often becomes noticeable; this and can shift from a short time issue to becoming 
a chronic problem. The treatment of chronic pain remains challenging. 
 In this thesis, I report on two common pain mechanisms resulting from cancer 
treatment: the acute inflammatory response and neuronal hyperexcitability. My team 
explored post-surgery and post-chemotherapy possibilities of modulating these 
mechanisms, as they play a role in the transition from acute to chronic pain.
 
Cancer
Cancer is a leading cause of death in many countries, regardless of their economic 
status, and this burden is expected to grow due to population growth and aging, as 
well as due to the emergence of specific cancers related to social and economic 
development. In 2018, the global cancer burden is estimated to have risen to 18.1 
million new cases with 9.6 million deaths. Lung cancer, female breast and colorectal 
cancer are the three most frequently diagnosed cancer types, each type contributing 
to approximately 2.1 million new diagnoses in 2018 (1).
 Although cancer is still a leading cause of death, survival rates have improved due 
to improved detection strategies and emerging treatment options (2). Currently, the 
total number of people who are alive within 5 years of cancer diagnosis is estimated at 
43.8 million worldwide (1). An analysis of 15.5 million Americans with a history of cancer 
who were alive on January 1, 2016, showed that the most common cancer sites in the 
survivor population were breast, prostate and colon/rectum cancers together 
accounting for approximately 55% of survivors (3). The majority (67%) were diagnosed 
five or more years ago, whereas 17% were diagnosed 20 or more years ago, and 
approximately 6% have survived 30 years or longer (3). 
 These patients are often referred as ‘cancer survivors’, a definition first was used 
by Fithugh Mullan in 1985 (4). A cancer survivor is any person who has been diagnosed 
with cancer from the time of diagnoses through the balance of life. Mullan described 
3 ‘seasons of survival’: (1) Acute, defined as including time from diagnosis to the end of 
initial treatment, (2) Extended, defined as period following treatment, and (3) 
Permanent, survival is most likely  (4, 5). The American Cancer Society redefined the 
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CHAPTER 1
definition, describing the range of cancer experiences and trajectories of someone 
with cancer: (1) Living cancer free: a) for the remainder of life, b) for many years but 
experiencing one or more serious, late complications of treatment, c) for many years, 
but dying after a late recurrence, d) developing a second cancer, and (2) Living with 
cancer: a) living with intermittent periods of active disease requiring treatment, b) 
without a disease-free period (3). 
 In this thesis, we use the term cancer survivor based on these definitions, but it is 
important to note that not all individuals with a cancer diagnosis identify with the 
term cancer survivor, as it implies that the cancer has been treated and the survivor 
can return to his or her pre-cancer life (6). The term cancer survivor has raised 
awareness in international medical organizations with regard to the psychological 
changes and the diminished QOL that can occur secondary to treatment (5, 7). As such, 
an American Society of Clinical Oncology position statement, “Achieving High-Quality 
Cancer Survivorship Care,” identified four critical aspects of survivor care: (1) developing 
the best models of care for cancer survivors, (2) articulating the purpose of a treatment 
summary and individualized care plan, (3) identifying gaps in research, and (4) ensuring 
access to care for survivors (8). 
 For more than 100 years, cancer cells have been considered different than the 
host cells, and unless they are destroyed and totally eliminated, these cells will 
overwhelm the host. This is the model on which oncologic research and treatment 
strategies and outcome measures of cancer treatment were based (9). In the late 
nineties there was a paradigm shift from ‘the killing paradigm’ to ‘a regulatory model’ 
of cancer, which views cancer cells as slightly differing from normal cells due to a few 
critical genetic changes that lead to dysregulation of growth (9). Under this new 
paradigm, the treatment approach is ‘debulking’ tumor burden followed by control of 
growth and the spread of residual disease; with the goal and expectation that cancer 
treatment as well as the endpoints of clinical trials can be adjusted (10). According to 
World Health Organization (WHO) guidelines, the current goal of cancer treatment is 
nowadays based on prolonging survival combined with maintaining a good QOL in 
both the long and short term, i.e. survivorship care (11).
In general, cancer survivors have an increased risk of long-term morbidity and 
premature mortality, related directly to the cancer itself, to pre-existing comorbidities, 
and to exposure to therapy (8). Side effects of cancer and its treatment can occur 
during active therapy or become evident months or years afterwards (12). Long-term 
effects vary depending on treatment exposure and individual factors; severity can 
range from mild to severe, debilitating, or even life-threatening; and can be temporary 
and/or improve over time, whereas others are progressive or permanent. The 
longitudinal diversity, differing outcome measures in studies and the effects of aging 
in general make it difficult to quantify the exact prevalence of various effects of 
cancer and its treatment (13). The incidence of survivors who report minimal 
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consequences of cancer and experience a good general health and good to excellent 
QOL can be up to 75% (13-15). Conversely, other studies show that in up to 60%, patients 
experience physical and/or psychosocial effects of cancer and its treatment (7). 
Health-related QOL may change over time, and is related to the type of cancer and its 
treatment, age, sex, comorbidities, genetics, and probably also to health-related 
habits (16).  
 The most common problems in cancer survivors are pain, fatigue, and emotional 
distress (3, 16-18), other well-known problems are cognitive impairment, bowel dysfunction, 
sexual dysfunction, osteoporosis, and sleep problems. Patients can experience a single 
symptom or a combination of symptoms, called the symptom burden, which affect 
quality of life by reducing physical and psychological functioning (17). 
Cancer-related pain
Cancer-related pain is a common problem among cancer survivors. Prevalence rates 
vary among different cancer types, disease stage, and in longitudinal evaluation. 
Current rates are about 39.3% after curative treatment, 55% during anticancer 
treatment, and 66.4% in patients with advanced disease. Of those patients with pain, 
38% report moderate to severe pain (19). Cancer-related pain can be due to either the 
disease process or its treatment: surgery, chemotherapy or radiotherapy, hormonal 
therapy, immunotherapy or target therapy, either in combination or alone. During 
active treatment or after treatment, pain arises; this can shift from being a short-term 
problem to a chronic problem. Cancer survivors can experience pain differently to 
non-cancer survivors, therefore a different approach is needed for this patient group. 
As with other causes of pain, persistent cancer-related pain can activate the hypotha-
lamic-pituitary-adrenal axis and the sympathetic nervous system, and can induce 
psychological distress (20, 21). Psychological stressors constitute a feedback system 
further activating the hypothalamic-pituitary-adrenal axis and the sympathetic 
nervous system, influencing the homeostasis of peripheral tissues and dysregulating 
immunoinflammatory reactions (20). The stressor-induced sympathetic input may 
disturb sleep, cause fatigue, and exaggerate the chronic pain by directly sensitizing or 
even exciting peripheral nociceptors (20). 
 Chronic pain rarely occurs in isolation; moderate-to-severe pain causes a marked 
decrease in all aspects of life in most patients. Patients have an increased risk of 
depression and anxiety disorders, causing an additional negative impact on 
functionality, family relationships, home responsibilities, and friendships. Chronic pain 
may interfere with work and often results in the loss of employment, early retirement, 
and disability—all of which have a devastating impact on psychosocial and functional 
well-being (22-24). Thus cancer survivors not only experience the burden of their 
sickness, but also that of chronic pain.  
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CHAPTER 1
Chronic pain has a great socio-economic impact and is increasingly being recognized as a 
public health concern, with major clinical, social, and economic burdens. Considerable 
direct and indirect healthcare costs are related to chronic pain, estimated at $560 - 635 
billion annually in the United States. Direct health care costs include medication and 
physician services. Indirect costs include disability compensation and lost work 
productivity (25). 
 Since the incidence of cancer survivors is increasing, health care providers will 
increasingly face patients with persistent pain as a result of cancer and its treatment. 
Although prevalence rates are consistently high among cancer survivors, pain affects 
QOL, and WHO-guidelines advise ‘survivorship-care’, pain is not systematically 
evaluated in patients. In six Dutch hospitals pain or absence of pain was registered in 
23% of all 987 visits to the oncologic outpatient clinic (26). Estimates of inadequate 
pain treatment ranges from 31% to 65% in patients with cancer (26). 
 Thus, raised  awareness among health care providers is needed with regards to 
pain in cancer survivors, and research scientists need to develop models to discern its 
underlying pathophysiology, as well as test prevention and treatment strategies, for 
clinical scientists to put into practice.
Pain pathophysiology
Acute tissue injury induces complex biochemical peripheral changes and disturbs 
local homeostasis. Locally a wide range of inflammatory mediators (e.g. bradykinin, 
prostaglandin, proinflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor 
necrosis factor-alpha) are released. These mediators interact with their corresponding 
receptors located on the peripheral nociceptive neurons, leading to depolarization of 
the cell membrane by influencing several ion-channels and subsequent impulse 
generation within Aδ- and C-fibers. C-fibers on itself can release substance P, calcitonin 
gene-related peptide, neurokinin A and nitric oxide, which amplify the whole process, 
resulting in further activation of ‘silent’ C-fibers with a reduction of pain threshold 
and increased excitability (peripheral sensitization). The systemic inflammatory 
response can activate the sympathetic system, releasing noradrenaline which can 
further activate peripheral nociceptors (27-29). 
 The activated primary afferent sensory fibers enter the spinal cord through the 
dorsal horn and synapse with the secondary afferent neurons at Rexed laminae (C- and 
Aδ-fibers: laminae I and II for nociceptive processing; Aβ-fibers: laminae III–VI for 
proprioception). Lamina V comprises wide dynamic range neurons, which are usually 
in a dormant state until sensitization occurs (30). Transmission of a nociceptive 
impulse from the central terminals of primary afferent nociceptors to the secondary 
afferent is facilitated by the secretion of excitatory substances such as glutamate, 
substance P, calcitonin gene-related peptide, and neurotrophic factors, which activate 
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the postsynaptic receptors and glial cells. These agents sensitize the post-synaptic 
neurons with a consequent increase in their responsiveness to mechanical, thermal 
and chemical stimuli (central sensitization). Concurrently, inhibitory mechanisms in 
the spinal cord are set in motion, which dampen and impede nociceptive transmission 
(29, 30). 
 Secondary afferent neurons from dorsal horn terminate at the thalamus and 
cerebral cortex via ascending pathways, like the spinothalamic tract, the spinoparab-
rachial and spinomesencephalic tracts. In the brain, multiple cortical areas are collab-
oratively activated by nociception: The posterior insula, medial parietal operculum 
and mid-cingulate cortex are responsible for the earliest response to a nociceptive 
input from the spinothalamic tract. The mid/anterior insula, anterior cingulated cortex 
and prefrontal cortex, the periaqueductal gray matter, rostroventromedial medulla, 
and reticular formation are responsible for fine distinction, inter-individual variability 
of pain experience, and consciousness. Descending pathways arise from periaqueductal 
gray matter, rostroventromedial medulla, and reticular formation, secreting either 
noradrenaline or serotonin; these descending pathways can have inhibitory or 
facilitatory effects on lamina I cells in the dorsal horn (29, 31, 32). 
 Thus, major contributors in nociceptive transmission are inflammatory and neuronal 
hyperexcitability mechanisms in the peripheral or central nervous system inducing 
peripheral and central sensitization. As healing progresses, acute nociception diminishes 
by restoring normal homeostasis between pro- and anti-inflammatory immune mediators 
and excitability of nerve membranes. Chronic pain can develop if a disbalance in the 
immune response or neuronal excitability persists (29). 
 It is important to note that immune responses or neuronal hyperexcitability are 
umbrella terms for a wide variety of underlying molecular mechanisms which interact 
with each other and influence nociceptive transmission. Also worth noting is that 
a hyperexcitability or a hyperinflammatory state on its own does not imply that a 
patient has pain. Pain is defined as “An unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such damage” (33). 
As such, pain has a psychological and functional impact, which again can have an 
effect on pain processing (34). Thus clinically, the mechanistic analysis of nociceptive 
transmission needs to be incorporated in a multidimensional approach (35). 
Chronic postsurgical pain 
Surgery remains a cornerstone of cancer treatment (36, 37) and can affect health 
related quality of life (38) due to adverse morbidity (39-41), of which persistent pain is 
a common reason. 
 Chronic postsurgical pain (CPSP) is defined as: (1) pain persisting at least 3 months 
after surgery (various authors report thresholds of duration from 2-6 months), (2) pain 
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CHAPTER 1
not present before surgery or that has different characteristics or increased intensity 
from preoperative pain, (3) pain localized to the surgical site or a referred area, and (4) 
other possible causes of the pain are excluded (42, 43).
 The incidence and the intensity of CPSP vary with the type of surgical procedure, 
the study methodology, and definition of CPSP. For some cancer operations, CPSP can 
occur in 30-50% after thoracotomy and in more than 50% after breast surgery. Of 
these patients, 2-10% will develop severe pain (44, 45). 
 Risk factors for developing CPSP can be divided into patient and surgical factors. 
The presence of preoperative pain and severe acute postoperative pain, younger age, 
female, psychosocial factors (catastrophizing, anxiety and depression, lack of social 
support), genetic predisposition, and preexistent radio or chemotherapy are known 
patient factors for developing CPSP. Surgical factors include nerve injury, longer 
duration of surgery and more traumatic surgical approaches (46-48). 
 Chronic pain can exist despite tissue healing; it results from persistently generated 
impulses to the central nervous system due to ongoing inflammation or nerve injury, 
which can induce long-term neuroplastic changes that amplify and maintain pain 
signaling, resulting in persistent peripheral and central sensitization (47, 49). Inflammatory 
mediators activate intracellular signaling pathways which lead to  phosphorylation of 
ion channels and receptors in the primary afferent neurons, reducing threshold and 
increased excitability of Aδ- and C-fibers. Prolonged peripheral input causes glutamate 
release and subsequent postsynaptic N-methyl-D-aspartate (NMDA) receptor 
activation. Concurrently, microglia and astrocytes in the dorsal horn and spinal cord 
are activated resulting in an enhanced release of proinflammatory cytokines and 
algesic mediators contributing to hyperexcitability and modification of the central 
nervous system by altered function of ion channels and receptors and increased 
excitatory transmitters and reduced inhibitory transmitters (29, 45). Nerve injury may 
alter neural connectivity and pain processing at various levels of the spinal cord dorsal 
horn and in various brain regions, causing maladaptive neural plasticity. Injured 
sensory neurons fire spontaneous action potentials as a result of increased and /or 
novel expression of sodium channels and neuroimmune interactions. The peripheral 
ectopic hyperexcitability contributes to central sensitization (29, 45, 47). Although 
common mechanisms for developing CPSP are known, not all pathophysiological 
underlying mechanisms are fully understood. Some patients have perioperative nerve 
injury without developing chronic pain; and what exactly a disbalance in the 
perioperative inflammatory response is, is still unknown.
 Consequently, there is no definitive way to prevent CPSP occurrence. Logically, 
by preventing the transiting from acute to chronic pain, it should be possible to reduce 
CPSP. Current preventive strategies for chronic surgical pain focus on blocking or 
limiting persistent pain sensitization and reducing remedial risk factors like refinements 
to surgical technique to make them less nerve damaging; stringent perioperative pain 
control; and preoperative psychological intervention (50). According to international 
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guidelines, perioperative pain management consists of multimodal analgesia combined 
with non-pharmacological interventions, which target different mechanisms of 
action in the peripheral and/or central nervous system (51). However, not all analgesic 
modalities that reduce acute pain, can prevent persistent pain. For example, for 
common cancer surgeries with a known high CPSP incidence, several studies have 
investigated the effect of interventions (procedural and pharmacological) on preventing 
and treating CPSP. For post-thoracotomy pain, thoracic epidural anesthesia has been 
shown to reduce acute postoperative pain and, in some studies, to have a beneficial 
effect reducing post-thoracotomy pain syndrome; though other techniques like 
intercostal block or pharmacological treatments with ketamine, COX-2 inhibitors or 
acetaminophen have no or only a modest effect on CPSP (52). Evidence shows that 
continuous local treatment with local anesthetics, single shot or continuous paravertebral 
block, intravenous (iv) lidocaine, and preoperative selective serotonin- noradrenalin 
reuptake inhibitor, successfully prevent occurrence of persistent pain after breast 
cancer surgery (53). However, comparing these studies and drawing definitive 
conclusions is difficult due to: (1) lack of clear definitions of the study population, 
i.e. variability in surgical and adjuvant treatment, and patient risk factors, (2) variability 
in definition of chronic pain and it’s measurement (54).
 By elucidating the neuroinflammatory mechanisms contributing to perioperative 
pain and by evaluating what specific interventions influence this mechanism; these 
together will hopefully reduce CPSP in future. 
Chemotherapy induced peripheral neuropathy
Neurologic complications secondary to cancer treatment-related toxicity arise either 
as a result of direct toxic effects on the nervous system or as an indirect consequence 
of treatment-induced metabolic, vascular, autoimmune, or infectious abnormalities. 
The most commonly described long-term neurotoxic complications is a peripheral 
neuropathy due to chemotherapeutic agents such as taxanes, platinum compounds, 
vinca-alkaloids, epothilones, protease inhibitors and thalidomide; this is defined as 
chemotherapy induced peripheral neuropathy (CIPN) (55). A meta-analysis of 4179 
chemotherapy-treated patients in 31 studies found the average prevalence of CIPN to 
be 68.1% within the first month of chemotherapy treatment, 60.0% at 3 months, and 
30.0% at 6 months, with considerable heterogeneity in the estimates from different 
studies (I2 = 98.2, P < 0.001) (56). The incidence and severity of CIPN varies between 
type and cumulative dose of chemotherapeutic agents, method of assessment, and 
period after cessation of chemotherapy (57-59). Some patient groups with neuropathy 
at baseline, older age, genetic varieties, or prior exposure to neurotoxic agents are 
more at risk for developing CIPN.
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 The histopathological changes associated with CIPN commonly involve large 
myelinated fibers, but small fibers can also be affected. Consequently, CIPN mainly 
presents as a dose-dependent sensory length-dependent neuropathy with  a ‘stocking 
and glove’ type of distribution.  The changes to the morphological and molecular 
physiology of peripheral nerves result in symptoms of numbness, paresthesias, loss of 
proprioception and hyperalgesia, and less often in motor weakness or autonomic 
changes (60, 61). 
 The cytotoxic mechanisms of action are often linked to the development of 
long-term neurotoxicity, implying the obvious difficulty with regard to reducing 
toxicity without diminishing their anti-cancer efficacy. Despite the varying mechanisms 
of action of the chemotherapeutic agents, the pathophysiology of CIPN has shared 
pathophysiologic mechanism, like alterations in axon degeneration, central sensitization, 
neuronal excitability, and neuroinflammation. Depending on the chemotherapeutic 
agent, several sites of the peripheral nervous system can be targeted through: 
a disrupted microtubule-mediated axonal transport, calcium homeostasis, oxidative 
stress, activation of apoptotic pathways, direct damage to the dorsal root ganglion or 
axons, reduction of nerve blood supply, and mitochondrial dysfunction (62, 63).  
 Chemotherapeutic drugs, and more specifically oxaliplatin, can also cause direct 
changes in peripheral excitability (64). Oxaliplatin is a third-generation platinum-based 
antineoplastic agent used for treating gastrointestinal cancer. Up to 90% of the 
patients develop a dose-limiting acute neurotoxicity, characterized by cold-induced 
paresthesia dysesthesia of the extremities and the perioral or laryngeal region, 
accompanied by fasciculations, and muscular cramps (64). This acute neurotoxicity is 
based on a sodium channelopathy (65), and severity of the acute symptoms are one of 
the risk factors for developing high-grade chronic CIPN (66).
 Although several non-pharmacological methods and pharmacological agents 
that act by various mechanistic pathways have been investigated, no effective 
preventive or curative strategies for chronic CIPN exists (67). Current prevention of 
CIPN consists of: (1) chemotherapeutic dosage modification based on informed 
decision of patients, thus patients and healthcare providers should be properly trained 
to recognize earliest evidence of CIPN, (2) doing exercise which might reduce patho-
physiologic mechanisms underlying CIPN, and (3) evaluation of patients’ nutritional 
status, since vitamin deficiencies can contribute to the development of CIPN. For 
treatment of CIPN, only duloxetin have been described as having modest analgesic 
efficacy (67).
 The lack of a universally accepted system for assessing and diagnosing CIPN in 
clinical trials, alterations in chemotherapy regimen during treatment and different 
endpoints in clinical trials reduce the ability to compare preventive and curative 
approaches. A search for preventive and curative treatments for CIPN is needed by 
intervening in the mechanisms of the specific chemotherapeutic agents.
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Aim of the thesis
My aim with this thesis is to gather fundamental knowledge and provide advice for 
future research and clinical explorations on how to improve the QOL of cancer 
survivors. The treatment of chronic pain is challenging, and preventing the transition 
from acute to chronic pain is an essential step in this process. One of the possible 
mechanisms to achieve this is to interfere in the inflammatory responses and/or 
increased hyperexcitability phenomena. We explored opportunities for modulating 
this inflammatory response and neuronal hyperexcitability following surgery and 
chemotherapy.
The following research questions were formulated: 
1. Is a sodium channel blocker a treatment option for patients with chronic pain 
resulting from chemotherapy?
2. What is the current state of knowledge concerning the in vitro and in vivo 
mechanisms of iv lidocaine, a non-specific sodium channel blocker, on the neuro-
inflammatory response in acute and chronic pain?
3. What is the role of the inflammatory response and nerve injury on the development 
of neuropathic pain in a two-hit murine surgical model. What is the effect of 
lidocaine on the inflammatory response and hyperexcitability?
4. What is the relation of the early inflammatory response with acute pain and 
postoperative complications in breast cancer surgery; and what is the effect of 
two anti-inflammatory drugs on the early inflammatory response?
5. Can surface electromyography (sEMG) recording be used as a noninvasive screening 
method for the detection of acute oxaliplatin-induced neuropathy? 
6. What is the effect of iv lidocaine on the pharmacokinetics of oxaliplatin? 
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Outline of the thesis
Chapter 1 describes the general background and rationale for this thesis. Currently, the 
goal of cancer treatment is based on prolonging survival combined with maintaining 
a good QOL in both the short and long term. Pain is one of the most commonly 
reported problems in cancer survivors, and can be caused either by the disease process 
itself or its treatment. The treatment of chronic pain is challenging, and preventing 
transition from acute to chronic pain is an important goal. One of the mechanisms for 
the transition from acute to chronic pain is a disbalance in the inflammatory response 
or increased neuronal hyperexcitability; this can be studied in surgery or after 
chemotherapy administration.
 Part I describes the clinical problem of chronic cancer-related pain and the 
discovery of an ‘old-school’ drug. In chapter 2, we describe a case series of 9 patients 
who had already received several analgesics for intractable pain after chemotherapy. 
Lidocaine has an analgesic, anti-inflammatory, anti-hyperalgesic effect mediated by 
an inhibitory effect on ion-channels, which may be beneficial in CIPN. The efficacy of 
iv lidocaine on pain scores and sensory symptoms is described and discussed in these 
patients with CIPN. Chapter 3 presents an overview, based on 88 articles, of the 
in vitro publications describing lidocaine’s target mechanisms in pain transmission, 
and numerous in vivo publications describing the effects of iv lidocaine in acute and 
chronic pain conditions. 
 Following this, we undertook preliminary investigations to explore the inflammatory 
response and hyperexcitability after surgery (part II) and oxaliplatin administration 
(part III).
 Part II: In chapter 4 we describe a murine model mimicking clinical surgical 
conditions. In many murine chronic constriction injury (CCI) models, animals are not 
mechanically ventilated. Most patients are ventilated during surgery, and mechanical 
ventilation (MV) induces an inflammatory response. We compared the postoperative 
inflammatory response and hyperexcitability symptoms after CCI, sham-surgery, or 
MV only. Additionally, we evaluated the effect of intraperitoneally administered 
lidocaine. 
 In chapter 5, we continued to investigate the perioperative early cytokine 
response and describe a randomized pilot study in 48 patients undergoing breast 
cancer surgery, a highly prevalent oncologic procedure. We hypothesized that the 
postoperative cytokine response, acute pain, and 30-day surgical complications were 
related. Furthermore, we hypothesized that iv lidocaine and dexamethasone 
modulates the cytokine response in an anti-inflammatory direction. 
 Part III: The severity of the acute oxaliplatin-induced neuropathy (OIN) has been 
shown to be one of the risk factors for developing high grade chronic CIPN. Accessible 
and objective monitoring evaluating the course of the acute hyperexcitability induced 
by oxaliplatin (and subsequently the effect of potential treatments can be evaluated) 
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is needed, so in chapter 6 we present a feasibility study which evaluates if sEMG is 
able to detect nerve hyperexcitability in patients with acute OIN. 
 Lidocaine may be a treatment option for acute OIN based on the mechanism of 
action of both drugs. However the effect of iv lidocaine on the pharmacokinetics of 
oxaliplatin during concomitant administration has never been studied. In chapter 7, 
we describe a cross-over study in 3 patients, evaluating the effect of iv lidocaine on the 
pharmacokinetics of oxaliplatin.  
 In chapter 8 we discuss the results of our research in a scientific context, and 
make recommendations for future research directions. Finally, we present a summary 
of the conclusions of this thesis in chapter 9. 
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Treatment of intractable pain due to chemotherapy induced peripheral neuropathy 
(CIPN) is a challenge. Intravenous lidocaine has shown to be a treatment option for 
neuropathic pain of different etiologies.  
Methods
Lidocaine (1.5 mg·kg-1 in 10 minutes followed by 1.5 mg·kg-1·hour-1 over 5 hours) was 
administered in nine patients with CIPN, and analgesic effect was evaluated during 
infusion and after discharge. The immediate effect of lidocaine on pressure pain 
thresholds (PPT) and the extent of the stocking and glove distribution of sensory 
abnormalities (cold and pinprick) were assessed.
Results
Lidocaine had a significant direct analgesic effect in 8 out of 9 patients (P = 0.01) with 
a pain intensity difference of > 30%. Pain reduction persisted in 5 patients for an average 
of 23 days. Lidocaine did not influence mean PPT, but there was a tendency that the 
extent of sensory abnormalities decreased after lidocaine. 
 
Conclusion
Iv lidocaine has a direct analgesic effect in CIPN with a moderate long-term effect, 
and seems to influence the area of cold and pinprick perception. Additional research 
is needed, using a control group and larger sample sizes to confirm these results.  
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Introduction
Chemotherapy induced peripheral neuropathy (CIPN) is a clinically relevant side effect 
of various chemotherapeutic drugs, that prevents an optimal treatment regimen in a 
significant proportion of patients (1, 2). Although CIPN has been described with many 
chemotherapeutic drugs, the occurrence and severity of CIPN depends on the type of 
chemotherapeutic drug, regimen, cumulative dose and individual patient factors (3). 
CIPN has a relatively high prevalence, varying from 68.1% within the first month after 
cessation of chemotherapy to 30% at six months or later (4). Several mechanisms have 
been described to explain the underlying pathophysiology of CIPN. Alterations in ion 
channel function, mainly sodium channels, are believed to play an important role in 
the pathophysiology of CIPN. These alterations induce changes in the cell membrane 
leading to spontaneous electric discharges, resulting in a hyperexcitability state of 
the nervous system (5, 6). Additionally, increased release of inflammatory cytokines is 
believed to contribute to occurrence of chronic neuropathic pain and CIPN (3, 7).
 Clinically, CIPN mainly manifests as a sensory peripheral neuropathy, although 
motor and autonomic nerve fibers may also be involved (2, 4). The sensory neuropathy 
is often distributed in a “stocking and glove” manner (i.e. affecting the feet, distal lower 
legs and hands), and causes symptoms like pain, sensory loss, allodynia, paresthesia, 
numbness and tingling (2, 3, 8). Symptoms frequently affect patients’ daily activities 
and decrease their quality of life (2, 3). Until now, no sufficient treatment option has 
been available for CIPN. Intravenous (iv) lidocaine has shown to be a successful option 
in treating various causes of chronic neuropathic pain (5, 9-11). The first description of 
iv lidocaines’ analgesic effect was in 1961, but with a high incidence of side effects at 
doses required for pain relief (12). A report of Boas et al. in 1982, led the analgesic use of 
lidocaine incline (13). Lidocaine, a non-specific sodium channel blocker, reduces ectopic 
nerve discharges, relieves hyperalgesia and modulates the inflammatory response, 
because of an inhibitory effect on sodium-, calcium-, and potassium ion channels, 
G-protein coupled pathways, NMDA-receptors and the glycinergic system (14). No 
study has been conducted yet to determine the effect of iv lidocaine on neuropathic 
pain in patients with CIPN, but theoretically it might be a potentially useful treatment 
modality. We experienced that iv lidocaine had an analgesic effect in individual 
patients with CIPN, and in some of them the stocking and glove distribution of sensory 
deficits changed. Therefore, our primary aim was to investigate the effect of a single 
infusion of iv lidocaine on neuropathic pain in patients with CIPN, and additionally we 
examined sensory symptoms.
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Patients were recruited in the period of January 2015 until November 2015 from 
the outpatient pain clinic of the Radboud university medical center, Nijmegen, The 
Netherlands. Patients aged 18 years or older, diagnosed with CIPN, who had a pain 
score of 5 or more on an 11 point numeric rating scale (NRS), were included. Exclusion 
criteria were: last chemotherapy infusion < 12 weeks ago, myocardial ischemia < 6 
months ago, cardiac arrhythmias or use of antiarrhythmic medication, nephropathy 
(glomerular filtration rate < 60 mL·min-1·1.73m-2), liver disease (serum bilirubin > 1.5 x 
above normal), hypokalemia, a known allergy for local anesthetics of the amide-type, 
diabetes mellitus or other known peripheral neuropathic disease, and pregnancy or 
lactation. Concomitant use of other analgesics drugs at the moment of inclusion was 
continued if necessary, without dosage modifications. Demographic characteristics 
like age, gender, medical history, previous analgesics usage and Hospital Anxiety and 
Depression Scale (HADS) were collected. Patients completed the National Cancer 
Institute-Common Toxicity Criteria (NCI-CTC) questionnaire before treatment with 
lidocaine. The NCI-CTC questionnaire is used to determine the grade of neuropathy, 
ranging from 0 to 4, where 0 corresponds to no neuropathic symptoms and 4 to the 
most severe neuropathic symptoms (15). The HADS is a questionnaire to determine 
the level of anxiety and depression, with a maximum of 42 points (16, 17). A total HADS 
> 12 (sensitivity 0.80 and specificity 0.74) indicates a state of depression or emotional 
distress (18).The study protocol was approved by the institutional review board and 
participants gave informed consent to use their data.
Treatment
The study used a prospective observational cohort design. Patients received the 
following regimen of iv lidocaine: a bolus of 1.5 mg·kg-1, infused in 10 minutes, 
followed by continuous infusion of lidocaine 1.5 mg·kg-1·hour-1 over a 5-hour period. 
This infusion algorithm is selected since the analgesic effect seems to be correlated 
with duration of infusion (11), and therapeutic plasma levels for pain treatment within 
1 – 5 µg·mL-1 (19, 20). Plasma levels of 2 – 4 µg·mL-1 will be achieved with a bolus of 
2 mg·kg-1 followed by continuous infusion 2 – 3 mg·kg-1·hour-1 (21), though awake 
patients can experience unwanted side effects when using these dosage schemes.  
 A three-lead electrocardiogram, blood pressure and oxygen saturation were 
monitored continuously throughout the study by an anaesthesiologist. Patients were 
observed for possible side effects till approximately 30 - 60 minutes after treatment with 
lidocaine, during this period no study measurements were performed. All measurements 
were performed by two clinicians (physician and medical student). 
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Clinical pain score
The intensity of pain was assessed using the numeric rating scale (NRS, 0: no pain, 
10: worst pain imaginable) (22). Pain ratings were obtained directly before start of 
infusion, every 15 minutes during the first hour, and subsequently every 30 minutes 
until the end of infusion. During lidocaine infusion, pain ratings were obtained 
separately for both hands and both feet. Correlation between duration of infusion and 
pain ratings was assessed. The difference between the NRS at baseline and the NRS 
after treatment with iv lidocaine were used to calculate the absolute pain intensity 
difference (PID) and the percentage pain intensity difference (PID%). An absolute 
decrease in pain intensity scores of ≥ 2 points on the NRS or a PID% of ≥ 30% was 
considered clinically significant (23). Patients with a clinical significant result were 
defined as responders. The other patients were seen as non-responders.
 The duration of the analgesic effect after discontinuation of lidocaine infusion 
was assessed by number of consecutive days till pain was returned to baseline. 
Patients received a pain diary, in which pain scores were asked 3 times daily, from day 0 
– 10 every day, from day 14 and further weekly. They were called by the physician every 
3 weeks after infusion, which asked if there has been any prolonged analgesic effect 
and what the duration of this effect was. If pain was returned to baseline, alternative 
pain management was discussed; and if there was still pain reduction, they were 
called again after 3 weeks.
Examination sensory symptoms
Pain sensitivity and sensory changes of the hand and feet were examined directly 
before and after treatment with lidocaine. The order of examination was successively: 
1. pressure pain thresholds, 2. mechanical sensory testing, and 3. thermal sensory 
testing.
Pressure pain thresholds
Baseline pain sensitivity was assessed by measuring the responses evoked by mechanical 
non-invasive stimuli, i.e. pressure pain thresholds (PPT) (24). PPT assessment has proven 
to be a method with satisfactory intra-individual reproducibility and reliability (25, 26), 
and can easily be determined by a trained professional with a pressure algometer (27).
 A hand held pressure algometer (Wagner force ten™ FDX digital force gage) with a 
contact area of 1 cm2 was used to give a standardized pressure stimulus of 50 kPa·s-1. 
PPT was assessed on both the right and left body side at the following locations: 
m. trapezius pars medialis, thenar eminence, m. rectus femoris (15 cm above patella) 
and the m. abductor hallucis. Patients received instructions to notify the investigator 
if their PPT was reached, subsequently the associated pain score (NRS) was obtained. 
To familiarize patients with the method of testing, measurements started with a 
pressure stimulus on the ventral side of the chest. 
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Mechanical en thermal sensory testing
The distribution of the sensory neuropathy was measured with a Tip-Therm stored 
on ice and a MRC PinPrick stimulator of 256 mN. In order to assess the location of 
sensory changes, cold and pinprick stimuli were repeatedly delivered on the arm and leg. 
Stimuli were given from the anterior attachment of the m. deltoideus to digitus III, 
respectively from the top of the patella to the hallux. Patients had to indicate the 
location of sensory change. The distance (cm) between this position and respectively 
digitus III or the hallux represented the extent of the distribution (Δ). The method of testing 
is shown in Figure 1. To familiarize patients with the method of testing, measurements 
started with a pinprick and cold stimulus on the ventral side of the chest.
Statistical analysis
Continuous data were expressed as means with standard deviation (SD) or as means 
with a two-tailed 95% confidence interval (CI) in case of normally distributed data. 
The Kolmogorov- Smirnov test was used to assess if data were normally distributed. 
Skewed data are presented as median with interquartile range (IQR). Paired data were 
analyzed using the paired t test or the Wilcoxon signed rank test, depending on the 
distribution. A Pearson correlation coefficient was calculated to detect a correlation 
between duration of infusion and NRS. The Bonferroni correction was used for multiple 
Figure 1. Method of thermal and mechanical testing.
1: Distance between point of sensory change and digitus III before iv lidocaine. 2: Distance between point of 
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comparisons adjustment. Statistical Package for Social Sciences, Version 22.0 (IBM 
Corporation, Armonk, NY, USA) was used for statistical analysis. Figures were created 
using GraphPad Prism, Version 5.03 (GraphPad Software Inc., La Jolla, CA, USA). 
A P value less than 0.05 was considered to be statistically significant. The Bonferroni 
corrected P value considered for statistical significance is equal to 0.006.
Results
Patient characteristics
Nine patients, 4 male and 5 female (mean age 52.7 (11.9)) were included during the 
study period. Patient characteristics are depicted in Table 1. 
 Patients were treated for various types of malignancies with one or more chemo-
therapeutic agents, which all could induce CIPN. Seven patients suffered neuropathy 
grade 4; 1 patient reported neuropathy grade 2; and another neuropathy grade 1 on 
the NCI-CTC scale. The median of the HADS - value was 17 [8.25 - 18.25). All patients 
reported pain in the lower extremities; 6 patients also experienced pain in the upper 
extremities. Most patients had already tried a wide variety of analgesics (e.g. NSAIDS, 
opioids, antidepressants, antiepileptics), but none were previously treated with iv 
lidocaine. During treatment with lidocaine no serious side effects occurred. All patients 
remained respiratory and hemodynamically stable (no cardiac arrhythmias were 
observed) and could be discharged within one hour after infusion.
Effect on clinical pain score
Treatment with iv lidocaine caused a clinically significant decrease in the NRS score at 
group level (P = 0.01). Eight out of 9 patients experienced an analgesic effect of 
lidocaine.  The mean NRS score was 7.7 before infusion; and dropped to a mean NRS 
score of 3.1 after treatment. The effect of iv lidocaine on pain (NRS scores) for every 
patient is presented in Table 2 and the change in mean NRS scores during infusion is 
displayed in Figure 2. 
 NRS scores of both hands and feet correlated significantly with duration of 
infusion, the correlation coefficient of hands and feet was  - 0.8 (P  < 0.01) and - 0.9 
(P < 0.01), respectively. At the start of infusion patients reported a higher NRS score for 
their feet (5.9 (2.2)) compared with their hands (2.4 (2.3)). Subsequently, the NRS of 
the feet showed a larger decrease than the NRS of the hands. 
 In three patients experiencing pain reduction during lidocaine treatment, 
the analgesic effect disappeared almost immediately after discontinuation of the 
infusion. Five patients experienced a more sustained analgesic effect, which varied 
from 3 days up to 56 days with a mean duration of 23 days.
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Pressure pain thresholds
Comparable results were obtained when PPTs and associated NRS scores were 
expressed separately for the left and right body side; therefore the means of left and 
right side measurements were used for analysis. The effect of iv lidocaine on the 
Table 2.  Individual NRS scores before and directly after treatment and duration of 







PID PID% Duration 
(days)
1 9 5 4 44 7
2 8 3 5 63 0
3 9 2 7 78 28
4 8 0 8 100 0
5 5 0 5 100 3
6 8 4 4 50 0
7 8 4 4 50 21
8 7 3 4 43 56
9 7 7 0 0 0
PID: Pain Intensity Difference,
PID%: Percentage Pain Intensity Difference
Figure 2. Change in mean NRS scores of hands and feet during lidocaine infusion.
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pressure pain thresholds (PPT) and associated NRS scores is shown in Table 3. There was no 
significant effect of iv lidocaine on the mean PPT and associated NRS score.  The effect 
on PPT before and after iv lidocaine varied between -2.31 to 1.16 N·cm-2 (P = 1); and for 
associated NRS score the effect varied between -0.67 to 0.06 NRS points (P = 0.204 - 1).
Thermal and mechanical sensory testing
Although individual patients could have an asymmetrical distribution of their stocking 
and glove distribution, no statistically significant difference was found between left 
and right side for the distribution of sensory changes for pinprick and cold in the whole 
group. Combining both limbs before and after lidocaine infusion, the cold detection 
level was significantly more caudal as the pinprick detection level (P = 0.008; difference 
= 6.1 cm; 95% CI 1.7 - 10.6) was found. For limbs and infusion separately, the pinprick 
detection level was always more cranial as the cold detection level; however in these 
subgroups with less observations the difference is not always statistically significant 
(P varies between 0.018 and 0.625). In 1 patient no changes in cold or pinprick sensation 
were observed.
Influence of lidocaine on thermal and mechanical sensory testing
The changes in distribution of pinprick and cold sensation in individual patients are 
presented in Table 4.
 In 4 patients the area of abnormality in cold perception decreased after infusion. 
Three patients reported an increase in area in the upper or lower extremity after 
infusion. One patient showed a combination of positive change in one leg and a negative 
change in the other leg. The area of cold perception decreased when combining the 
limbs in all patients (P = 0.292; difference = 3.7 cm; 95% CI -3.5 – 10.8).
Table 3. PPTs and associated NRS scores before and after treatment with iv lidocaine.
Location Before * After * Effect T-statistic 95% CI P-value 
**
PPT M. trapezius pars medialis 51.7 (14.3) 52.0 (12.5)   0.34 - 0.086 (- 9.6 - 8.9) 1
Thenar eminence 58.0 (18.2) 58.3 (14.9)   0.33 - 0.070 (- 11.4 - 10.7) 1
M. rectus femoris 71.3 (26.4) 69.0 (16.2) - 2.31   0.257 (- 18.5 - 23.1) 1
M. abductor hallucis 55.6 (27.7) 56.8 (18.3)   1.16 - 0.192 (- 15.0 - 12.7) 1
NRS M. trapezius pars medialis 5.6 (2.0) 5.4 (2.4) - 0.11   0.187 (- 1.3 - 1.5) 1
Thenar eminence 5.6 (1.9) 5.1 (1.8) - 0.56   2.294 (- 0.0 - 1.1) 0.204
M. rectus femoris 4.9 (2.3) 5.0 (2.0)   0.06 - 0.127 (- 1.1 - 1.0) 1
M. abductor hallucis 6.3 (2.0) 5.7 (2.0) - 0.67   1.193 (- 0.6 - 2.0) 1
PPT: Pressure Pain Threshold, N∙cm-2;  NRS: Numeric Rating Scale, scale 0-10
* Data are expressed as means (SD); ** Bonferroni-corrected P values are reported
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 In 4 patients the area of abnormal pinprick sensation in the upper or lower 
extremities decreased after infusion, in 1 patient it increased in both upper and lower 
extremities. Three patients showed a combination of both increase in one area and 
decrease in another. The area of abnormal pinprick sensation decreased when 
combining the limbs in all patients (P = 0.099; difference = 6.4 cm; 95% CI -1.3 – 14.1).
Discussion
A single infusion of lidocaine decreased pain in 8 out of 9 patients with CIPN, which 
was correlated with duration of iv lidocaine infusion. The long-term analgesic effect of 
lidocaine was moderate with a mean duration of 23 days. Lidocaine had no effect on 
pain sensitivity measured by PPT. The distribution of sensory abnormalities was 
influenced by lidocaine. 
There have been other studies that assessed the effect of iv lidocaine on neuropathic 
pain, but to our knowledge no study has specifically investigated the effect of lidocaine 
in CIPN. A Cochrane review that included 30 RCTs, showed that iv lidocaine and its oral 
analogues, mexiletine and tocainide, reduce neuropathic pain (9). This review included 
heterogeneous studies that looked at various etiologies of peripheral neuropathic 
pain (e.g. diabetic, posttraumatic, central pain) and lidocaine dosages also varied 
(1 – 5 mg·kg-1 in 30 – 60 minutes) between studies. Tremont-Lukats et al. investigated 
three dosing regimens of lidocaine (1, 3 and 5 mg·kg-1·hr-1 during 6 hours) in various 
Table 4.   The change in distance (Δ) for cold and pinprick stimuli before and after 
treatment with iv lidocaine.
Cold Pinprick
Arm Leg Arm Leg 
Patient 
no.
Right Left Right Left Right Left Right Left
∆ (cm) ∆ (cm) ∆ (cm) ∆ (cm) ∆ (cm) ∆ (cm) ∆ (cm) ∆ (cm)
1 - 22 - 14 - 45 - 3 - 28 - 22 - 30 - 41
2 0 - 26       - 8 - 2 0 + 7 +23 + 17
3 - 13 - 11       - 7 - 3 - 25 - 16 - 10 - 6
4 0 0        0 0 0 0 0 0
5 0 0    + 24 + 45 +2 -2 -2 - 3
6 0 0 0 + 12 - 7 - 11 + 27 + 5
7 0 0 -8 -8 0 0 - 26 0
8 0 + 19 + 1 0 + 19 + 3 - 6 - 6
9 0 0 - 2 +6 0 0 -5 - 2
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neuropathic pain syndromes. Pain scores continued to decrease till 4 hours after start 
of lidocaine infusion. Lidocaine at 5 mg·kg-1·hr-1 was more effective at relieving 
neuropathic pain than lower dosages, and this effect persisted for at least 4 hours 
after end of infusion. Three other studies investigated the effect of lidocaine in 
homogenous patient groups. In two small groups of patients with peripheral nerve 
injury, lidocaine (5 mg·kg-1 in 30 minutes or 4 hours) had conflicting analgesic efficacy 
and long-term effects were not evaluated (28, 29). Lidocaine (5 mg·kg-1 or 7.5 mg·kg-1 
in 4 hours) had a significant effect in reducing pain in a group of 15 patients with 
intractable diabetic neuropathy. This effect lasted for up to 28 days (30), which is 
comparable to our results. 
Sensory testing
PPT is increasingly used to compare pain sensitivity before and after treatment (31, 32). 
No influence of lidocaine was found on PPT and associated NRS. Previous studies 
investigating the analgesic effect of agents targeting neuronal excitability have shown 
that pre-treatment PPT can predict analgesic efficacy of treatment (33). In our study, 
no correlation between PPT and efficacy of treatment was found. The mean PPT in our 
population were comparable to thresholds described in healthy individuals (34). 
 Spread of sensory abnormalities showed a marked variance between patients; 
however the mean affected area for cold detection had a tendency to be smaller than 
for pinprick. Cooling the skin to 4°C activates Aδ- and C-fibers sensitive to innocuous 
cooling and cold-sensitive nociceptors. The perception of pinprick pain intensity is 
related to activity in Aδ- fiber nociceptors (35). Krøigård et al. observed in patients with 
CIPN caused by oxaliplatin and docetaxel that mechanical detection threshold 
measured with von Frey hairs was more affected as the cold detection threshold (36). 
These results indicate that CIPN affects both small and large nerve fibers. It has to be 
noted that some patients found it challenging to indicate the exact location of sensory 
change, possibly resulting in a test with a lower accuracy and sensitivity. 
 The effect of lidocaine on the distribution of sensory abnormalities showed 
unexpected results, with an increase of sensory abnormalities in some and a decrease 
in other patients. Although these changes were not statistically significant, it is 
interesting that a pharmacological agent can influence and maybe decrease sensory 
abnormalities. These results could provide a basis for further research on developing 
treatments, including specific sodium channel blockers, which reduce or even treat 
sensory disturbances in polyneuropathy.
 CIPN is known to be a common dose limiting side effect of chemotherapeutic 
agents like taxanes, vinca alkaloids and platinum compounds (1, 2). Proposed 
mechanisms for taxane-induced neuropathy are a disrupted axonal microtubule 
structure and a toxic effect on mitochondria in primary afferent neurons. Vinca 
alkaloids induce alterations in neuronal cytoskeleton leading to impaired axonal 
transport and degeneration. Platinum compounds accumulate in the dorsal root 
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ganglia resulting in decreased cellular metabolism and axoplasmic transport (1-3). 
Most of these agents will be combined with other types of chemotherapy in cancer 
treatment, like antimetabolites, topoisomerase inhibitors or antitumor antibiotics, 
which can have equally a neuropathy as a side effect. 
 In this study, patients with various types of malignancies were included, who were 
also treated with different chemotherapeutic agents, which may have resulted in 
heterogeneity of their sensory profiles. From these data no conclusions can be drawn 
which sensory abnormalities can be seen in CIPN caused by a specific type of 
chemotherapy or which responds best to lidocaine treatment. Since several trials 
indicate that sensory phenotyping can predict drug responsiveness (37, 38), a larger and 
more detailed study could untangle the different pathophenotypes of CIPN and their 
responsiveness to treatment. Drawbacks of our study are its small sample size and lack 
of control group. However, despite the small sample size, a significant direct analgesic 
effect was observed, even though patients received various types of chemotherapy 
and had different comorbidities. Additionally, most patients had severe neuropathy, 
had previously received various analgesics and the median HADS – value was 17 (39). 
These factors can render a subject more susceptible to non-successful pain treatment.
Conclusion 
Iv lidocaine, an old-school drug, significantly reduced intractable pain in patients with 
CIPN for an average of 23 days in our study and there was a tendency for a decreased 
extent of sensory abnormalities. Our results are therefore promising and show a 
potential role for iv lidocaine in patients with CIPN, when standard treatment 
algorithm for neuropathic pain fails (40). This might prevent them finishing the 
intended optimal chemotherapy regimen. Furthermore, patients who do not respond 
with a long lasting effect to lidocaine can be prescribed an oral sodium channel 
blocker like mexelitine, carbamazepine or lamotrigine. These promising results provide 
a basis for the development of larger randomized trials, investigating the role of 
lidocaine in the treatment of CIPN. 
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The neuroinflammatory response plays a key role in several pain syndromes. Intravenous 
(iv) lidocaine is beneficial in acute and chronic pain. This review delineates the current 
literature concerning in vitro mechanisms and in vivo efficacy of iv lidocaine on the 
neuroinflammatory response in acute and chronic pain.
Databases and data treatment
We searched PUBMED and the Cochrane Library for in vitro and in vivo studies from 
July 1975 to August 2014.  In vitro articles providing an explanation for the mechanisms 
of action of lidocaine on the neuroinflammatory response in pain were included. 
Animal or clinical studies were included concerning iv lidocaine for acute or chronic 
pain or during inflammation. 
Results
Eighty-eight articles regarding iv lidocaine were included: 36 in vitro studies evaluating 
the effect on ion channels and receptors; 31 animal studies concerning acute and 
chronic pain and inflammatory models; 21 clinical studies concerning acute and 
chronic pain. 
 Low dose lidocaine inhibits in vitro voltage gated sodium channels, the glycinergic 
system, some potassium channels and Gαq-coupled protein receptors. Higher lidocaine 
concentrations block potassium and calcium channels, and NMDA receptors. Animal 
studies demonstrate lidocaine to have analgesic effects in acute and neuropathic pain 
syndromes and anti-inflammatory effects early in the inflammatory response. Clinical 
studies demonstrate lidocaine to have advantage in abdominal surgery and in some 
neuropathic pain syndromes.
Conclusions
Iv lidocaine has analgesic, anti-inflammatory and anti-hyperalgesic properties mediated by 
an inhibitory effect on ion-channels and receptors. It attenuates the neuroinflammatory 
response in perioperative pain and chronic neuropathic pain.
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1.  Background and objective
The neuroinflammatory response plays a key role in acute and chronic pain syndromes. 
Even though pain is typically categorized as either inflammatory or neuropathic many 
similarities exist between these two conditions (1-5).
 After tissue injury, proinflammatory cytokines and chemokines are synthesized 
and immune cells migrate to the injury site. This “inflammatory soup” reduces firing 
thresholds of Aδ- and C-fiber nociceptors and causes acute pain (6). Chronic pain can 
exist despite tissue healing and results from persistently generated impulses to the 
central nervous system due to ongoing inflammation or nerve injury (7, 8). These 
induce ligand- and voltage gated ion channels in the peripheral and central nervous 
system. Prolonged peripheral input causes glutamate release and subsequent 
N-methyl-D-aspartic acid (NMDA) receptor activation, resulting in hyperexcitability 
and modification of the central nervous system (7, 9). Concurrently, microglia and 
astrocytes in the dorsal horn and spinal cord are activated resulting in an enhanced 
release of proinflammatory cytokines and algesic mediators contributing to 
development and persistence of chronic pain (3, 10). Although the pathophysiology of 
pain is further elucidated; treatment of pain is still challenging and a more mechanistic 
based treatment is warranted.
Intravenous (iv) lidocaine has been used to treat acute and chronic pain syndromes 
due to its analgesic, anti-inflammatory and anti-hyperalgesic properties (11). Over the 
last years, an increasing number of in vitro publications has emerged describing 
lidocaine’s target mechanism in pain transmission, and of in vivo publications, which 
describe the effects of iv lidocaine in acute and chronic pain conditions. An overview 
of these studies is lacking in current literature. 
 In vitro studies show lidocaine to modulate potassium- and calcium channels, 
G protein-coupled receptors, NMDA receptors and the glycinergic system lidocaine; 
besides its ability to block sodium channels. These channel and receptor effects play 
each their role in lidocaine’s efficacy in pain syndromes. The first aim of this review is 
to present an overview of preclinical studies describing lidocaine’s target mechanisms, 
which can contribute to an improved comprehending of iv lidocaine in the complex 
nature of pain syndromes. 
 Animal studies concerning iv lidocaine for acute and chronic pain and inflammatory 
conditions show lidocaine to reduce perioperative and neuropathic pain and to 
modulate inflammation. An overview of the effects of iv lidocaine in animal studies 
can contribute in translation of these effects to a clinical situation. Reviews concerning 
clinical studies describe lidocaine to have beneficial effects in abdominal surgery 
(12-14) and some neuropathic pain syndromes (15). However, these reviews only 
discussed a specific type of acute pain, acute pain alone, or are relatively dated. Since 
then other randomized control trials have been performed, which show additional 
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insights in the effects of iv lidocaine in acute and chronic pain. Our second aim is to 
present an overview of animal and clinical studies concerning the efficacy of iv lidocaine. 
 In conclusion, this review delineates the current literature concerning in vitro 
mechanisms and in vivo efficacy of iv lidocaine on the neuroinflammatory response in 
acute and chronic pain.
2.  Databases and data treatment
2.1  Search
A systematic literature search was performed. We used the electronic database 
PUBMED from July 1975 till November 2014 for in vitro studies explaining lidocaine’s 
mechanisms of action. We searched PUBMED and the Cochrane Library from July 1975 
till November 2014 for studies regarding the effects of iv lidocaine on nerve injury and 
inflammation in acute and chronic pain. Furthermore, reference lists were searched 
for relevant articles. The search was restricted to articles written in English or Dutch 
and published as ‘full paper’. 
 We used the following terms for our search: ‘lidocaine’, ‘lignocaine’ ‘intravenous 
lidocaine OR systemic lidocaine’, ‘intravenous lignocaine OR systemic lidognocaine’. 
Additional search terms included: ‘chronic and acute pain’, ‘hyperalgesia’, ‘inflammation’, 
‘cytokines’, ‘perioperatieve’, ‘peroperative’.  
 In vitro articles were included when they described the target mechanisms of 
lidocaine in the neuroinflammatory response in acute and chronic pain. In vitro articles 
evaluating the effect of lidocaine on ion channels (sodium-, potassium-, and calcium 
channels), receptors (NMDA-, G-protein coupled- and glycine receptors) and the 
inflammatory response were included.
 Animal or clinical studies were included concerning iv lidocaine for acute or 
chronic pain or during inflammation. Researchers independently assessed abstracts of 
possible relevant studies. A data collection was assembled consisting of reviews, 
randomized controlled clinical trials, intervention and some retrospective studies in 
humans and animals. Studies were excluded for the following reasons: evaluation of 
locoregional, epidural or local applied lidocaine, pain or inflammatory response was 
not used as an outcome measure, the effectiveness of lidocaine treatment on pain or 
the inflammatory response was not the aim of the study. Other reasons for exclusion 
were as follows: studies were already described in included systematic reviews, the 
manuscripts concerned case studies or opinion articles, or articles were of poor 
methodological quality.  Studies were considered to be of poor methodological quality 
when the aim was not clearly described; the research design, selection of participants 
or data collection were inadequate; and analysis of data, the description of results and 
conclusions were not accurate or clearly described. 
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2.2  Analysis
In vitro literature concerning lidocaine was categorized in two groups evaluating the 
effect on: 1) ion channels (sodium-, calcium- and potassium channels); 2) receptors 
(G-protein coupled, NMDA and glycine). We described these studies regarding their 
general characteristics: a) objective: effect lidocaine on which channel, current or 
inflammatory mediators. Which cell type (Xenophus oocytes, dorsal horn neurons 
etc) and which technique (voltage, patch clamp etc) was used. b) applied lidocaine 
concentration; c) results: inhibitory concentration to block 50% of the current (IC50), 
characteristics of blockade. 
 In vivo studies concerning iv lidocaine were subdivided in animal and clinical 
studies. Animal studies were categorized in three groups: 1) acute pain; 2) chronic 
pain; 3) anti-inflammatory effects. We compared these studies regarding the following 
characteristics: a) which acute or chronic pain syndrome or inflammatory response 
was studied and which animal was studied; b) lidocaine dose; c) Effect of iv lidocaine 
in specific pain syndrome or inflammatory response. Clinical studies were categorized 
in two groups: 1) acute pain; 2) chronic pain. We compared these studies regarding the 
following characteristics: a) which acute, chronic pain syndrome was studied; b) 
lidocaine dose; c) Effect of iv lidocaine in a specific pain syndrome. 
3.  Results
Eighty-eight articles were included in total. Thirty-six articles were in vitro studies, 
of which 18 studies concerning ion channels, 13 studies concerning receptors and 5 
additional studies concerning the inflammatory response. Thirty-one articles were 
animal studies, of which 12 studies concerning acute pain, 7 studies concerning chronic 
pain and 12 studies evaluated the effect of lidocaine in inflammatory models. 
Twenty-one articles were included describing the clinical efficacy of iv lidocaine in 
acute (10 articles) and chronic (11 articles) pain. The results are presented in table 1 to 7. 
3.1  Mechanism of action of lidocaine:  In vitro research 
Ion channels (Table 1)
Sodium channels
Voltage-gated sodium channels (VGSC) are compromised of a pore-forming α-subunit, 
Nav1.1 - Nav1.9, with one or more smaller β-subunits, β1-β4. The α-subunit regulates 
Na+ currents (16) and the β-subunits are multifunctional channel modulators, member 
of the immunoglobulin superfamily and cell adhesion molecules (17). Each isoform 
has its own electrophysiological characteristics and is expressed in specific neuronal 
tissue. Changes in expression of VGSC isoforms occur in chronic neuropathic and 
inflammatory pain conditions (9, 16, 18-20).  
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 After depolarization, VGSC eventually assume a nonconducting state through a 
distinct process known as inactivation and cannot reopen during a certain period. 
After a train of depolarizations, the availability of channels to reopen declines, which 
is called use-dependence. Lidocaine preferentially binds to the inactivated state, 
thereby enhancing use-dependence and suppressing cellular excitability, particularly 
at high rates of stimulation (21). Lidocaine produces a tonic block of sodium currents 
after depolarization (22).
 Lidocaine has differing potencies on the various sodium channel isoforms. 
Lidocaine decreases conduction in Nav 1.4, by enhancing the transition to slow 
inactivation (23-25). This implies that lidocaine induces a conformational gating 
change of Nav 1.4 linked to a stable inactivated state. Lowering extracellular sodium 
concentration enhances use-dependent blockade (24). Chevrier et al. (26) studied 
Nav 1.7 and Nav 1.8 expressed in Xenopus oocytes. Lidocaine enhances tonic and 
use-dependent block and the transition to slow inactivation in both channels, though 
Nav 1.8 is 4.4-fold more sensitive to lidocaine than Nav 1.7. 
 Sheets et al. (27) showed a decreased transition to slow inactivation in Nav 1.7. 
An explanation for these opposing results can be that Sheets et al. studied Nav 1.7 
in Human Embryonic Kidney cells (HEK cells) and Chevrier et al. in Xenopus oocytes; 
additionally, they applied other lidocaine dosages and stimulation pulses. 
 Tetrodotoxin sensitive (TTXs) VGSC are 5-fold more sensitive for lidocaine as 
tetrodotoxin resistant (TTXr) VGSC. Stimulating TTXr at higher frequencies reduces its 
IC50, implicating a slower activation and higher stimulation threshold of TTXr neurons 
(28). Aδ- and C-fibers can be divided into tonic, adapting and single spike neurons 
according to their response to sustained depolarization. Lidocaine suppresses adapting 
firing neurons by interacting with VGSC (29). 
 Inhibition of VGSC plays a role in modulation of inflammation. Huang et al. (30) 
revealed that lidocaine dose dependently inhibits the expression of inducible nitric 
oxide (iNOS) and cationic amino acid transporter (CAT-2) in lipopolysaccharide (LPS) 
stimulated murine macrophages, presumably by blocking VGSC. Upregulation of iNOS 
and subsequent nitric oxide overproduction is critical factor in the sequence of sepsis. 
This research group further explored the role of lidocaine on toll-like receptor 4 (TLR-4) 
and nuclear factor (NF)-κβ and mitogen-activated protein kinases (MAPK’s) since 
these mediate iNOS mediated inflammation, and demonstrated lidocaine to attenuate 
activation of TLR-4, NF-κβ and MAPK’s in activated macrophages, with involvement of 
VGSC (31).
Calcium channels
Voltage gated calcium channels (VGCC) are involved in neuronal excitement and 
diverse physiological functions and can be subdivided into low voltage-activated 
T-type and high voltage-activated L-, N- and R-type channels. Changes in biophysical 
properties and expression levels of VGCC are observed in neuropathic pain (32). 
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 Lidocaine inhibits calcium currents in amphibian neurons in a dose- and voltage 
dependent manner (33, 34). At an IC50 for blocking sodium currents (100µM), 35% of 
the calcium currents were blocked in frog neurons (34). However, the concentration 
needed for blocking calcium currents in snail neurons was about ten times higher 
(1mM) (33). These opposing results may be attributed to the differently applied 
external Ca2+ concentration (2mM in frog, and 10mM in snail one), since the efficacy 
of lidocaine is reduced for increased external Ca2+ concentrations (33).
 Studies in mammalian neuronal preparations revealed a dose-dependent inhibition 
of high voltage-activated calcium channels (35) and lidocaine to interact with L-type 
VGCC subtypes (36). Binding of local anesthetics to VGCC appears to be dependent on 
lipid solubility. Lidocaine dosages needed for VGCC blockade were relatively high 
(1-10mM) probably as a result of its relative low lipophilicity (VGSC: IC50 = 60 - 200µM). 
Potassium channels
Potassium channels are important regulators of membrane potentials, action potential 
shape, and firing adaptation in excitable tissues including sensory neurons (37). 
Various potassium channels are involved in pain modulation and inflammation: voltage- 
gated potassium channels (VGPC), voltage independent potassium channels, tandem 
pore domain potassium channels (2P K+ channels) and ATP-sensitive potassium channels. 
Lidocaine inhibits K+ currents in various neuronal preparations, including rapidly 
inactivating K+ currents in rat dorsal horn neurons (22) and sustained K+ currents in rat 
dorsal root ganglion neurons (38) and amphibian sciatic nerves (39). Although the 
affinity of lidocaine for VGPCs is 6-fold lower compared with VGSCs, blockade of 
VGPCs contributes to the broadening of the action potential in the presence of 
lidocaine. Inhibition of the outward potassium currents causes partial depolarization 
and leads to an increased amount of inactivated sodium channels. Inactivated sodium 
channels are more sensitive to lidocaine. Thus, inhibition of outward potassium currents 
promotes sodium channel inactivation (39). Kindler et al. (40) investigated members 
of 2P K+ ion channel family, which are widely expressed in the central nervous system 
and the molecular entities of background or leak potassium conductances involved 
in the control of resting membrane potential and firing pattern of excitable cells. 
Lidocaine inhibited tandem pore weak inward rectifying K channel (TWIK)-related 
acid-sensitive K+ channel 2 (TASK-2) in a dose-dependent manner (IC50 = 1mM).
 Lidocaine suppresses tonic firing Aδ- and C-fibers by interacting with VGPC (29). 
The flicker potassium is a voltage independent potassium channel found in most of 
the thin nerve fibers and generates the resting membrane potential of these fibers. 
In a frog sciatic nerve, lidocaine blocks the flicker potassium channel intracellular 
(IC50 = 219µM) and binding is pH-dependent, id est improved binding at higher 
pH-values and reduced binding at low pH-values (41).
 Lidocaine modulates mitochondrial adenosine triphosphate (ATP)-sensitive potassium 
channels resulting in a reduction of cytokine-induced cell injury in vascular smooth 
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muscle and endothelial cells. Cell survival improved as they were incubated with 
increasing dosages of lidocaine (42). 
Receptors (Table 2)
G-coupled protein receptors 
The G-protein-coupled receptors (GPCRs) consist of a large family (nearly 2000 GCPRs), 
which are of fundamental importance for intra- and intercellular communication 
pathways (43). Following injury, a variety of inflammatory mediators are released 
which activate GCPRs expressed on sensory neurons. Downstream GPCR signaling, 
diverse intracellular enzymes are activated, which converge upon ion channels that 
transduce noxious input or modulate basal excitability of nociceptors (44). Specifically, 
the Gq-protein α-subunit plays an important role in pain modulation and inflammation 
(44, 45) and seems to be a relevant target site for lidocaine.
 Lidocaine inhibits m1 and m3 muscarinic receptors in clinically relevant dosages. 
Dosages needed for inhibition of m1 (IC50 = 18nM) are about 21-fold less as for m3 
muscarinic (IC50 = 370nM) signaling, which are both significantly less compared with 
those needed for VGSC blockade (60 - 200µM) (46, 47). Lidocaine binds intracellular to 
the Gq-protein α-subunit of the m1 and m3 receptor. The m1 receptor has an additional 
major extracellular binding site, which clarifies its sensitivity for lidocaine (46, 47). 
Inhibition of Gq-protein function is not restricted to Xenopus oocytes; mammalian 
Gq-protein is also inhibited by lidocaine (43). Lidocaine has a time dependent biphasic 
response on m1 and m3 receptor signaling: Initially, m1 and m3 receptors are inhibited; 
after 8 hours m1 and m3 signaling is enhanced. This enhancement may be attributed 
to an interaction with an extracellular receptor domain and subsequent modulation 
of PKC activity and receptor phosphorylation (48).
 Lidocaine inhibits immune modulatory Gαq-protein coupled receptors, such as 
lysophosphatidic acid (LPA), platelet activating factor (PAF) or tromboxane A2 (TXA2) 
receptors. Interestingly, after prolonged lidocaine administration an increased 
inhibitory potency is exhibited (49-51). LPA is an intracellular phospholipid mediator 
that is released at injury sites and has chemoattractive and priming effects towards 
human polymorphonuclear neutrophil (hPMN). PAF plays a pivotal role in inflammatory 
disorders and also can effectively prime hPMNs. hPMN are of great importance in host 
defense, as they move actively to the site of inflammation, where a multicomponent 
enzyme complex generates oxygen metabolites. Priming of hPMN potentiates the 
response of hPMNs to a subsequent activating stimulus and is a critical component of 
hPMN-mediated tissue injury. Lidocaine inhibits LPA en PAF mediated priming of 
hPMN in clinically relevant concentrations (51, 52). TXA2 is a potent platelet aggregator 
and vasoconstrictor, dosages needed for inhibition are relatively high (IC50 = 1.1mM) 
(50).
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N-methyl-D-aspartate receptor
The N-methyl-D-aspartate (NMDA) receptors are involved in rapid excitatory neuro-
transmission and modulation of nociceptive information, contributing to the 
development of hyperalgesia and chronic pain (9, 53). NMDA receptors are protein 
complexes composed of two classes of co-assembling subunits: the essential subunit 
GluN1 and the modulating subunit GluN2 (A-D). 
 Hahnenkamp et al. (54) and Gronwald et al. (55) expressed human GluN1/GluN2A 
NMDA receptors in Xenopus oocytes and stimulated these with glutamate/glycine. 
Lidocaine inhibits the NMDA receptor in a dose dependent manner via an intracellular 
binding site. Addition of structural derivates of lidocaine, revealed NMDA receptor 
binding is stereoselective. Various mechanism of NMDA receptor inhibition have been 
proposed: altering receptor phosphorylation state as a result of PKC pathway 
inhibition (55), binding to various sites on the NMDA receptor (56), or modulation of 
the glycinergic system (57). Lidocaine dosages needed for NMDA receptor blockade 
are relatively high (IC50 = 0.8 – 1.2mM).
Glycinergic system
Glycine serves a dual role in central neurotransmission. It is not only an obligatory 
inhibitory neurotransmitter, but also a coagonist at the excitatory NMDA receptor. 
These actions depend on extracellular glycine levels, which are regulated by glycine 
transporter 1 (GlyT1) and glycine transporter 2 (GlyT2). GlyT1 is responsible for removal 
of glycine from the synaptic cleft, whereas GlyT2 is required for re-uptake of glycine 
into nerve terminals, allowing neurotransmitter reloading of synaptic vesicles (58). 
During high neuronal activity, glycine released from inhibitory interneurons escapes 
from the synaptic cleft, reaches nearby NMDA receptors by so-called spillover and 
facilitates NMDA receptor currents (59, 60). Lidocaine exerts a biphasic response on 
the glycine receptor. Low dose lidocaine (10µM) enhances and high dose lidocaine 
(1mM) inhibits glycinergic signaling (61). Werdehausen et al. (57) revealed that not 
lidocaine, but its metabolites mediate the actions on glycinergic transmission by 
inhibiting GlyT1 in clinically relevant concentrations (55µM). Inhibition of glycine 
re-uptake reduces glycine binding to the NMDA receptor and subsequent activation.
3.2  Mechanism of action of lidocaine: In vivo research
3.2.1  Research in animals
Acute pain (Table 3)
Woolf et al. (62) and Sotgiu et al. (63) investigated the effects of iv lidocaine on 
neuronal activity and the site of action of in rats. Iv lidocaine (1 - 5 mg·kg-1) suppresses 
polysynaptic C-fiber evoked flexor response to noxious heat and chemicals, without 
blocking the conduction block at the peripheral nerve (62). Iv lidocaine reduces 
responsiveness of wide dynamic range neurons to noxious evoked activity, but not to 
spontaneous activity or non-noxious stimuli (63). In an acute pain rat model using a 
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formalin test, pretreatment with lidocaine significantly reduces thermal hyperalgesia 
measured by paw withdrawal (64). Agonists of glycine binding sites at the NMDA- 
receptors inhibit these nociceptive effects, implicating lidocaine or its metabolites to 
have a modulating effect on glycinergic signaling (65). These studies implicate 
lidocaine to have a selective effect on nociceptive transmission at the level of the 
spinal cord. 
 Small studies evaluating the effect of iv lidocaine on acute pain in dogs, demonstrate 
lidocaine to provide some analgesic effects. Lidocaine has comparable results with 
meloxicam (66) or has no extra analgesic effect in addition to opioids during 
ovariectomy (67), although it reduced preoperative inhalation anesthetic need (67). 
During ocular surgery, iv lidocaine provides similar post-operative analgesia as 
morphine (68). During orthopedic or soft tissue surgery, iv lidocaine reduced 
significantly supplemental intra-operative analgesic usage (69). Though, no anti- 
nociceptive effects were observed in conscious dogs, even if they showed signs of 
mild to moderate sedation (70). Dogs received a bolus of 1 - 2 mg·kg-1 followed by an 
infusion of 1.5 - 3 mg·kg-1·h-1.  
 Iv lidocaine during abdominal surgery has in some horse studies beneficial effects. 
Two studies showed a reduction in length of stay and incidence of postoperative ileus 
in horses, which is often a fatal complication (71, 72), although no difference in pain 
assessment was obtained (72). A recently performed study found no beneficial effects 
of iv lidocaine in 36 horses scheduled for a laparotomy for colic (73).
Chronic (neuropathic) pain (Table 4)
Various dosages of iv lidocaine provide analgesia in rat models based on nerve 
constriction injury. Lidocaine silences ectopic neuroma and dorsal root ganglion 
discharge without affecting nerve conduction. The median effective dose of lidocaine 
for blocking dorsal root ganglion cells was significantly lower than for neurons at the 
injury site (74). Lidocaine attenuates allodynia after nerve ligation and reduces ectopic 
discharges in injured afferent fibers (75). Sotgiu et al. (76) found lidocaine (4 mg·kg-1) 
to reduce receptive field and hyperesthetic sensation for 35 min. Dorsal horn neurons 
were more sensitive as ganglionic neurons (76). Agonists of the glycine-binding site at 
the NMDA-receptors inhibit nociceptive effects, indicating an general glycine-like 
action of lidocaine or its metabolites (65). Thus, reduction of peripheral and central 
excitability is most likely a component of lidocaine’s analgesic properties.  
 Constant rate infusion of lidocaine results in a prolonged alleviation of allodynia 
in nerve-ligated rats without affecting motor function (64, 77). These long lasting 
analgesic effects were not achieved after intrathecal or perineural administration (77). 
Lidocaine has a threshold value (2.1 µg·mL-1) and a ceiling effect for relief of allodynia 
(78).  
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Anti-inflammatory effects (Table 5)
Iv lidocaine exerts anti-inflammatory effects during the acute inflammatory response. 
Timing of lidocaine administration seems to be a critical factor in its efficacy. 
Pretreatment with lidocaine in a rabbit endotoxemia model induced by Escheria coli 
reduces release of complement and cytokines and PMN activation, and improves lung 
mechanics (79). Early posttreatment slightly attenuates endotoxin-induced lung 
edema, without affecting chemical mediators in bronchoalveolar lavage fluid (80). 
In another endotoxin rabbit model, lidocaine administered immediately after endotoxin 
injection reduces release of IL-6 and IL-8 and improves hemodynamics (81). Acute lung 
injury induced by phospholipase A2 and trypsin is attenuated when phospholipase A2 
is co-administered with lidocaine (82). Similar dosages were used (B: 2 - 3 mg·kg-1 + CRI 
2 mg·kg-1·h-1) in these rabbit studies. 
 Iv lidocaine (2.5 - 5 mg·kg-1·h-1 for 7 days) during septic peritonitis in mice reduces 
tumor necrosis factor α (TNF-α), ICAM-1 and chemokines, improves organ dysfunction 
and reduces mortality (83).
 In an endotoxemia model in horses induced by lipopolysaccharide (LPS), lidocaine 
reduced discomfort and levels of TNF-α in plasma and peritoneal fluid (84). Rats 
receiving an intravenous bolus or aerosolized lidocaine before treatment with LPS had 
lower levels of cytokines in bronchoalveolar fluid of IL-1β and TNF-α, without changes 
in plasma cytokine level (85). 
 Studies evaluating iv lidocaine during reperfusion injury show varying beneficial 
effects depending on the species and reperfusion injury model used. Lidocaine 
attenuates ischemic injury, improves mucosal barrier (86), and reduces mucosal 
cyclooxygenase 2 and plasma levels of prostaglandin E2 in the equine jejunum after 
surgery (87). Lidocaine (3 - 4 µg·mL-1) reduces reperfusion injury and improves gas 
exchange in lung allografts in dogs by inhibiting PMN adhesion and subsequent 
neutrophil migration. Neutrophils mediate post-ischemic tissue injury by oxygen 
radical and proteolytic enzyme release (88). Pretreatment with iv lidocaine reduces 
infarct size after reperfusion in a murine myocardial ischemia model most likely due a 
reduction of hypoxia induced apoptosis. Lidocaine had no effects on leucocyte rolling 
or adhesion (89). In a porcine model of myocardial ischemia, lidocaine had no effect 
on myocardial damage. However, retrograde infusion before coronary reperfusion 
reduces myocardial infarct size (90). 
3.2.2. Clinical studies
Acute pain (Table 6)
Sun et al. (14) performed a meta-analysis of 21 trials concerning iv lidocaine during 
open and laparoscopic abdominal surgery. Lidocaine reduces pain scores, opioid 
consumption, postoperative nausea and  vomiting (PONV), length of stay (LOS) and 
duration of ileus. In some of these trials, an attenuation of postoperative rise of proin-
flammatory cytokines is revealed. Vigneault et al. (13) and Mc Carthy et al. (12) 
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confirmed the beneficial effects in gastrointestinal surgery, although iv lidocaine has 
no or minimal impact on postoperative analgesia or outcome in cardiac surgery, 
gynecologic procedures, tonsillectomy and  total hip arthroplasty. Mc Carthy et al. 
performed a systematic review of 16 trials, which described specifically the effects of 
iv lidocaine on different subtypes of surgery. Vigneaults meta-analysis included 29 
trials, was more extensive and provided a comprehensive understanding of lidocaine 
on perioperative outcomes. 
 Randomized control trials published after these meta-analysis confirm the 
beneficial effects of perioperative iv lidocaine in gastrointestinal surgery (91-93). 
However, Yon et al. (93) found no difference in PONV and LOS in patients undergoing 
gastrectomy.
 Iv lidocaine has differing efficacy in other types of surgery. Iv lidocaine has no 
influence on LOS, postoperative pain, return of bowel function or inflammatory and 
stress response measured by plasma cortisol levels and CRP in major laparoscopic 
renal surgery (94). Iv lidocaine improves pain scores from 5.5 to 4.4 on an 11-point 
Likert scale, reduces 48h opioid requirements by approximately 25% and patients 
exhibit greater physical scores at 1 and 3 months after major spine surgery (95). In 36 
patients undergoing breast surgery no difference in intraoperative or postoperative 
opioid consumption was found (96). Nevertheless, postoperative pain scores were 
reduced at 4 hours and a significant reduction of chronic pain and hyperalgesia was 
observed at 3 months follow up (11.8% vs 47.4%). Terkawi et al. (97) found no difference 
in pain scores, opioid consumption, PONV and LOS in 71 patients undergoing breast 
surgery. Long-term effects were not evaluated in this study.
Chronic (neuropathic) pain (Table 7)
Challapalli et al. (15) performed a Cochrane review of 30 RCT concerning the efficacy of 
iv lidocaine and its oral analogues on relieving neuropathic pain in 2005. The treatment 
intervention was iv lidocaine in16 trials, mexelitine in 12 trials, sequential mexelitine 
and iv lidocaine in one study and tocainide in one study. Iv lidocaine and mexelitine 
were more effective as placebo in decreasing neuropathic pain. 
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In a subgroup analysis, iv lidocaine tended to be more effective for relieving 
neuropathic pain caused by diabetes, trauma or cerebrovascular disease. No serious 
adverse effects were observed during these studies. However the number of studies 
was relatively small and their methodology not always consistent. Minor side effects 
occurred in about 35% of the patients compared to 12% of the patients allocated to 
placebo. The most common adverse effects were sleepiness, fatigue, nausea, dizziness, 
perioral numbness and metallic taste. Since 2005, many other trials have been 
published that explored the use of iv lidocaine for chronic (neuropathic) pain. 
 Three randomized crossover trials, examining the effect on neuropathic symptoms 
and pain, found differing results in neuropathic pain syndromes. Lidocaine (5 mg·kg-1 
in 30 min, iv) relieves spontaneous pain and brush evoked dysesthesia in 24 patients 
with spinal cord injury but without effect on cold allodynia, pinprick hyperalgesia and 
pain evoked by repetitive pinprick (98). 
 In a small group of 13 patients with nerve injury, lidocaine (5 mg·kg-1, iv) reduces 
brush evoked pain and cold allodynia and has a tendency to reduce spontaneous pain. 
The presence of mechanical allodynia did not predicted response to lidocaine (99). 
Conversely, lidocaine (5 mg·kg-1 in 30 min, iv) had minimal to no effect on spontaneous 
pain, brush evoked pain or cold allodynia in 20 patients with nerve injury. Lidocaine 
reduced pain evoked by repetitive pinprick (100).
 Tremont-Lukats et al. (101) investigated lidocaine (5 mg·kg-1 in 6h, iv) versus placebo 
in 31 patients with variable causes of peripheral neuropathic pain in a randomized 
crossover trial. Lidocaine was more effective than placebo in relieving neuropathic 
pain, and pain reduction persisted for 4h after discontinuation of infusion. Lidocaine 
(5 or 7.5 mg·kg-1 in 4h, iv) reduces significantly severity and quality of pain for 14 days 
and persisted for up to 28 days in 15 patients with intractable diabetic neuropathy 
(102). No difference in analgesic effect was found between saline, lidocaine 1 mg·kg-1 
and lidocaine 5 mg·kg-1 in patients with neuropathic pain as a result of failed back 
surgery syndrome (103).
 Some retrospective studies imply a beneficial effect of iv lidocaine in chronic pain 
syndromes. In a retrospective chart review of 768 patients acutely admitting to a 
hospice; patients receiving iv lidocaine for pain relief were evaluated. A great deal of 
them had neuropathic pain symptoms (78%) and 52% of the 61 patients were opioid 
refractory. Significant pain reduction was achieved in 50 patients (82%), partial 
response in 5 patients (8%) and no response in 6 patients (10%) (104). Iv lidocaine 
during 5 days reduces pain, thermal and mechanical allodynia and inflammatory 
symptoms for 3 months in 76% of patients presenting with CRPS. In general, by 6 
months, CRPS factors had returned to baseline (105). Iv lidocaine reduced pain in 68 
cases of refractory chronic daily headache for averagely 8.5 days (106). Adolescents 
receiving lidocaine (2.4 - 3.6 mg·kg-1·h-1, iv) for refractory headache or neuropathic 
pain had reduced pain scores during 80% of the infusions. Only minor side effects 
were reported, which resolved quickly after discontinuation of infusion (107). 
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In vitro studies 
• VGSC are inhibited in a dose and use dependent manner and enhances a transition 
to slow inactivation; both these effects result in a more prolonged inhibition of 
VGSC. Lidocaine has differing effects on VGSC isoforms: Nav 1.4 = Nav 1.8 > Nav 1.7 
and TTXs > TTXr. Inhibition of VGSC attenuates upregulation of inflammatory 
mediators, like iNOS, CAT-2, TLR-4, NF-κβ.
• Calcium currents are inhibited by lidocaine in relatively high dosages, and can be a 
contributing factor in reducing membrane hyperexcitability.
• Lidocaine inhibits VGPCs, voltage independent potassium channels, TASK-1 and 
TASK-2; lidocaine’s affinity for potassium channels is about 6-fold lower compared 
with VGSCs. Though, inhibition of outward potassium currents promotes sodium 
channel inactivation by causing partial depolarization. Inactivated sodium channels 
are more sensitive to lidocaine. Inhibition of ATP-sensitive potassium channels 
attenuates cytokine induced cell injury.
• The Gq-protein α-subunit of GCPR is a relevant target site for lidocaine. Inhibition is 
time- and dose-dependent and plays a role in PAF- and LPA-mediated inflammatory 
processes. 
• Inhibition of NMDA receptor and glycinergic signaling contributes to reduction of 
hyperalgesia and wind up seen in acute as well as chronic pain conditions. 
Animal studies
• Iv lidocaine affects hyperexcitable neuroma, dorsal root ganglion neurons and 
dorsal horn neurons without affecting normal nerve conduction. Dorsal horn 
neurons are more sensitive to lidocaine as peripheral neurons. It should be noted 
that an effect on supraspinal pathways further has to be elucidated.
• Pretreatment with lidocaine reduces hyperalgesia mediated by an effect on 
glycinergic signaling in rats.
• Decline in peroperative analgesia in dogs and postoperative analgesia. Iv lidocaine 
reduces LOS and improves bowel function in horses.
• Lidocaine reduces proinflammatory cytokines and neutrophil migration during the 
acute phase of the inflammatory response in endotoxemia and reperfusion injury 
models in horses, rats and rabbits. Lidocaine reduces acute lung injury in rabbits. 
Clinical studies
• During abdominal surgery, iv lidocaine reduces pain scores, opioid consumption, 
PONV, LOS and some studies reveal an attenuation of IL-6, IL-8 and IL-1 receptor 
antagonist. Lidocaine has no clear beneficial effect during cardiac, THP, laparoscopic 
renal surgery and tonsillectomy. Recent studies demonstrate iv lidocaine to have 
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prolonged analgesic effects during complex spine surgery and to reduce chronic 
pain after breast surgery.
• Iv lidocaine reduces pain in chronic pain syndromes, especially neuropathic pain 
caused by diabetes, trauma or cerebrovascular disease. Neuropathic symptoms like 
brush evoked pain, cold allodynia or pinprick hyperalgesia can be reduced by 
lidocaine. Iv lidocaine has a possible role in chronic daily headache and intractable 
pain in advanced cancer.  
Dosing of lidocaine
The therapeutic range for pain treatment seems to be between 1 - 5 µg·mL-1 (108, 109). 
Lidocaine bolus 2 mg·kg-1 followed by continuous infusion of 2 - 3 mg·kg-1·h-1 reaches 
plasma levels of 2 - 4 µg·mL-1 (110). Minor side effects like light-headedness, periorbital 
numbness, vertigo or sedation can develop in therapeutic concentrations. Plasma 
levels above 5 µg·mL-1 can cause gradual symptoms of cardiovascular or central 
nervous system toxicity. Cardiovascular compromised or patients with a reduced liver 
or kidney function are more at risk for developing toxicity symptoms (111). 
 Based on the current literature we can recommend to administer a bolus of 1.5 - 
2 mg·kg-1 followed by a continuous infusion of 1.5 - 2 mg·kg-1·h-1 perioperatively. Pretreatment 
with lidocaine reduces the hyperinflammatory response; therefore start of infusion 
seems to be a critical factor. Duration of infusion ranges from discontinuation direct 
postoperative until 24 hours postoperative. Most likely, perioperative administration 
is sufficient because modulatory action on the inflammatory response primarily takes 
place during surgery and sustained lidocaine concentrations in cerebrospinal fluid 
extend beyond infusion time (112). However, in vitro studies showed a time dependent 
enhancement on GCPR (48, 49). 
 For neuropathic pain syndromes, mostly a bolus of 5 mg·kg-1 is administered over 
a period ranging from 30 minutes till 6 hours. It is not clear whether a short or prolonged 
infusion time improves analgesic efficacy. 
Clinical administration of intravenous lidocaine
After tissue injury, inflammatory mediators and immune cells reduce firing thresholds 
of Aδ- and C-fiber nociceptors and cause acute pain (6). Tanelian et al. (113) found 
lidocaine to inhibit tonic discharges in acutely injured Aδ- and C-fibers in clinically 
relevant concentrations (5.7 µg·mL-1); concurrently lidocaine reduces a hyperinflam-
matory response. Both these mechanisms contribute to lidocaine’s efficacy in acute 
pain syndromes. However, until now iv lidocaine is only proven to be beneficial during 
abdominal surgery. This can be explained by the additional central anti-hyperalgesic 
effect of lidocaine (65), and reduction of sympathetic tone (114). Hyperalgesia is found 
in patients undergoing bowel surgery with peritoneal irritation, which induces 
inhibitory gastrointestinal reflexes. More studies are needed to evaluate the effects of 
iv lidocaine on the neuroinflammatory response during other types of surgery like 
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breast surgery, complex spine surgery or major orthopedic surgery; and studies which 
report long term results after perioperative iv lidocaine.
 Chronic pain results from persistently generated impulses to the central nervous 
system due to ongoing inflammation or nerve injury (7, 8), which induce conformational 
changes in ligand- and voltage gated ion channels and NMDA-receptor activation 
(7, 9). Concurrently, proinflammatory cytokines and algesic mediators contribute 
to the persistence of chronic pain (3, 10). Iv lidocaine reduces pain and neuropathic 
symptoms in nerve injury syndromes, however not very consistently. A plausible 
explanation is the distinct underlying pathophysiological mechanisms in neuropathic 
pain syndromes. Although lidocaine blocks all sodium channel isoforms, it has an 
increased sensitivity for TTXs, Nav 1.4 and  Nav 1.8. Therefore, pain syndromes with 
an increased expression of these VGSC may be particular sensitive to lidocaine. 
An increased expression of sodium channels in dorsal root ganglia and around the 
injury site of injured axons contributes to spontaneous firing of nerve fibers after 
injury (74). Both Nav 1.7 and Nav 1.8 play specific roles in the neurobiology of neuro - 
pathic pain and are upregulated in inflammatory and  neuropathic pain states (20). 
An increased expression of Nav 1.8 is observed in neuromas (115, 116). An increased 
expression of Nav 1.3, 1.7, 1.8 and 1.9 isoforms is observed in neuronal cell bodies 
following inflammatory lesions (115, 117). It would be interesting to investigate the 
effects of iv lidocaine on some specific sodium channel opathies, like erythromelalgia 
or oxaliplatin induced acute neuropathy; however, no studies have evaluated this 
until now.
Limitations
There are some shortcomings that need to be taken into account when considering 
the findings of this review. 
 A limitation of in vitro and in vivo studies is the variety of dosing regimens and 
methodology, making it hard to draw definite conclusions about lidocaine’s efficacy or 
compare between studies. Moreover, extrapolation of dosages from in vitro to in vivo 
situation encounters some difficulties. Whereas iv lidocaine in vivo induces favorable 
effects at clinically relevant concentration (1 - 15µM equals 0.3 - 4.5 µg·mL-1), in vitro 
concentrations to block ion channels or receptors are frequently higher to achieve the 
desired effect. One difference between in vivo and in vitro studies is the exposure time 
to lidocaine: exposure in most in vitro settings is 10-30 minutes, compared with hours 
or days in vivo. Comparable therapeutic and toxic plasma levels in animals and humans 
have been described in literature, so extrapolation of lidocaine dosages from animal 
to a clinical situation should be more convenient. 
 Furthermore, a problem in placebo-controlled studies is that most subjects 
experience some minor side effects, therefore bias cannot be ruled out. Additionally, 
long-term effects, like development of chronic pain after surgery, duration of analgesic 
effects in case of chronic pain treatment or whether attenuation of the hyperinflam-
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matory response induces subsequent immune suppression, have not been conclusively 
documented.  Finally, the main limitation of most studies is small study size. 
Conclusions
This review describes the current literature concerning in vitro mechanisms and 
in vivo efficacy of iv lidocaine in acute and chronic pain. Iv lidocaine reduces ectopic 
discharges, hyperalgesia, and modulates the inflammatory response, which is 
mediated by an inhibitory effect on VGSC, VGCC, potassium channels, the NMDA- 
receptor, glycinergic system and Gαq-protein pathways. Animal studies show pain 
relieving effects in neuropathic pain syndromes and anti-inflammatory effects during 
the first phase of a hyperinflammatory response. Clinical studies demonstrate 
lidocaine to have a beneficial effect in abdominal surgery and in some neuropathic 
pain syndromes. We recommend more trials to be performed, with larger study size 
and impeccable methodology to determine the effect of iv lidocaine on the neuroin-
flammatory response in acute and chronic pain. More research has to be done 
assessing optimal dosing regimen of iv lidocaine and the effects of the lidocaine’s 
metabolites. Considering amide local anesthetics share common properties and the 
potential of iv lidocaine, investigation of the efficacy of other amide local anesthetics 
seems only a matter of time.
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Mechanical ventilation (hit one) during surgery (hit two) is often needed and both 
induce an inflammatory response. Dysregulation of the inflammatory response can 
cause chronic postoperative pain.
Methods
Healthy C57BL6 mice (n = 56) were mechanically ventilated (MV) and allocated to 
receive sham (MV-sham) or mechanically ventilation with chronic constriction injury 
(MV-CCI) surgery in the left hind paw. Plasma interleukin (IL)-1β, IL-6, IL-10, keratinocyte 
derived chemokine (KC) and tumor necrosis factor (TNF)-α were determined on day 0 
and 16. Sensory testing was performed on day 0, 3, 7 and 16 by cold plate test (number 
of lifts (NOL) and cumulative reaction time (CRT)) and von Frey test. The effect of 
lidocaine on cytokines and sensory testing was analyzed. 
Results
MV-Sham showed an increase in IL-1β and TNF-α, and MV-CCI-lido increased levels of 
KC compared with MV on day 0. No difference in cytokine levels was observed on day 
16. NOL of the left paw versus the right was increased in MV-CCI on day 7, and in 
MV-CCI-lido on day 7 and 16. The NOL of the left paw was decreased in MV-sham and 
MV-CCI-lido compared with MV-CCI on day 16.
The CRT of the left paw was increased for MV-CCI on day 3 and 7, and for MV-CCI-lido 
on day 7. On day 16, MV-sham and MV-CCI-lido showed a decreased CRT of the left 
paw compared with MV-CCI. 
Conclusion
Nerve injury and not systemic inflammatory response seems mandatory for 
development of neuropathic pain in this ‘two-hit’ model. Lidocaine attenuates cold 
allodynia in mice.
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Introduction
Several studies have been investigating ‘two-hit’ models in trauma or surgical patients 
(1). In the ‘two-hit’ hypothesis, the initial insult primes the host as a first step. 
An activating event subsequently triggers the immune system, resulting in an augmented 
immune response (2, 3). During surgery patients are often exposed to multiple hits, 
like the surgery itself and mechanical ventilation. The response to surgical injury is a 
combination of complex physiological and behavioral changes with an important role 
for the local and systemic immune system (4). The severity of injury seems to correlate 
with the inflammatory response (4, 5) involving interleukin (IL)-6, IL-1, IL-8 and tumor 
necrosis factor α (TNF-α) (5). After injury the host defense is aimed at restoring 
homeostasis, and the release of anti-inflammatory and proinflammatory cytokines 
seems equally important (6). Most patients are being ventilated during surgery. 
Mechanical ventilation (MV) without surgery can result in an inflammatory response, 
characterized by release of inflammatory cytokines and influx of immune cells such as 
neutrophils (7-10).
 Interestingly, dysregulation of the inflammatory response can play a role in pain 
after surgery and the development of chronic pain (11-15). Inflammatory mediators 
released at the site of injury cause a reduction in firing threshold of afferent nerve 
endings, i.e. peripheral sensitization (16) and an upregulation of voltage gated sodium 
channels (17). Proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 induce acute or 
short-term and chronic hyperalgesia and allodynia which results from ongoing input 
in the central nervous system and subsequent central sensitization (18). 
 Additionally, perioperative nerve injury is a major risk factor for developing chronic 
postoperative pain (16). However, nerve transection does not always lead to neuro - 
pathic postoperative pain (19).
 Current strategies for prevention of chronic postoperative pain consist of 
identification of patients at risk, administering multimodal analgesia and using nerve- 
sparing surgical techniques (20). Until now these have a suboptimal efficacy and more 
mechanism-based treatment strategies are warranted. 
 Intravenous lidocaine seems to be an interesting agent for prevention of post -
operative neuropathic pain, since it interacts with the inflammatory response and 
has anti-hyperalgesic properties mediated by an inhibitory effect on ion channels and 
receptors. It attenuates the neuroinflammatory response in perioperative pain and 
chronic neuropathic pain (14, 21, 22). 
Animal pain models representing the clinical situation and contributing to the etiology 
of persisting pain states after surgery are needed. A chronic constriction injury (CCI) 
model, ligating the sciatic nerve, is frequently used to study neuropathic pain in animal 
models (23, 24). However, in many of the current available CCI models animals are not 
mechanically ventilated, and most patients are ventilated during surgery.
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In this study we aimed to create a murine ‘two-hit’ model by combining CCI (hit one) 
and mechanical ventilation (hit two). We investigated the postoperative inflammatory 
response after chronic constriction injury (CCI) versus sham, and we determined 
mechanical and thermal allodynia after mechanical ventilation (MV) and CCI versus 
sham. Secondly, we analyzed if intraperitoneally administered lidocaine could modulate 
the postoperative inflammatory response and the development of thermal and 
mechanical allodynia.
Material and methods 
All experiments were approved by the Regional Animal Ethics Committee in Nijmegen 
and performed according to the guidelines of the Dutch Council for Animal Care and 
The National Institutes of Health. 
Animals
Studies were performed in C57BL/6J male mice (n = 56; Charles River). Female mice 
were excluded due to possible hormonal influences. Mice were acclimatized to their 
environment and were aged between 8 - 12 weeks for the start of the experiment, 
with a mean weight of 24 gr. Mice were housed in a light and temperature controlled 
room under specific pathogen free (SPF) conditions. Standard pelleted chow (1.00% 
Ca; 0.22% Mg; 0.24% Na; 0.70% P; 1.02% K; SSNIFF Spezialdiäten GmbH, Soest, 
Germany) and drinking water were available ad libitum.
Study Groups
Animals (n = 56) were divided into 2 separate groups and the experiment consisted 
of 2 parts. 
 During the first part (n = 32) of the experiment we investigated the inflammatory 
systemic response after surgery, comparing MV (n = 8), MV-sham (n = 8), MV-CCI (n = 8) 
and MV-CCI with systemic low dose lidocaine (MV-CCI-Lido, n = 8) (Figure 1).
 In part 2 (n = 24), we investigated in MV-sham (n = 8), MV-CCI (n = 8) and 
MV-CCI-lido (n = 8) the effect of low dose lidocaine on the development of neuropathic 
pain with postoperative sensory testing on day 3, 7 and 16 (see paragraph ‘postoperative 
testing’) and measured the inflammatory response on day 16 (Figure 2). 
 Previous investigations demonstrated cytokine levels of unventilated mice are 
below or extremely close to detection limits; therefore an unventilated group was not 
included (10, 25, 26).
 Lidocaine or NaCl 0.9% was administered via an intraperitoneal catheter in 
equivalent volumes. A bolus of lidocaine 1.5 mg·kg-1 was administered before start of 
surgery followed by continuous infusion of 2 mg·kg-1·h-1 till end of surgery (27). Mean 
duration of lidocaine administration was 2 hours. 
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Figure 1. First part of experiment, lasting 2.5 hours.
WT=wildtype, MV=Mechanical ventilation, CCI=chronic constriction injury.
Figure 2. Second part of experiment lasting 16 days. 
WT=wildtype, MV=Mechanical ventilation, CCI=chronic constriction injury.
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Mechanical ventilation and surgical procedure
Both sham and CCI-mice were operated. Before surgery, the mice received carprofen 
subcutaneously according to their weight (0.1 ml carprofen per 10 gram). The mice 
were anesthetized using isoflurane inhalation (1 - 4%). After oral intubation with a 20 
gauche catheter, the mice were mechanically ventilated (MiniVent®, Hugo Sachs 
Elektronik- Harvard Apparatus, March-Hugstetten, Germany). The ventilation settings 
used were based on measured tidal volume and respiratory rate during spontaneous 
ventilation in C57Bl/6 mice (28): a tidal volume of 8 ml·kg-1 body weight and a 
frequency of 150·min-1. All animals received 4 cm H2O positive end-expiratory pressure 
(PEEP), and fraction of inspired oxygen was set to 0.4. Rectal temperature was 
monitored continuously and maintained between 36.0°C and 37.5°C using a heating 
pad. Under a dissecting microscope, the left common sciatic nerve was exposed at 
the level of the mid-thigh by dissecting through the biceps femoris. In the CCI-mice 
three ligatures (silk 6.0) were loosely tied around the sciatic nerve proximal to the 
nerve trifurcation (while taking care to preserve epineural circulation), at about 1 mm 
spacing, until they elicited a brief twitch in the related hind paw. The muscle layer 
was then stitched and the incision in the shaved skin layer was closed using clips. 
Sham-mice had only sciatic exposure without ligation and were used as controls. 
After surgery the mice received carprofen subcutaneously once a day according to 
their weight on day 1 and day 2 in order to provide analgesia from a human perspective. 
On day 10, the clips were removed. 
General well being
In the second part of the experiment in the first week after surgery, animals were 
weighted daily. When they lost too much weight (> 30% directly postoperative or 20% 
in the days after surgery) or did not recover within 1 week the humane endpoint had 
been reached and the animal was excluded from the experiment and consequently 
postoperative pain testing. They were also tested on activity, state of the surgical 
wound and eventual damage on the left feet or toes (by autotomy). 
Postoperative testing
Responses to thermal and mechanical stimuli were tested in all mice before (baseline) 
and 3, 7 and 16 days after surgery. 
 Thermal allodynia was measured using the Cold Plate test. The mice were exposed 
to a temperature of 2 - 2.5°C to regain the best response. Measurements were 
performed on both the ipsilateral and contralateral hind paws. Mice were scored for 
5 minutes on scratching with the paw, jumping and lifting up the paw in the same 
place and licking on the toes. The amount of lifting of the hind paw was measured 
and analysed as number of lifts. Also the amount of jumps was counted and the 
duration of reaction was measured and analysed as cumulative reaction time (23, 29). 
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 Mechanical allodynia was measured using the Von Frey test, before surgery, 
on day 3, 7 and 16.  Mechanical allodynia was induced by application of pressure of the 
skin (30). Mice were placed in a test cage with a wire mesh metal floor and the rigid tip 
of a von Frey filament (punctuate stimulus) was applied to the skin of the mid plantar 
area of the hind paw until it bended. Different filaments, ranging from 0.145 to 5.1 
gram, made of nylon, were used to an increasing force, starting below the threshold of 
detection (hair number 7 or 8; 0.145 - 0.320 gram) and increasing until the animal 
removed its paw. Withdrawal threshold of ipsilateral and contralateral paws was 
measured 3 - 5 times and the maximal force before withdrawal was the mean of the 
evaluations (31). 
Cytokine analysis 
After the animals were killed during anesthesia, blood was collected by exsanguination 
and centrifuged at 14,000 rpm (Eppendorf 5414 C; Nether-Hinz GmbH, Hamburg, 
Germany) for 2 min, and plasma was stored at -80°C.
 As described previously (27), a Luminex® assay was used to determine plasma 
cytokine levels of TNF-α, IL-6, IL-10, KC and IL-1β  (Milliplex, Millipore, Billerica, MA). 
Lower detection limits were as follows: IL-1β: 40 pg·mL-1; TNF-α: 32 pg·mL-1; IL-6: 160 pg·mL-1; 
IL-10: 16 pg·mL-1 and KC: 160 pg·mL-1.  
Statistical Analysis
For both parts of the experiment separate power analysis were performed.
First part: We performed a sample size calculation based on previous investigations 
considering a difference of 40% in cytokine levels between ventilated and control 
mice with a type 1 error of 5% (α = 0.05) and a power of 80% (β = 0.2) (10, 25, 32). This 
resulted in a group size of 8 animals per group. 
 Shapiro-Wilk tests showed that data were not normally or log normally distributed. 
Data are therefore expressed as median with interquartile range [IQR] and depicted 
as column bar graphs. Differences between control versus lidocaine and between 
ventilated groups were studied using Mann Whitney tests. Statistical analysis was 
performed using Graphpad Prism 5 software (Graphpad Software, La Jolla, USA). 
P-values < 0.05 were considered significant.
 Second part: The experimental group size calculation for the behavioural test is 
performed based on previously published information [26], using the following 
formula: n = 1 + 2C(s/d)2 (33) to compute sample size for continuous variables where s 
is an estimation of the standard deviation of the variable, d is the magnitude of 
the difference we wish to be detected, and C is a constant dependent on the value 
of α and β selected.  C = 10.5 for α = 0.5 and 1 - β = 0.9, then sample size is n = 1 + 21 x 
(5/10)2 = 6.25. This analysis showed that to detect differences of 10% with a power of 
90% and statistical significance at the P < 0.05 level, 7 mice per group are needed. 
Therefore all groups originally started with n = 8. Results of the behavioural tests were 
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 96
96
CHAPTER 4
normally distributed and are presented as mean values with standard error of the 
mean. All statistical analyses were performed with Graphpad Prism 5 software 
(Graphpad Software, La Jolla, USA). Pre-operative measurements were compared with 
post-operative measurements using Mann Whitney tests. Comparisons between left 
and right hind paw were made by a paired samples T-test. A P-value of  < 0.05 is 
considered statistically significant. 
Results 
General well being
We used isoflurane as a monoanesthetic  during surgery. We observed some hiccupping 
during monoanesthesia with isoflurane and a somewhat longer recovery time compared 
with previous experiments where we performed CCI in spontaneous breathing mice.
 During part 1 of the experiment, one of eight animals died during intubation in MV 
and in MV-CCI-lido group. In MV-CCI group, one of eight animals died during ventilation. 
 During part 2 of the experiment, one of eight mice was excluded from the 
experiment with paralysed hind extremities in MV-sham group. In MV-CCI group two 
of eight mice died the day after surgery. No autotomy was observed. 
Cytokine analysis
During part 1 of the experiment (day 0), MV-Sham (n = 8) showed a significant increase 
in IL-1β and TNF-α compared with MV (n = 7). MV-CCI-lido (n = 7) showed a significant 
increase in KC compared with MV. No significant differences were observed for IL-6 
and IL-10, although they were elevated in MV-sham, MV-CCI (n = 7), MV-CCI-lido 
compared with MV (Figure 3).
 During part 2 of the experiment (day 16), no difference in cytokine levels were 
observed between MV-sham (n = 7), MV-CCI (n = 6) and MV-CCI-lido (n = 8) (Figure 4).
Cold plate test – number of lifts
The number of lifts (NOL) of the left and the right hind paw were determined in the 
cold plate test. 
Differences in NOL between left (CCI) and right hind paw were determined. 
MV-sham showed no differences between both hind paws on several consecutive 
days. The NOL of the right paw were significantly decreased compared with the left 
paw in MV-CCI on day 7. The NOL of the right paw were significantly decreased 
compared with the left paw in MV-CCI-lido on day 7 and 16 (Figure 5).
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 97
97
NEUROPATHIC PAIN, THE CYTOKINE RESPONSE AND LIDOCAINE’S EFFECTS HEREON IN A MURINE CCI-MODEL
4
Figure 3. Cytokine levels in plasma after 2 hours MV. 
Levels of interleukin (IL)-1β, IL-6, IL-10, keratinocyte derived chemokine (KC) and tumor necrosis factor (TNF)-α 
keratinocyte derived chemokine (KC), in ventilated mice (MV, n = 7) compared with MV sham mice (MV-sham, 
n = 8), MV chronic constriction injury (CCI) mice (MV-CCI, n = 7) and MV-CCI mice receiving lidocaine at 1.5 mg 
per kilogram per hour (MV-CCI-lido, n = 7). 
MV-Sham showed an increase in IL-1β compared with MV. MV-CCI lido showed an increase in KC compared 
with MV. MV-Sham showed an increase in TNF-α compared with MV. Data are expressed as median with 
interquartile range [IQR]. (* = P < 0.05)
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Figure 4. Cytokine levels in plasma 16 days after surgery. 
Levels of interleukin (IL)-1β, IL-6, IL-10, keratinocyte derived chemokine (KC) and tumor necrosis factor (TNF)-α 
keratinocyte derived chemokine (KC), in MV-sham (n = 7), MV-CCI (n = 6) and MV-CCI-lido (n = 8). 
No differences were observed between the different groups. 
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine
Data are expressed as median with interquartile range (IQR). (* = P < 0.05)
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Figure 5. Number of lifts (NOL) comparing left (CCI) versus right paw on day 0, day 3, 
day 7 and day 16 ), in MV-sham, MV-CCI and MV-CCI-lido mice.
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine.
Data are expressed as mean with standard error of the mean (SEM). (* = P < 0.05)
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The differences between groups of NOL of the left paw were also investigated.
The number of lifts of the left paw was decreased in MV-sham compared with MV-CCI 
and significant lower in MV-CCI -lido compared with MV-CCI mice on day 16 (Figure 6). 
Cold plate test – cumulative reaction time
The cumulative reaction time (CRT) was determined in the cold plate test. 
Differences between the CRT of the left (CCI) and right paw were determined. We 
observed no differences in CRT of the left and right hind paw on day 0, 3, 7 and 16 in 
the MV-sham mice. The CRT of the left paw was significantly increased compared with 
the right hind paw in MV-CCI mice on day 3 and day 7. In MV-CCI-lido mice the CRT of 
the left paw was increased on day 7 (Figure 7). 
Figure 6. Number of lifts (NOL) of the left paw measured by cold plate comparing  
MV-sham, MV-CCI and MV-CCI-lido mice on day 0, day 3, day 7 and day 16.
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine.
Data are expressed as mean with standard error of the mean (SEM). (* = P < 0.05)
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Figure 7. Cumulative reaction time (CRM) measured by cold plate comparing  
left versus right paw in MV-sham, MV-CCI and MV-CCI-lido mice on day 0, day 3,  
day 7 and day 16.
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine. 
Data are expressed as mean with standard error of the mean (SEM). (* = P < 0.05)
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The differences between groups in CRT of the left paw were also investigated. The 
CRT was higher in MV-CCI mice than in MV-sham mice on day 16. CRT was also higher 
in MV-CCI mice than in MV-CCI-lido on day 16 (Figure 8).
Von Frey test – maximal force before withdrawal
The maximal force before withdrawal was tested in the von Frey test. MV-CCI-lido 
scored lower in the left hind paw on maximal force before withdrawal than the right 
hind paw on day 16 (Figure 9).
No differences in maximal force before withdrawal of the left paw were demonstrated 
comparing the different groups (Figure 10).
Figure 8. Cumulative reaction time (CRM) of the left paw measured by cold plate 
comparing MV-sham, MV-CCI and MV-CCI-lido mice on day 0, day 3, day 7 and day 16.
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine.
Data are expressed as mean with standard error of the mean (SEM). (* = P < 0.05)
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Figure 9. Maximal force of withdrawal by von Frey comparing left versus right paw in 
MV-sham, MV-CCI and MV-CCI-lido mice on day 0, day 3, day 7 and day 16.
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine.
Data are expressed as mean with standard error of the mean (SEM). (* = P < 0.05)
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To our knowledge, this is the first study, which investigates in a murine model a 
‘two-hit’ inflammatory response on the development of pain and the effect of 
lidocaine on this inflammatory response and pain. We found that MV (hit one) induces 
a rise in acute phase cytokines and surgery (hit two) has a an additive effect on the 
inflammatory response. Additionally, CCI but not sham surgery or MV leads to the 
development of neuropathy in mice. Lidocaine decreases thermal allodynia.
Inflammatory response
Earlier experimental models showed an augmentation of the inflammatory response 
after multiple or sequential hits (1, 34). Fan et al. demonstrated that neutrophil 
recruitment to the lung was increased when hemorrhagic shock was followed by 
inoculation of LPS, if compared to hemorrhagic shock alone (35). Li et al. demonstrated 
Figure 10. Maximal force of withdrawal of the left paw measured by von Frey 
comparing MV-sham, MV-CCI and MV-CCI-lido mice on day 0, day 3, day 7 and day 16.
MV = Mechanical Ventilation, CCI = chronic constriction injury, Lido = lidocaine.
Data are expressed as mean with standard error of the mean (SEM). (* = P < 0.05)
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an increase in plasma TNF-α, IL-1 and IL-10 in a two-hit LPS stimulated ARDS rat model 
(36). Several other trials focussed on modulation of this hyperinflammatory response 
in order to reduce organ dysfunction (34).
 We demonstrated a significant rise of IL-1β, TNF-α in MV-sham and of KC in 
MV-CCI-lido; and there was a tendency of increased levels of IL-6 and IL-10 in MV-sham, 
MV-CCI and MV-CCI-lido compared with MV. These results seem to support that 
surgery induces an additional inflammatory reaction, compared with mechanical 
ventilation alone. After injury, TNF-α and IL-1β will rise initially and then stimulate the 
production of IL-6 and IL-8 (IL-8 equals KC in mice), which subsequently intensifies the 
inflammatory response (6). 
 Although, lidocaine reduces proinflammatory cytokines and neutrophil migration 
during the acute phase of the inflammatory response (22), this was not demonstrated 
in our experiment. In a previous investigation we have demonstrated an increase of 
IL-10 after 4 hours of MV with systemic administration of lidocaine (27). Other 
investigations demonstrated lidocaine to attenuate activated endothelial IL-1, IL -6 
and IL-8 concentrations and ICAM-1 expression in vitro (37, 38) and reduces levels of 
TNF-α, IL-1β, IL-6 and Il-8 in animal endotoxemia models (39-41). 
 Unfortunately, in MV, MV-CCI-lido and MV-CCI one mouse died and this can 
account for statistical drawbacks since we did not meet the number of animals we 
had determined in the power calculation. This may be an explanation for not finding a 
difference in all measured postoperative cytokines and modulating effect of lidocaine 
on the postoperative inflammatory response. Additionally, the entire procedure lasted 
only 2 hours and not all measured cytokines can reach peak concentrations in such a 
short period of time (42, 43).
 Previous literature describes an acute phase response to MV but also to anesthetic 
drugs (44). Isoflurane has been shown to attenuate the inflammatory response after 
MV (45). Carprofen attenuates IL-6, induced by LPS in equine synoviocytes (46); and it 
decreases interferon-γ, TNF-α, IL-17 and increases expression of IL-10 in cows (47). Thus, 
very likely carprofen interacts with cytokine synthesis, however this effect is equal for 
all mice.
No differences in systemic cytokine levels were observed after 16 days. Cytokine levels 
were almost below detection limits, indicating a return to preoperative status consisted 
with previous investigations (10, 25, 32). A limitation is that cytokine measurements on 
day 16 are performed in different animals. 
Pain
An increase in thermal and mechanical allodynia was revealed in MV-CCI mice, and a 
sham operation did not lead to alter sensory testing. This indicates that although a 
systemic inflammatory response is caused by sham operation and MV, nerve injury is 
needed for altered sensory testing in our ‘two-hit’ model. Perhaps a more extended 
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surgical procedure or an infectious component without neurological damage, will alter 
sensory testing after surgery as has been shown in a model of inflammatory pain (48).
 Mice receiving lidocaine had significantly less symptoms of cold allodynia on day 16 
measured by NOL and in CRT in the cold plate tests. Several studies indicate that 
perioperative intravenous lidocaine can reduce postoperative complications and 
neuropathic pain (22). Lidocaine acts like an anti-hyperalgesic and anti-inflammatory 
agent mediated by an effect on voltage-gated sodium channels in damaged nerves 
and inhibits the release of nociceptive mediators by keratinocytes (49, 50). Lidocaine 
targets neuropathic pain by a decrease in ectopic discharges and prevention of central 
hyperalgesia (51-53). We did not find a significant difference in the von Frey tested 
groups, however this could be attributed to a power problem since two mice died in 
the CCI group. 
 We used cold plate testing to asses cold allodynia and von Frey testing to asses 
mechanical allodynia.
 Cold allodynia is mediated by C- and Aδ-fibers and mechanical allodynia by 
Aβ-fibers through peripheral and central sensitisation, although the exact underlying 
mechanisms are not completely understood (54). Cold allodynia in mice can mimic 
cold allodynia observed in patients (55). Cold plate testing has high behavioural 
variability and is mainly used for neuropathy models (56, 57). Von Frey testing to 
determine mechanical allodynia can reliably be used in mice (56, 57). During cold plate 
testing we found high baseline values with high variability (figure 5, 7). We believe 
that habituation is a contributing factor in the gradual decline of our measurements 
and perhaps a longer period of acclimatization should be applied in research with cold 
plate testing in mice (58). Concerning the von Frey testing, the bending forces applied 
by Von Frey filaments can be influenced by ambient humidity, temperature, washing 
and drying (59). Increased weight of the CCI mice during the experiment could also 
be a conflicting factor in the von Frey test (60). 
 These findings insinuate lidocaine to have a greater effect on Aδ-fibers and 
C-fibers than on Aβ-fibers and to prevent central hyperalgesia, since it has been posed 
that mechanical allodynia is caused by central sensitization (54).
Moderate to severe pain after surgery can lead to a reduction in the quality of life in 
the immediate postoperative period,  is an important reason for delayed discharge 
and can lead to chronic pain (61, 62). Since this is the first ‘two-hit’ animal model 
investigating the effect of the inflammatory response on postoperative pain further 
studies are needed. Since mice are genetically modifiable, chronic constriction injury 
research in mice could create opportunities in exploring the role of inflammatory 
receptors or channel pathology in neuropathic pain, and subsequent development 
of new treatment targets. Investigating the effects of a more extended surgical 
procedure or an infectious component without neurological damage on the 
inflammatory response and development of pain, would be of interest. Secondly, 
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cytokine measurements on several consecutive moments in the postoperative phase 
will reveal more insights in the postoperative inflammatory response and correlation 
with postoperative chronic pain. Thirdly, study of the mechanisms contributing to 
altered sensory testing caused by lidocaine is needed, since modulation of the 
inflammatory response and nociceptive processing by lidocaine may offer strategies 
to reduce postoperative neuropathic pain. Further studies are needed to assess the 
effect of other anesthetics in this murine model, for example ketamine, dexmedeto-
midine and opioids that are known for their anti-inflammatory and pain modulating 
effects (5, 63).
Conclusion
The current study indicates that surgery (CCI) induces an additional inflammatory 
response if combined with mechanical ventilation in a murine model.  Although, both 
induce a systemic inflammatory response, nerve injury seems mandatory for 
development of neuropathic pain in this ‘two-hit’ model. Lidocaine attenuates cold 
allodynia in healthy mice. 
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An imbalance in peri-operative cytokine response may cause acute pain and 
postoperative complications. Anesthetic drugs modulate this cytokine response, but 
their role in non-major breast cancer surgery is unclear. In an exploratory study, we 
investigated whether intravenous lidocaine and dexamethasone could modulate the 
cytokine response into an anti-inflammatory direction. We also evaluated interrela-
tionships between cytokine levels, pain scores and postoperative complications. Our 
goal is to develop multimodal analgesia regimens optimizing outcome after breast 
cancer surgery. 
Patients and methods
Forty-eight patients undergoing a lumpectomy were randomly assigned to placebo 
or lidocaine (1.5 mg·kg-1 followed by 2 mg·kg-1·h-1) supplemented by dexamethasone 
zero, 4 or 8 mg, yielding six groups of eight patients. Interleukin (IL)-1β, IL-1Ra, IL-6, 
IL-10 levels and pain scores were measured at baseline and 4 hours postoperatively. 
We assessed postoperative complications occurring within 30 days. We noted persistent 
pain and infections as potential immune-related complications (PIRC). We used multiple 
regression to disentangle the effects of the individual study drugs (given by their 
partial regression coefficients (b)). Odds ratios (OR) estimated the link between pain 
scores and complications. 
Results
Dexamethasone 8 mg increased IL-10 (b = 12.70, 95%CI = 8.06 – 17.34; P < 0.001). 
Dexamethasone 4 mg and 8 mg decreased the ratio IL-6/IL-10 (b = -2.60, 95%CI = -3.93 
– -1.26; P < 0.001; and b = -3.59, 95%CI = -5.04 – -2.13; P < 0.001, respectively). We could 
not show modulatory effects of lidocaine on cytokines. High pain scores were linked 
to the occurrence of PIRC’s (OR = 2.028, 95%CI = 1.134–3.628; P = 0.017). Cytokine levels 
were not related either to acute pain or PIRC.
Conclusions
Dexamethasone modulated the peri-operative cytokine response into an anti- 
inflammatory direction. An overall lidocaine effect was not found. Patients with higher 
pain scores suffered from more 30-day PIRC’s. Cytokine levels were not associated 
with pain or more postoperative complications, even not with PIRC. Larger studies in 
breast cancer surgery are needed to confirm these explorative results.
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Plain language summary
Cytokines are small proteins that are crucial in controlling the activity of the body’s 
immune system. The body’s response to an injury or other trigger like surgery is called 
‘inflammation’.
 Surgery is a cornerstone of breast cancer treatment, but induces the release 
of pro-inflammatory and anti-inflammatory cytokines. An imbalance into the pro- 
inflammatory direction results in more pain and more morbidity after an operation. 
This may contribute to the potential negative impact of breast cancer surgery on 
the quality of life in up to half of the patients. Anesthetic drugs used during surgery, 
such as lidocaine and dexamethasone, may however counteract the cytokine 
imbalance beneficially.
What is unknown?
	The impact of dexamethasone and lidocaine on cytokine responses is unclear for 
patients undergoing conservative breast cancer surgery, like lumpectomy without 
axillary lymph node dissection.
	The interrelationships between cytokine levels, pain scores and complications after 
lumpectomy are unknown.
 We investigated 48 patients undergoing breast cancer surgery to answer two 
questions. Do lidocaine and/or dexamethasone steer the immune response into a 
beneficial anti-inflammatory direction? Does an interrelationship exist between cytokine 
levels, pain scores and postoperative complications?
What this article adds
	The immune response of patients receiving dexamethasone 4 mg or 8 mg goes into 
an anti-inflammatory direction.
	Patients experiencing less pain suffer less from postoperative complications.
 Results for lidocaine were inconclusive and we could not demonstrate a link 
between patient’s cytokine levels and complications. Larger studies are thus needed 
to confirm our results and to help optimizing perioperative outcomes.
549977-L-bw-Heuvel




Surgery is a cornerstone of breast cancer treatment, but induces a systemic 
inflammatory response characterized by the release of cytokines. Proinflammatory 
cytokines like interleukin (IL)-1β, IL-6 and tumor necrosis factor alpha are released after 
tissue injury. Anti-inflammatory cytokines, like IL-10 and IL-1Ra, are also released to 
restore homeostasis (1). An imbalance between pro- and anti-inflammatory cytokines 
activates an inflammatory cascade resulting in increased postsurgical morbidity. 
Increased levels of IL-6 and ratio of IL-6/IL-10 are proven predictors for developing 
infectious complications after surgery (2-4).
 Postoperative pain, chronic pain and postoperative infectious complications 
contribute to the overall negative impact of breast cancer surgery on the quality of life 
in up to half of the patients (5, 6). Acute postoperative pain, which is a risk factor for 
the development of chronic pain (7, 8), may be related to the inflammatory responses 
after surgery (9). This may help to explain why higher pain scores after surgery 
contribute to postoperative complications, especially health care-associated infections 
(10).
 Various pharmacological regimens proved to counteract the surgery-induced 
proinflammatory response beneficially, thus reducing morbidity after operation (11). 
Dexamethasone, given in a high dose of up to 100 mg before cardiac surgery with 
cardiopulmonary bypass, shifted the cytokine profile into the anti-inflammatory 
direction (12). Intravenous (iv) lidocaine attenuates the hyperinflammatory response 
after tissue injury, thus reducing pain and improving outcomes (13, 14).
 For patients undergoing breast cancer surgery, and specifically in conservative 
surgery like lumpectomy without axillary lymph node dissection, the impact of 
dexamethasone and iv lidocaine on cytokine responses is unclear. The question 
thereby arises if a single low dose of dexamethasone could be effective enough. Four 
mg is commonly administered for its anti-emetic effect and 8 mg for its additional 
analgesic effect (15). Furthermore, the interrelationships between cytokine levels, pain 
scores and postoperative complications after lumpectomy have not yet been 
investigated. Understanding immune-mediated mechanisms underlying acute pain 
and complications could help develop multimodal analgesia regimens and optimize 
outcome after breast cancer surgery.
 Therefore, we performed an explorative study including patients undergoing a 
lumpectomy for breast cancer. First, we aimed to evaluate whether a low dose of 
dexamethasone or iv lidocaine modulates the early cytokine response into an anti- 
inflammatory direction. Second, we aimed to confirm the link between higher pain 
scores and 30-day surgical complications. Third, we aimed to investigate whether a 
proinflammatory-oriented cytokine balance is associated with higher pain scores and 
immune-mediated surgical complications.
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Material and Methods 
We consecutively performed three double blinded randomized explorative studies at 
the Alexander Monro Hospital, a non-teaching hospital (10 hospital beds) specialized 
in breast cancer care (Bilthoven, The Netherlands). The Institutional Review Board 
approved all study protocols and documents. The study was registered prior to patient 
enrollment at the European Clinical Trial Register (EudraCT 2012-002222-70; Principle 
Investigator: Prof. K.C.P. Vissers; Date of registration: November 15, 2013), and the 
protocol can be accessed at protocols.io (https://www.protocols.io/edit/targeting- 
the-inflammatory-response-after-breast-c-bc56iy9e). Procedures followed were in 
accordance with the Declaration of Helsinki and adhere to the applicable Consolidated 
Standards of Reporting Trials (CONSORT) guidelines. Participating patients gave 
written informed consent.
Patients
We assessed potential participants for eligibility during the preoperative anesthesia 
consultation. Female patients aged older than 18 years undergoing primary breast 
cancer surgery without axillary lymph node dissection were eligible for inclusion. 
Exclusion criteria were: allergy to amide type local anesthetics, myocardial ischemia 
within the previous six months, renal impairment (creatinine clearance < 60 mL·min-
1·1.73m-2) or liver function impairment (international normalized ratio > 1.8), hypo - 
kalemia (< 3.5 mmol.L-1), pregnancy or breast feeding, use of anti-arrhythmic drugs, 
chronic opioid use, a history of chronic pain, corticosteroid use, and the inability to 
provide written informed consent. 
Patient groups
In the three consecutive studies patients received no dexamethasone or dexa -
methasone 4 mg or dexamethasone 8 mg before induction of general anesthesia. In 
each of the studies patients were randomly assigned in a 1:1 ratio to one of two groups 
(iv lidocaine or iv placebo) using a sealed envelope with blocks of eight. 
 An external pharmacy delivered the blinded study medication to the anesthetic 
department in identically appearing 50 ml syringes. Lidocaine 1.5 mg.kg-1 or placebo 
(saline 0.9% in a same volume) was administered as a bolus in ten minutes before 
induction of anesthesia, followed by a continuous infusion of iv lidocaine at 2 
mg·kg-1·h-1 or placebo until one hour after end of surgery. The lidocaine dosing regimen 
is consistent with most references, but the optimal dosing is unknown (13). Potential 
adverse events caused by iv lidocaine were noted. They were reported by patients or 
observed by site staff monitoring patient’s vital signs. 
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There were four measuring points: at baseline, when patients arrived on the operation 
theater complex before surgery (t0), admission on post-anesthesia care unit (PACU) 
(t1), 4 hours after end of surgery (t2), and 30-days after surgery.
 Pain scores were assessed using the Numeric Rating Scale (NRS 0 = no pain, NRS 
10 = worst pain imaginable) (16). NRS was recorded at t0, t1, and t2. 
 Cytokine levels of IL-6, IL-10, IL-1β and IL-1Ra were measured at t0 and t2. Ethylene-
diaminetetraacetic anticoagulated blood was centrifugated immediately after 
withdrawal at 2000g for ten minutes at 4°C, after which plasma was stored at 
-80°C. Cytokines were analyzed batch-wise by Simplex AssaysTM  according to the 
manufacturer’s instructions as previously described (17). Baseline levels of low 
abundance cytokines, including IL-6, IL-10 and IL-1β, proved to be below the lower limit 
of quantification by standard enzyme-linked immunosorbent assays. The Ella micro - 
fluidic analyzer (Protein Simple, San Jose, CA, USA) was therefore used to assess 
cytokine concentrations in the fg·mL-1 to low pg·mL-1 range (18). 
 We classified any medical adverse outcome occurring between admission and 
30-days after surgery according to the Clavien Dindo Classification (CDC) of surgical 
complications. The CDC systematically scores postoperative complications in five 
grades and is a preferred method for outcome assessment after surgery (19). 
A complication with a potential immune-mediated pathway, i.e. an infection or 
persistent postsurgical pain, was noted as a potential immune-related complication 
(PIRC) (3, 9, 20). The study physician searched retrospectively for complications and 
then classified them according to CDC. A medical researcher, who was not involved in 
the study or patient’s care, checked the records to ensure completeness of data. 
Perioperative management
Acetaminophen 1 gr PO was given one hour before operation. We induced anesthesia 
with iv propofol and sufentanil and maintained it with continuous infusion of iv 
propofol supplemented with sufentanil according to clinical needs. The total dose of 
sufentanil at end of surgery was recorded. Intraoperative monitoring included pulse 
oximetry, capnography, electrocardiography and non-invasive blood pressure 
measurement. Iv diclofenac 75 mg was administered at end of surgery unless there 
was a contraindication for non-steroidal anti-inflammatory drugs.
 Patients remained at the post anesthesia care unit (PACU) for at least one hour 
until discontinuation of the study medication. Postoperative nausea and vomiting, 
and the Aldrete score were assessed by nurses per standard protocols. Patients with 
NRS ≥ 4 at admission on the PACU received iv piritramide 2.5 mg at ten minutes 
intervals until NRS ≥ 3. Clonidine 75 µg was given at ten minutes intervals when, 
despite administration of piritramide, the NRS remained ≥ 4 on condition that the 
heart rate was ≥ 80 bpm and systolic blood pressure was ≥ 120 mmHg. Postoperative 
pain management on the ward consisted of acetaminophen 1 gram four times daily, 
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 119
119
THE CYTOKINE RESPONSE, ACUTE PAIN AND COMPLICATIONS AFTER BREAST CANCER SURGERY
5
diclofenac 50 mg three times daily and piritramide 0.1 mg·kg-1 six times daily as 
needed.
 After discharge patients received standard care. One week post-surgery a 
follow-up visit was scheduled with a nurse and the surgeon. Thereafter patients 
received regular clinical care by their radiotherapist, surgeon or nurse, depending on 




Our study is based upon the analysis of pooled data obtained in three consecutive 
randomized controlled trials. As this was an explorative study, no formal sample size 
calculation was made. Our results should therefore be regarded as explorative and 
hypothesis-generating.
 Results for all variables are given as mean (SD) [minimum - maximum], unless 
stated otherwise. The differences between plasma levels of cytokines at t2 and those 
at t0 are given as ΔIL-6, ΔIL-10, ΔIL-1β and ΔIL-1Ra. The balance between pro- and anti-
inflammatory cytokines is described by the ratio of IL-6/IL-10 and the ratio of IL-1β/
IL-1Ra. The differences between these ratios at t2 and those at t0 are given as ΔIL-6/
IL-10 and ΔIL-1β/IL-1Ra.
 Multiple linear regression analysis was used to evaluate the null hypothesis that 
lidocaine or dexamethasone had no effect on ΔIL-6, ΔIL-10, ΔIL-1β, ΔIL-1Ra, ΔIL-6/IL-10 
and ΔIL-1β/IL-1Ra. Descriptive analysis preceded formal statistical analysis. Based on a 
striking pattern in the dataset, we introduced ‘post hoc’ the duration of surgery as an 
independent variable. 
 Univariate binary logistic regression models using pooled data were estimated to 
evaluate the potential association between NRS at t2 and the occurrence of any 
complication according to CDC or a PIRC. The association between the cytokine levels 
and their ratios at t0 and t2 on one hand, and the occurrence of a PIRC on the other 
hand, was evaluated similarly.
 A Spearman’s Rho correlation was used to determine if NRS at t2 was related to 
each of the cytokine levels at t0 and t2.
Statistical analysis was performed using IBM SPSS Statistics V25.0 and GraphPad Prism 
V8.0 (GraphPad Software). P < 0.05 was considered statistically significant. 
Results
We analyzed data for 48 patients with eight patients in each of six groups (Fig. 1). 
 The groups were similar in respect of physical and clinical characteristics, except 
surgery duration (Table 1). All patients underwent breast conserving surgery with a 
sentinel node biopsy. The intraoperative and direct postoperative course was 
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 120
120
CHAPTER 5
uneventful. All patients could be discharged from the PACU one hour after admission 
(Aldrete score ≥ 13). 
 We supply patients’ characteristics of pooled lidocaine groups and pooled 
dexamethasone groups in the Supplementary Table S1 and all raw cytokine levels in 
the Supplementary Table S2. IL-1β levels at baseline were lower in the study with 
dexamethasone 8 mg than those in the other two studies. 
Pain and its treatment
Pain scores and pain treatment are summarized in Table 1. At t1, 94% of the patients 
had NRS ≥ 4 and 96% at t2. Opioid and diclofenac use was similar among patient 
groups during and after operation. Rescue drug clonidine was not administered in the 
third study where dexamethasone 8 mg was given alone or combined with iv lidocaine.
Figure 1.  Consolidated Standards of Reporting Trials (CONSORT) flow chart.
Study 1
No dexamethasone
November 2014 - March 2015
Study 3
Dexamethasone 8 mg
June - October 2016
Study 2
Dexamethasone 4 mg






















































































































Processed on: 29-10-2020 PDF page: 121
121
THE CYTOKINE RESPONSE, ACUTE PAIN AND COMPLICATIONS AFTER BREAST CANCER SURGERY
5
Postoperative complications
A total of 23 postoperative complications occurred in 22 (45.8%) patients (Table 1). 
Sixteen patients (33% of the total) had a CDC grade I complication. Four patients (8%) 
had a CDC grade II, and two patients had a CDC grade III complication. The groups 
were similar in respect of complications. 
 Eight patients suffered from a PIRC: persistent pain (n = 3), mucositis (1), surgical 
site infection treated with antibiotics (2), and abscess treated with antibiotics and 
surgery (2). Fourteen patients suffered from the following complications: hematoma 
(6), seroma (3), nausea (3), constipation (1), light headedness (1), and a transient 
ischemic attack (1). One of these fourteen patient suffered from two CDC grade I 
complications. 
Effects of dexamethasone and lidocaine on postoperative 
cytokine levels
Figs. 2 and 3 reveal patterns in the individual observations. Observations above the 
zero line in Figs. 2 and 3 are increases in cytokine levels or their ratios between t0 and t2. 
 In most patient groups the levels of IL-6 and IL-10 (Fig. 2A-B) and IL-1Ra (Fig. 3B) 
seemed to increase after surgery. In contrast, IL-1β levels (Fig. 3A) appeared not to 
change. Lidocaine had little or no effect on the cytokine levels and their ratios in 
comparison with placebo (Fig. 2A, Fig. 2C, Fig. 3A-C), except that it seemed to increase 
IL-10 levels when combined with dexamethasone 8 mg (Fig. 2B). Dexamethasone 4 
and 8 mg appeared to reverse ΔIL-6/IL-10 (Fig. 2C) but seemed to have no effect on IL-6 
(Fig. 2A), IL-1β (Fig. 3A), and IL-1Ra (Fig. 3B) levels. Dexamethasone 8 mg appeared to 
increase the IL-10 level (Fig. 2B). Fig. 2C and Fig. 3C suggest that a longer duration of 
surgery increased ΔIL-6/IL-10 but decreased ΔIL-1β/IL-1Ra.
 Multiple regression confirms our descriptive analysis and untangles the separate 
effects of lidocaine, dexamethasone 4 mg, dexamethasone 8 mg and duration of 
surgery (Table 2). An overall effect of lidocaine on measured cytokines was not found. 
There is only suggestive evidence that dexamethasone 4 mg increased IL-10 level (P = 
0.045; positive ‘b’ in Table 2 means increase). Dexamethasone 4 mg decreased IL-6/
IL-10 (P < 0.001; negative ‘b’ means decrease). Dexamethasone 8 mg increased the 
IL-10 level (P < 0.001) and decreased IL-6/IL-10 (P < 0.001). As a ‘post hoc’ independent 
variable the duration of surgery increased postoperative IL-6 levels (P = 0.026) and 
IL-6/IL-10 (P=0.04), but decreased IL-1β/IL-1Ra (P = 0.016). ). E.g. the result for surgery 
time in Table 2 means that the average increase in IL-6 level was 0.162 pg·mL-1 per 
minute or 9.72 pg·mL-1 per hour of surgery time, independently from the other 
independent variables.
 IL-1Ra increased from 268 pg·mL-1 to 8075 pg·mL-1 in one patient of the 
dexamethasone 8 mg - lidocaine group (Fig. 3B). As this outlier was not an influential 
observation, it was not excluded from regression analysis. 
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Figure 2. Difference (Δ) between interleukin (IL)-6, IL-10 plasma levels and  
ratio IL-6/IL-10 at baseline (t0) and those 4 hours after surgery (t2) in six groups 
(n=8 per group).
Each symbol represents one patient. A symbol above or below the zero line represents an increase or decrease, 
respectively, from t0 to t2. Error bars are the 25th-75th percentiles around the medians. (a) Observations for 
ΔIL-6 and (b) for ΔIL-10 per group. (c) Observations for the ratio ΔIL-6/IL-10 per group and linear regression of 
the pooled observations on the duration of surgery. The full regression line is accompanied with dotted lines 
showing its 95% confidence limits. There is one missing value in the group dexamethasone 8 mg with placebo 
for ΔIL-10 and ΔIL-6/IL-10. Plac = placebo, Dexa = dexamethasone, Lido = lidocaine.
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Figure 3. Difference (Δ) between interleukin (IL)-1β, IL1Ra plasma levels  
and ratio IL-1β/IL-1Ra at baseline (t0) and those 4 hours after surgery (t2) in six groups 
(n=8 per group).
Each symbol represents one patient. A symbol above or below the zero line represents an increase or decrease, 
respectively, from t0 to t2. Error bars are the 25th-75th percentiles around the medians. (a) Observations for 
ΔIL-1β and (b) for ΔIL-1Ra per group. (c) Observations for the ratio ΔIL-1β/IL-1Ra per group and linear regression 
of the pooled observations on the duration of surgery. The full regression line is accompanied with dotted 
lines showing its 95% confidence limits. Plac = placebo, Dexa = dexamethasone, Lido = lidocaine.
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Relationships between cytokine levels, pain scores  
and postoperative complications
Patients who experienced higher pain scores at t2 seemed to be prone to suffer from 
any complication according to CDC within 30-days after surgery (OR = 1.464, 95%CI = 
0.941 – 2.278; P = 0.091) (Table 3). A statistically significant association exists between 
having postoperative pain and the occurrence of a PIRC: the odds ratio associated with 
a one-point increase in NRS is 2.028 (95%CI = 1.134 - 3.628; P = 0.017). This implies that 
patients who score an NRS of 5 have eight times the odds of having immune-related 
complications as those with an NRS of 2 (2.0283 = 8.341, where the exponent 3 is the 
difference between 5 and 2).
 Cytokine levels showed no relation with the occurrence of a PIRC (Table 3), 
although there is some suggestive evidence that the preoperative ratio of IL-6/IL-10 
could relate to the occurrence of a PIRC (OR = 2.918, 95%CI = 0.848 – 10.047; P = 0.089).
Table 3.   Relationships between cytokine levels, pain scores and postoperative 
complications.
Odds ratio (95% CI) P
NRS t2 1.464 (0.941 – 2.278)† 0.091
t2 2.028 (1.134 – 3.628)‡ 0.017
IL-6 t0 1.359 (0.918 – 2.010) 0.125
t2 1.036 (0.992 – 1.082) 0.113
IL-10 t0 0.690 (0.207 – 2.301) 0.546
t2 1.053 (0.963 – 1.151) 0.255
IL-6/IL-10 t0 2.918 (0.848 – 10.047) 0.089
t2 1.196 (0.917 – 1.559) 0.186
IL-1β t0 0.321 (0.007 – 14.874) 0.561
t2 0.802 (0.228 – 2.822) 0.731
IL-1Ra t0 1.003 (0.999 – 1.007) 0.136
t2 1.000 (0.999 – 1.001) 0.940
IL-1β/IL-1Ra* t0 0.521 (0.167 – 1.623) 0.261
t2 1.251 (0.601 – 2.605) 0.549
Odds ratios with 95% confidence intervals (CI) obtained from univariate binary logistic regressions estimating the 
association between pain scores or cytokine levels on one hand and the occurrence of a 30-day complication on 
the other. For pain scores, which were obtained with Numeric Rating Scale (NRS) at 4 hours after operation (t2) the 
dependent variable was the occurrence of any complication according to the CDC† or only a potentially immune-
related complication‡ (PIRC). For cytokine levels and two of their ratios at baseline (t0) and t2, the dependent 
variable was the occurrence of a PIRC. NRS was associated with PIRC in these univariate analyses. *Results for IL-1β/
IL-1Ra are to be multiplied by 10-3.
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 No correlation was found between NRS at t2 and cytokine levels at t0 or t2. 
The low P-value (P = 0.078), for the correlation between postoperative IL-10 levels and 
pain scores at t2 might be regarded as ‘indicative’. However, no correction for the 
number of tests was done  (Supplementary Table S3). 
Discussion 
This prospective explorative study in 48 patients undergoing a lumpectomy for breast 
cancer has several findings, but the small sample size in each group precludes drawing 
firm conclusions. Dexamethasone 4 mg or 8 mg, but not iv lidocaine, modulated 
the early cytokine response into an anti-inflammatory direction. Raw cytokines levels 
were not clearly related with postoperative pain scores or the occurrence of a PIRC. 
However, there was suggestive evidence that a more pro-inflammatory cytokine 
balance at baseline could result in more PIRC’s.
 Despite the small number of patients, we may be more confident in the evidence 
supporting a link between higher pain scores noted 4 hours postoperatively and PIRC 
in our homogenous group of patients as our finding accords with previous research 
(10). In a cohort of 1014 patients undergoing a broad spectrum of surgeries, higher 
pain scores or unacceptable pain after surgery were associated with more 30-day 
complications, especially health care-associated infections (10).
 Anesthetic agents may aid to improve postoperative outcomes (21, 22) by counter -
acting the neuroendocrine stress response to surgery or through a direct effect on 
immune cells. The choice of anesthetic agents can even be crucially important for 
patients with pre-existing immune dysfunction or tumor burden (21) (22). However, 
the impact of lidocaine or dexamethasone, which have different immune-modulating 
effects on cytokine responses, has not been investigated after lumpectomy.
 Iv lidocaine is known to reduce a hyperinflammatory response (13), and to decrease 
proinflammatory cytokines in abdominal surgery (23, 24). Under the circumstances of 
our study no overall effect of lidocaine on postoperative cytokine levels was found. 
Most likely, lumpectomy is a surgical procedure with less inflammatory stimuli (23), 
where lidocaine may have little effect. 
 Dexamethasone’s anti-inflammatory effects depend on its dosage in relation to 
the extent of tissue trauma. After high dose corticosteroids for major abdominal or 
thoracic surgery, earlier reports demonstrated a shift towards an anti-inflammatory 
balance characterized by suppressed IL-6 and increased IL-10 levels, while effects on 
IL-1 and IL-1Ra levels were absent or showed a decrease (12, 25, 26). A lower dose, 
like dexamethasone 8 mg, during abdominal surgery had no effect on IL-10 levels, and 
reduced (27) or showed no effect on IL-6 levels (28). As lumpectomy can be regarded 
as minimally invasive surgery, when compared with abdominal or cardiac surgery, 
a less pronounced increase of pro-inflammatory cytokines could be expected. 
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Accordingly, we found a decrease in IL-10 levels and in the ratio IL-6/IL-10, but no 
significant effect on the levels of IL-6 and IL-1β. Surprisingly, patients in the third pilot 
study had pre-existent lower levels of IL-1β, which could have masked a potential 
effect of dexamethasone 8 mg on the postoperative IL-1β levels in this group.
Increased IL-6 levels proved to be related to infectious complications (3, 4) and higher 
pain levels (29, 30). Also in pathological pain models, elevated expressions of IL-6 and 
IL-1β in the spinal cord and dorsal root ganglia have been found (31, 32). In our study we 
found a link between higher pain scores and more PIRC’s, suggesting a similar 
underlying immune-mediated mechanism. However, we failed to find a statistically 
significant relation between cytokine levels and pain scores or PIRC’s. Besides a small 
sample size, potential explanations are: the postoperative cytokine response was 
influenced by dexamethasone, the postoperative inflammatory response was minimal, 
the time of measurement was not well chosen, or the range of pain scores was too 
small. Interestingly, patients with a pre-existent higher IL-6 to IL-10 ratio tended to 
develop more postoperative complications, which can indicate a vulnerability in a 
subset of patients.
 Our study was not powered to find a statistically significant difference in 
postoperative pain scores between patient groups, but a clear pattern was present. 
All patients, who received dexamethasone 8 mg, did not need extra clonidine as 
rescue analgesic. Those patients who received also lidocaine, apart from the dexa -
methasone 8 mg, had no pain immediately after surgery. These findings accord with 
those of others (33-36). 
 Our study has important limitations that are to be avoided in future research. 
We performed the three studies in a consecutive order so that dexamethasone 
was not blindly administered (Fig.1). This may have influenced expectations and 
subsequently postoperative pain scores. A further limitation was the small number 
of patients in each group. Thus, negative results are to be interpreted with caution. 
Furthermore, we only measured cytokine levels measured at a single time point post-
operatively. Hence, we cannot draw any firm conclusions whether the early post -
operative immune imbalance could explain the acute pain and complications. Lastly, 
we used current literature (3, 9, 20) to designate not only infections but also pain as 
complications with a potential immune-mediated mechanism. Notwithstanding, we 
conceivably missed other specific immune-mediated complications which could have 
influenced our results.
 A strength is that we performed a single center study with a small team and 
a strictly protocolized environment. Consequently, inclusion rate was rather low. 
An extra delaying factor was that we had to switch from a standard to a more sensitive 
measuring method to assess very low cytokine concentrations (18). Thus, time bias 
cannot be ruled out.
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Our study suggests research subjects for future larger scale studies in patients 
undergoing a lumpectomy for breast cancer: 1) Confirming that dexamethasone 4 mg or 
8 mg, but not iv lidocaine, modulates the cytokine response into an anti-inflammatory 
direction. These effects should be evaluated by measuring cytokine levels on several 
time points postoperatively and surgery duration should be included as a variable. 2) 
Investigating the relation between acute pain and postoperative complications, 
especially PIRC’s. 3) Investigating the relation between 30-day complications and the 
preoperative ratio IL-6/IL-10 or other immune-mediated mechanisms. 
 Perioperatively a dynamic balance exists between pro- and anti-inflammatory 
cytokines. It is still an ongoing debate about the kind of immune balance we should 
aim at (22). Although larger studies are needed, we provided new pieces of information 
that may help developing a multimodal approach to the prevention of complications 
after breast cancer surgery.
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Supplementary Table 1.  Patients’ peri-operative characteristics of the pooled 
dexamethasone and lidocaine groups.











Age (yr) 57 (12) [34-75] 58 (10) [43-75] 58 (10) [47-80] 57 (11) [34-75] 58 (10) [42-80]
BMI (kg m-2) 27 (5) [20-36] 24 (4) [19-33] 25 (4) [21-35] 25 (4) [20-35] 25 (5) [19-36]
ASA physical status (n)
   1 6 9 10 10 15
   2 10 7 6 14 9
Tumour classification (n)
   Carcinoma In situ 4 3 2 5 4
   T1 9 9 11 15 14
   T2 3 4 3 4 6
Node classification (n)
   N0 15 13 12 19 21
   N1 1 3 4 5 3
Surgery duration (min) 98 (39) [35-156] 84 (29) [24-133] 66 (21) [36-109] 83 (33) [39-152] 82 (33) [24-156]











   at t0 0.5 (0.9) [0 - 3] 0.5 (1.0) [0 - 4] 0.2 (0.8) [0 - 3] 0.4 (0.8) [0 - 3] 0.4 (1.0) [0 - 4]
   at t1 1.6 (1.8) [0 – 5] 1.3 (1.6) [0 - 5] 0.9 (1.7) [0 - 6] 1.5 (1.9) [0 - 6] 1.0 (1.4) [0 - 4]
   at t2 2.1 (1.9) [0 - 7] 2.0 (1.4) [0 - 6] 2.5 (1.0) [0 - 4] 2.3 (1.5) [0 - 7] 2.0 (1.4) [0 - 6]
Diclofenac (n) 
       0 mg 1 1 1 2 1
     75 mg 12 14 15 21 20
   125 mg 3 1 0 1 3
Piritramide (mg) 8.9 (5.8) [0-20] 8.6 (5.4) [0-20] 9.7 (3.9) [5-20] 9.3 (4.7) [0-20] 8.9 (5.4) [0-20]
Clonidine (n)
      0 μg 11 14 16 21 20
    75 μg 3 2 0 2 3
   150 μg 2 0 0 1 1
30-day complications (N)
   CDC I 4 9 3 10 6
   CDC II 1 1 2 0 4
   CDC IIIb 1 0 1 1 1
Notes: Data are mean (SD) [minimum - maximum], number of patients (n) or number of complications (N). At t0 = 
baseline, t1 = direct postoperative, and t2 = 4 hours after surgery.
Abbreviations: Dexa, dexamethasone; BMI, Body Mass Index; ASA, American Society of Anesthesiologists; T, tumor 
staging; NRS, Numeric Rating Scale; CDC, Clavien Dindo Classification.
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Supplementary Table 3.  Spearman’s Rho correlation between NRS at 4 hours 




t0 IL-6 -0.041 (-0.329 – 0.254) 0.783
IL-10 -0.114 (-0.393 – 0.184) 0.439
IL-6 / IL-10 0.043 (-0.252 – 0.331) 0.771
IL-1β -0.175 (-0.444 – 0.124) 0.235
IL-1Ra 0.005 (-0.288 – 0.296) 0.975
IL-1β / IL-1Ra -0.170 (-0.440 – 0.128) 0.248
t2 IL-6 0.065 (-0.231 – 0.351) 0.658
IL-10 0.260 (-0.038 – 0.515) 0.078
IL-6 / IL-10 -0.120 (-0.400 – 0.182) 0.423
IL-1β -0.041 (-0.329 – 0.254) 0.781
IL-1Ra 0.023 (-0.271 – 0.313) 0.877
IL-1β / IL-1Ra -0.167 (-0.434 – 0.131) 0.257
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Simple surface EMG recording as 
a noninvasive screening method for 
the detection of acute oxaliplatin-induced 
neurotoxicity: a feasibility pilot study
Sandra A.S. van den Heuvel, Jonne Doorduin, Monique A.H. Steegers, 










Oxaliplatin-induced neurotoxicity can be a dose-limiting side effect to effective chemo- 
 therapy. Acute hyperexcitability causes cold-evoked sensory and motor symptoms, 
which resemble neuromyotonia. An accessible and non-invasive technique for early 
detection could help select patients for potential treatments. We assessed the use of 
a simple surface electromyography (sEMG) in patients directly after oxaliplatin 
infusion.
Methods
In  patients with colorectal cancer, acute neurotoxicity was evaluated by means of a 
physical examination, a questionnaire, and sEMG directly after the second and fourth 
cycle of oxaliplatin. Questionnaires were also assessed 1 day after infusion. 
Results
14 patients were measured after the second cycle and 8 patients were also measured 
after the fourth cycle of oxaliplatin. All patients reported to a variable degree oxaliplatin 
induced neurotoxicity symptoms: sensitivity to touching cold or swallowing cold 
items were reported as most severe. Clinical signs of hyperexcitability were observed 
in 55% of the measurements. Spontaneous activity compatible with neuromyotonia 
was observed in 82% of the sEMG recordings. 
Conclusions
Patient reported symptoms, physical examination and simple sEMG are complementary 
measurements to detect acute oxaliplatin induced neurotoxicity. After further 
validation, sEMG recording can be used as a simple objective screenings tool to detect 
nerve hyperexcitability directly after oxaliplatin administration. 
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Introduction
Oxaliplatin is a third generation platinum based antineoplastic agent used for treating 
gastrointestinal cancer (1-3). Up to 68.1% of the patients treated with oxaliplatin 
progressively suffer from neuropathy (4). This neuropathy presents with an acute form, 
which is characterized by peripheral nerve hyperexcitability immediately after 
administration of oxaliplatin, and a chronic form that manifests as a sensory neuro- 
nopathy involving the dorsal root ganglia (5, 6). Both these forms can induce symptoms 
that are severe enough necessitating dose reduction and even premature discontinuation 
of treatment (7-10).
 The acute neuropathy occurs in about 90% of the patients immediately after 
infusion of the drug. It will often diminish over the next days, only to reappear during 
the next infusion of oxaliplatin (11, 12). Symptoms include cold-induced paresthesia or 
dysesthesia of the extremities and the perioral or laryngeal region, accompanied by 
fasciculations, and muscular cramps (12-15). The mechanism for the acute neurotoxicity is a 
sodium channelopathy (16-19). This acute neurotoxicity shows substantial similarities 
with the clinical and electrophysiological presentation of neuromyotonia (15, 20) a 
disease also caused by hyperexcitability of the peripheral axon due to channelopathy. 
This hyperexcitability is usually confirmed with needle electromyography (nEMG) 
examination of muscles, when repetitive myokymic discharges and neuromyotonic 
runs can be observed (20). It can also be demonstrated by a newer technique called 
threshold tracking, but this is currently limited to research settings only (21).
 Previous studies used nerve conduction studies (NCS) (20, 22, 23), nEMG (15, 20), 
high-density surface electromyography (HD-sEMG) (24), and threshold tracking (21) 
for measuring oxaliplatin-induced neuropathy, but these methods are either not very 
sensitive for detecting acute hyperexcitability or focus on chronic neuropathy that 
occurs over time with oxaliplatin use (NCS), or invasive (nEMG), or too labor intensive 
for clinical use (HD-sEMG, threshold tracking). Very little is known yet about the ability 
of simple 2-channel surface electromyography (sEMG) to detect nerve hyper 
excitability (25-27). Bipolar surface recording of muscle activity is a noninvasive, low- 
cost, and fast technique for collecting information on muscle activation. In oxaliplatin-
i nduced neurotoxicity (OIN), sEMG may easily help to select patients for potential 
treatments that can reduce the acute symptoms (28, 29).
 In this prospective feasibility pilot study, we enrolled patients with colorectal 
adenocarcinoma, all receiving intravenous oxaliplatin treatment every 3 weeks. Acute 
neurotoxicity was assessed clinically directly after oxaliplatin infusion in cycle 2 and 4 
by a standard neurological examination and questionnaire. A simple 2-channel sEMG 
signal was recorded from a single hand muscle. As a proof of principle test, our aim 
was to determine whether a short, simple and non-invasive sEMG measurement would 
be able to detect nerve hyper excitability in patients with acute OIN. Additionally, we 
evaluated if clinical symptoms correlated with sEMG findings. 
549977-L-bw-Heuvel





Participants were recruited prospectively from December 2015 until April 2017. Eligible 
participants were aged ≥ 18 years, and received an oxaliplatin containing chemotherapy 
regimen for the (curative of palliative) treatment of colorectal adenocarcinoma. 
Exclusion criteria involved pre-existing neuropathy of any cause, previous systemic 
chemotherapy, a history of chronic pain syndrome, use of opioid analgesics ≥ 6 months, 
diabetes mellitus, alcoholism or inability to comply with testing procedures or to give 
informed consent. The study population was recruited from the Medical Oncology 
outpatient department setting at the Radboud university medical center, Nijmegen, 
the Netherlands. The study protocol was approved by the institutional review board of 
Medical Ethical Committee of Arnhem/Nijmegen and participants provided informed 
consent to use their data.
 The chemotherapy regimen consisted of intravenous oxaliplatin (130 mg·m2) 
with or without bevacizumab (7.5 mg·kg-1) in cycles of 3 weeks, which was followed by 
capecitabine (1000 mg·m2) orally twice daily for 14 consecutive day. Dose reductions 
were applied (25% reduction) when participants reported grade ≥ 3 toxicities according 
to National Cancer Institute-Common Toxicity Criteria. 
Measurements to detect acute neurotoxicity
Measurements to detect acute neurotoxicity were carried out during cycle 2 and 4 of 
the oxaliplatin treatment, since from cycle 2 on most patients tend to experience 
acute OIN symptoms (12). Day 0 is directly after oxaliplatin infusion, and day 1 is 24 hours 
after oxaliplatin infusion. On day 0 after cycle 2 and 4 sEMG recordings, a questionnaire 
and a standardized physical examination were performed. The questionnaire was 
repeated during a telephone interview on day 1.
 Surface EMG recording: Participants remained fully dressed for this part of the 
study and were placed supine on the examination table upon a heated undersurface 
set at 37°C placed below the bed sheet in order to keep the skin temperature > 30°C 
during sEMG measurements. The sEMG signal was recorded from the left first dorsal 
interosseus muscle, in a tendon-belly montage with the active electrode over the 
motor point, using reusable stainless steel disc surface electrodes (Kendall TM H59P 
Cloth Electrodes, 1 cm diameter). The screen time base was set at 100 ms/division and 
the amplitude was set at 20 µV/division. Participants were instructed to relax their 
arm and hand, using direct feedback from the running EMG signal played over 2 
loudspeakers, and additional support of a small pillow for the hand if needed. EMG 
signals were captured from the muscle for a period of 2 minutes, using a Synergy EDX 
EMG machine (Natus Neurology Incorporated, Middleton, Wisconsin USA), and stored 
as “liveplay” files for offline analysis. As a quality control measure, 2 participants in 
whom spontaneous activity was detected during the measurement were asked and 
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agreed to also undergo a single 30 gauge concentric nEMG exam of the left first dorsal 
interosseus muscle, measuring another 2 minutes of spontaneous activity at rest. 
Signals were exported for visual and auditive readback using the videocapture mode 
of the EMG machine during replay of the recorded signal. Videos were captured as .avi 
files, in addition captured signals were exported as .wav files for further quantitative 
analysis. 
 Questionnaire: Patient reported outcomes (PRO) of OIN were assessed: the 
degree of sensitivity when touching cold objects or swallowing cold food/drinks, 
throat complaints, the pain score in hands and feet (12). These items were scored using 
a numeric rating scale (NRS) from 0 (= no problem) to 10 (= major problem) (30). 
 Physical examination: The presence of calf fasciculations, action myotonia in the 
hands and eyelids was examined.
 The participant sat on a chair and the right calf was inspected for 1 minute, 
followed by active plantar flexion of the right foot for 30 seconds and again a visual 
inspection of the right calf for 1 minute. If voluntary muscle twitching was seen at rest 
or after muscle contraction, fasciculations were noted to be present (31).
 Eyelid closure action myotonia was tested by instructing the participant to close 
the eyes as forcefully as possible for 10 seconds and then rapidly to open their eyes on 
command, which was repeated 5 times. The time from the command to open the eyes 
was timed, and action myotonia was present if relaxation time was > 1 second during 
any of the trials (32). Hand-grip action myotonia was tested by instructing the 
participant to forcefully close the fingers of the right hand in a fist for 10 seconds, and 
then rapidly open the fist on command, which was repeated 5 times. The time from 
the command to open the right fist until relaxation of the handgrip muscles was 
timed and action myotonia was present if relaxation time was > 1 second during any 
of the trials (32). 
Data analysis
The clinical data collection was stored in a Castor database (Castor EDC 2017.6.1, Ciwit 
B.V.) and transferred to a SPSS Statistics file (version 22.0, IBM Corporation, Armonk, 
NY, USA) for analysis. Categorical data were presented as counts and percentages of 
cases, continuous variables were presented as mean (SD), and skewed data were 
presented as median with interquartile range. As all analyses relate to comparisons 
within participants, paired t-test were used for analysis. The correlation between PRO 
and AUC of sEMG was analyzed using the Spearman’s rank correlation coefficient.  A P 
value < 0.05 was considered to be statistically significant. Figures were created using 
GraphPad Prism, Version 5.03 (GraphPad Software Inc., La Jolla, CA, USA). 
 Qualitative analysis of the sEMG data was performed twice, by offline playback of 
the captured EMG signals from the Synergy live play files and by revision from signal 
from the videocaptured.avi files. Signals were screened by the traditional method 
of visual and auditive inspection by an experienced clinical neurophysiologist (NvA). 
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The presence or absence of any spontaneous muscle activity and any voluntary 
contraction activity was scored in a yes/no fashion and the type of activity (e.g. 
fasciculation potentials, myotonic runs, myokymic discharges, neuromyotonic 
discharges) was noted according to standard clinical practice as described by for 
example Preston and Shapiro (33). Endplate noise (i.e. low-amplitude monophasic 
negative potentials with an irregular firing rate between 20 - 40 Hz) was ignored.
 Quantitative AUC analysis of sEMG data was performed using a dedicated 
software script created by one of the authors (JD), using MATLAB version R2014b 
(The Mathworks Inc., version R2014B, Natick, Massachusetts U.S.A.). Analysis settings 
were a horizontal time axis of 1000 ms (100 ms/division) and a vertical EMG signal 
amplitude axis of - 1 mV to +1 mV (0.2 mV/division). The sEMG signals were rectified, 
and divided in 1 second epochs (10 divisions) per screen. Each epoch was manually 
scored for the presence of spontaneous activity by another author (NvA). Subsequently, 
the area under the curve (AUC) of the rectified signal was calculated above a noise 
threshold of 0.05 mV.
Results
Fourteen participants were included in the study (Table 1). All were measured for the 
first time after their second oxaliplatin infusion, and 8 participants were also measured 
a second time after the fourth infusion. 
Surface EMG recording
Spontaneous activity was found in 18 of the total of 22 (82%) sEMG recordings. It was 
found 12 times during the first measurement and 6 times during the second 
measurement. The spontaneous activity observed consisted of myokymic discharges 
and/or neuromyotonic runs of varying amplitudes and durations; no other phenomena 
were observed. Examples of electrical discharges are shown in Figure 1. This spontaneous 
activity was present in all participants measured only once. In 6 out of 8 participants 
who could be assessed twice the results were congruent, showing the presence (5/8) 
or absence (1/8) of spontaneous activity during both measurements. In 1 participant 
the activity was absent during the first measurement and present during the second. 
In the final participant measured twice, the second measurement could not be 
assessed for spontaneous activity because of continuous motor unit activation 
which could not be voluntary stopped by the participant. Needle EMG examination 
in 2 participants with myokymic discharges and/or neuromyotonia corroborated 
the surface data findings.
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Quantitative analysis showed that the AUC of the spontaneous activity varied widely 
between measurements (Median 1.6 mV·s-1, IQR 0.7 – 5.7) (Table 2). 
Patient reported outcomes 
All participants (100%) experienced at least 1 acute neuropathy symptom during 
treatment with oxaliplatin. Only 1 participant reported no symptoms directly after the 
second cycle of oxaliplatin, though this participant did experience acute symptoms on 
the following day. Most symptoms, besides throat discomfort during cycle 4, increased 
in severity the day after oxaliplatin administration. There was a wide interindividual 
variability in grading of each symptom. For all 4 measurements sensitivity to touching 
and swallowing cold were rated significantly higher than the remaining components 
of the PRO (P = 0.033 for cycle 4, day 0; P < 0.001 for all other moments; mean 
differences ranged between 3 and 5) (Figure 2). 
Figure 1. A panel showing the different forms of spontaneous activity (A = several 
multiplets, B = a neuromyotonic run, C = a combination of repetitive multiplets and  
a neuromyotonic run). 
Time scale horizontal axis: 1 s, vertical amplitude scale 20 µV/division.
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Figure 2. Boxplots are shown of patient reported outcomes on acute neurotoxicity 
symptoms induced by oxaliplatin directly after (D0) and one day (D1) after 
oxaliplatin cycle 2 (n = 14) and cycle 4 (n = 8). 
A numeric rating scale (NRS; 0: no problem, 10: major problem) was used to assess ‘sensitivity touching cold 
items’, ‘discomfort swallowing cold items’, ‘throat discomfort’, ‘muscle cramps’, ‘pain hand’ and ‘pain feet’.
Table 2.   Results of quantitative analysis of spontaneous activity (AUC in mV/s of  
the rectified surface EMG signal).









6 1.0 0.4 (75% oxaliplatin)
7 2.1 0.1
8 0.0 0.0 (75% oxaliplatin)
9 25.9
10 1.3
11 0.7 0.3 (75% oxaliplatin)
12 0.0 3.2
13 3.3
14 1.0 0.2 (75% oxaliplatin)
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Clinical signs of hyperexcitability were found in 12 of the 22 examinations (55%). 
During the physical exam after the second treatment cycle, 8 of the 14 participants 
showed signs of increased nerve hyperexcitability, with fasciculations in 7 participants, 
eyelid closure action myotonia in 1 participant, and hand-grip action myotonia in 1 
participant. After the fourth cycle, 4 of the 8 participants showed clinical increased 
nerve hyperexcitability, with fasciculations in 3 participants and hand-grip action 
myotonia in 1 participant.
Surface EMG recording and clinical measurements 
All but 1 participant who had spontaneous activity on sEMG reported neuropathy 
symptoms directly after oxaliplatin treatment. No correlation with the AUC of the 
sEMG signal and any of the neuropathy symptom on D0 or D1 was found (Rho = 0.312, 
P = 0.098 for throat discomfort on Day 0; the P value of the Pearson correlation for all 
other neuropathy symptoms with AUC had higher P values).
 In 10 out of 18 measurements in which spontaneous activity on sEMG was found, 
clinical signs of hyperexcitability were observed. Thus, during 8 measurements where 
spontaneous activity was found on sEMG, no clinical signs of increased hyperexcit-
ability were noticed. In 2 participants who had no spontaneous activity on sEMG, 
fasciculations were observed during the physical examination. 
Discussion
This study demonstrates that a simple 2-channel sEMG study of the first dorsal 
interosseus muscle is a feasible and non-invasive method to screen for objective signs 
of nerve hyperexcitability directly after oxaliplatin administration. All participants 
reported to a variable degree symptoms of acute OIN; and signs of nerve hyperexcit-
ability could be detected with physical examination in 55%, which was less sensitive 
than the sEMG (82% detection). Surface EMG recordings may have missed spontaneous 
discharges from motor units lying deep in the muscle, which hampers a 100% 
detection rate.
 Other studies have established the presence of neuromyotonic discharge patterns 
within 1 – 4 days after the first oxaliplatin administration by performing nEMG of 
different leg muscles (15, 20, 34). In 100% of the participants spontaneous high 
frequency discharges were found in 1 or more muscles when 3 muscles were sampled 
(15). We explored a simplified method and found spontaneous activity in 82% of the 
sEMG measurements of the first dorsal interosseus muscle within 1-2 hours after the 
second or fourth oxaliplatin infusion. Although nEMG corroborated our sEMG results 
in 2 participants, further study is needed to determine the optimal muscle sample size 
to detect hyperexcitability. 
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 In line with previous observations, participants reported cold evoked symptoms 
as most severe (7, 12, 16, 22). Contrary to other reports (10, 12), there was a slight 
decrease in severity of symptoms during the fourth cycle, probably caused by dose 
reduction in some participants and by other participants dropping out the study. The 
severity of the acute symptoms has been shown to be one of the risk factors for 
developing high grade chronic OIN (35), so monitoring and preferably treating these of 
symptoms is of paramount importance to ensure chemotherapy compliance. A recent 
study demonstrated that motor nerve hyperexcitability was correlated with acute 
cold induced symptoms in 12 patients within 3 days after oxaliplatin infusion (19), 
though we did not find this. 
 Our study has some limits. We excluded patients with a preexistent neuropathy, 
and we did not perform a baseline physical neurologic examination. The major aim of 
our study methodology was focused on detecting signs of hyperexcitability and 
normally no hyperexcitability is present in patients, although theoretically this could 
have biased our results. Also, during the second measurement 6/14 patients dropped 
out of the study due to a worsening clinical status, which may have influenced charac-
teristics of the PRO, the physical examination and sEMG results. Finally, we did not 
perform serial measurements on consecutive days after oxaliplatin administration, so 
it is unknown if repeated measurements could improve the detection rate further and 
how the hyperexcitability evolves over time. 
In conclusion, 2-channel sEMG is a simple, non-invasive and feasible screening tool to 
complement the subjective reported symptoms for monitoring nerve hyperexcitabili-
ty after oxaliplatin infusion. Surface EMG improves the objective detection of hyper-
excitability compared with the physical examination. Further validation of the 
technique and studying a possible correlation with chronic OIN and sEMG findings can 
help guide in future intervention studies.
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Oxaliplatin is a chemotherapeutic agent used to treat malignancies of the gastrointes-
tinal tract. Neuropathy is a frequent dose-limiting side-effect of oxaliplatin therapy, 
without preventive or curative strategies. Concomitant administration of intravenous 
lidocaine could be a promising treatment. However, the effect of intravenous lidocaine 
on oxaliplatin pharmacokinetics was never studied before. We evaluated the effect of 
lidocaine on the area under the curve (AUC) and Cmax of oxaliplatin as a part of a larger 
study addressing the prevention and treatment of oxaliplatin induced peripheral 
neuropathy (OIPN) with lidocaine. 
Methods
In this prospective cross-over trial, three patients received oxaliplatin with and without 
lidocaine (bolus 1.5 mg.kg-1 followed by 1.5 mg·kg-1·h-1). Levels of oxaliplatin, measured 
as ultrafiltrable platinum, were determined at 10 minutes after cessation of oxaliplatin 
infusion and hourly until 6 hours thereafter. Primary outcome was the mean 
percentual difference in the area under the curve (AUC) of oxaliplatin, secondary 
outcome was the percentual difference (%Δ) in the peak plasma concentration (Cmax) 
of oxaliplatin. 
Results 
No difference in the %Δ AUC of oxaliplatin was found (-2.40 (7.66); 90%CI = -15.31 - 10.50,
P = 0.641). The %Δ Cmax of oxaliplatin (-28.72 (6.01); 90%CI = -38.85 - -18.59, P = 0.014) 
was significantly decreased during administration of lidocaine. No adverse events 
were reported.
Conclusions 
Lidocaine does not affect the AUC of oxaliplatin, which is the most important 
parameter in drug interaction studies and for oxaliplatin treatment effect. The Cmax 
of oxaliplatin during lidocaine administration is remarkable decreased, but with an 
unknown exact mechanism or clinical significance, making further research desirable.
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Introduction
Oxaliplatin is a third generation platinum based antineoplastic agent used for treating 
metastasized and non-metastasized gastrointestinal cancer (1-3). Neuropathy is a 
common major dose-limiting adverse effect of oxaliplatin, which may lead to 
decreased efficacy and survival (4-6),  This neuropathy presents in an acute or chronic 
form (7), which can result in a substantial reduction of the quality of life (8).  Up to 80 
- 90% of the patients suffer from acute oxaliplatin induced neuropathy (OIN). OIN is 
characterized by peripheral nerve hyperexcitability (9), which induces cold triggered 
pain and paresthesias in the face, throat and distal extremities (10). The chronic 
neuropathy  causes distal sensory neuropathy and paresthesias (7). 
 The postulated mechanism for development of acute OIN is a sodium- and 
potassium channelopathy and inflammatory processes (11). Lidocaine, a non-specific 
sodium channel blocker, has analgesic, anti-hyperalgesic and anti-inflammatory 
properties (12-14). A previous study in rats revealed that lidocaine relieved mechanical 
allodynia and cold hyperalgesia induced by oxaliplatin (15). Thus, concomitant 
administration of iv lidocaine with oxaliplatin could be a promising strategy to prevent 
and treat OIN, which can potentially improve chemotherapeutic efficacy and quality 
of life of cancer patients. 
 The effect of iv lidocaine on the pharmacokinetics of oxaliplatin was never studied 
before, but needs to be evaluated for its safety and potential effects. Lidocaine is 
metabolized through CYP3A4 metabolism (16, 17). Oxaliplatin undergoes rapid and 
extensive nonenzymatic biotransformation and is not metabolized (17).
 Thus based on currently known pharmacokinetic profile of oxaliplatin and 
lidocaine, we hypothesized in this prospective cross-over study that iv lidocaine will 
not influence oxaliplatin pharmacokinetics.
Materials and methods
This prospective cross-over drug interaction study was conducted in the Radboudumc, 
Nijmegen, the Netherlands. The study had been approved by the local ethics 
committee (CMO Arnhem-Nijmegen) and registered at the EU Clinical Trials Register 
(2015-002202-37). Procedures followed were in accordance with the Declaration of 
Helsinki. Participating patients gave written informed consent.
Patients
All subjects were recruited at the outpatient clinic of medical oncology. Eligible 
patients were ≥ 18 years, and received at least two identical cycles of oxaliplatin for the 
treatment colorectal adenocarcinoma. Exclusion criteria involved an allergy to amide 
type of local anesthetics, recent myocardial ischemia (< 6 months), cardiac arrhythmias, 
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anti-arrhythmic drugs, renal function disorder (creatinine clearance < 60 mL·min-
1·1.73m-2), liver function disorder (bilirubin > 1.5 times the upper limit of normal), 
hypokalemia (< 3.5 mmol·L-1), pregnancy or lactating, or inability to comply with 
testing procedures or to give informed consent.
Study design
In Figure 1 the study design is presented. Patients received intravenous oxaliplatin 
dosage according to local oncology guidelines. During two consecutive oxaliplatin 
 administrations, the study measurements were performed: Cycle 1: without lidocaine, 
cycle 2: lidocaine administration. Patients received the following regimen of iv lidocaine 
from 30 minutes before until 30 minutes after administration of oxaliplatin: a bolus of 
1.5 mg·kg-1, infused in 10 minutes, followed by continuous infusion of lidocaine 1.5 
mg·kg-1·h-1. Monitoring during lidocaine administration included pulse oximetry, 
capnography, electrocardiography and non-invasive blood pressure measurement, 
and patients were observed for potential side effects (18).
 Patients received 2 intravenous lines. One for the standard treatment with 
oxaliplatin, and one for lidocaine infusion. After infusion of oxaliplatin, this infusion 
line was flushed for 10 minutes. A dummy sample was taken before the oxaliplatin 
blood sample to prevent the study sample was influenced. Thereafter the first blood 
sample was taken, the other samples were taken 1, 2, 3, 4 and 6 hours after the first 
blood sample. 
Pharmacokinetic analysis
In vivo, oxaliplatin is extremely unstable, and a nonenzymatic rapid biotransformation, 
without metabolization, takes place to form platinum derivatives as well as unbound 
platinum. It then binds irreversible to various proteins and erythrocytes. This makes it 
technically difficult to determine a reliable concentration of intact oxaliplatin in human 
blood or plasma. The unbound platinum is thought to be the pharmacologically active 
Figure 1. Graphic presentation of the study protocol. 
Asterix (*): timing of sampling.
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compound of oxaliplatin. For these reasons determination of the concentration of 
unbound platinum in ultra-filtrate is a generally accepted strategy to analyze blood 
levels of platinum containing chemotherapeutic agents as oxaliplatin (17, 19-21). Taking 
this into account, in this study the concentration of unbound platinum was analyzed 
to study the pharmacokinetics of oxaliplatin with and without lidocaine. 
 Samples were immediately centrifuged at 1500g during 10 minutes at 4̊ C. 
Hereafter the plasma was ultra-filtrated (YM-30 Microcon units, Millipore, Bedford, 
MA, USA) for 20 minutes at 2000g at 4̊ C. During the process and transport samples 
were stored on ice. After processing the samples were stored in -80˚C until analysis in 
an extern lab (22, 23).
 In ultra-filtered plasma, the unbound free platinum concentration was determined 
by inductively coupled plasma mass spectrometry (ICP-MS), where heating to 2600˚C 
takes place, upon which there is destruction to the atomic level and loose atoms are 
measured with mass spectrometry. The lower limit of quantification was 1 µg·L-1.
 The pharmacokinetic parameters were calculated by doing a non-compartmental 
analysis using Phoenix WinNonlin 6.4 software (Certara USA, Inc., Princeton, NJ, USA). 
Endpoints
Primary outcome was the mean percentual difference (%Δ) in the area under the 
curve (AUC) of the concentration versus time from the first to the last sample. 
Secondary outcome was the %Δ in the peak plasma concentration (Cmax).
Statistical analysis
According to the Guideline on the investigation of drug interactions written by the 
European Medicines Agency the 90% confidence interval (CI) was calculated for each 
pharmacokinetic parameter (24). A paired sample t-test was done to analyze the %Δ in 
AUC and Cmax of unbound platinum with and without lidocaine. The results were 
considered to be significant if the %Δ between both groups fell outside the 90%CI. 
 Since intra- and inter-patient variability of oxaliplatin pharmacokinetics is small, 
a study group of 3 subjects is sufficient to study the effect of lidocaine on the pharmaco-
kinetics of oxaliplatin (22). Data was analyzed using IBM SPSS Statistics for Windows 
version 25.0 (IBM Corp, Armonk, NY, USA, 2017).
Results
Patients
Five patients gave informed consent for participating in the study, and 2 patients were 
excluded for analysis after the first chemotherapy cycle (n = 1 wrong processing of 
blood samples, n = 1 dose reduction of oxaliplatin during the second cycle). Three 
subjects completed the study. No changes occurred in the use of other drugs in the 
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time between the two cycles, other than the start of nadroparin 11400IE once daily by 
the third patient for the treatment of venous thrombosis of the arm. Figure 2 presents 
a study flow diagram. Demographic and baseline characteristics of the patients are 
displayed in Table 1.
Pharmacokinetic parameters
Table 2 shows the pharmacokinetic parameters of free platinum in ultra-filtered 
plasma with and without lidocaine; and Figure 3 is a graphical presentation of the 
pharmacokinetic parameters. No difference was found in the AUC of oxaliplatin with 
and without lidocaine administration: %Δ in AUC of oxaliplatin -2.40 (7.66); 90%CI = 
-15.31 - 10.50, P = 0.641. The %Δ of the Cmax of oxaliplatin was lower with lidocaine 
administration: -28.72 (6.01); 90%CI = -38.85 - -18.59, P = 0.014. 
 During lidocaine infusion no adverse effects were reported and vital parameters 
remained stable.
Figure 2. Clinical trial flow diagram
Assessed for eligibility (n=5)
Included (n=5)
Analysed (n=3)
Excluded from analysis (n=0)
Discontinued intervention (n=2)
 Subject 1 (wrong processing of blood samples)
 Subject 4 (necessary dose reduction in second cycle)
Excluded (n=0)
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 159
159
LIDOCAINE’S EFFECT ON THE PHARMACOKINETICS OF OXALIPLATIN
7
Table 1.  Demographic and baseline characteristics
Patient 1 2 3
Age (years) 51 60 50
Gender Male Male Female
Weight (kg) 75.8 68.2 65.9
Height (m) 1.78 1.64 1.67
Calculated body surface (m²) 1.94 1.76 1.75
Chemotherapy regimen Cap/beva Folfb Folfb
Oxaliplatin dosage (mg) 250 90 150
Oxaliplatin dosage (mg∙m-2) 128.8 51.1 85.7
ASAT (U∙L-1) 31 43 26
Bilirubin (µmol∙L-1) 10 7 5
Creatinine clearance (mL∙min-1∙1.73m-2) 73 90 61
a Capecitabine and oxaliplatin (CAPOX) with bevacizumab;
b Folinic acid, fluorouracil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX); 
ASAT = aspartate aminotransferase
Table 2.   Pharmacokinetic parameters of free platinum in ultra-filtered plasma  
with and without lidocaine (n=3)
Subject Treatment AUC0-t (µg∙L-1∙h) Cmax (µg∙L-1)
1 OX 1712.7 1716
OX + LIDO 1812.7 1230
2 OX 620.2 504
OX + LIDO 562.6 328
3 OX 1381.73 842
OX + LIDO 1329.73 649
%Δ (SD); 90%CI -2.40 (7.66); -15.31 - 10.50 -28.72 (6.01); -38.85 - -18.59
AUC = area under curve; Cmax = maximum (or measured peak) concentration.
OX = oxaliplatin containing chemotherapy regimen; LIDO = lidocaine 
%Δ = mean percentual difference; SD = standard deviation; CI = Confidence Interval
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This study reports an unique clinical observation which explores the effect of lidocaine 
on the pharmacokinetics of oxaliplatin. There was no difference in the AUC of free 
platinum (derivative of oxaliplatin) with and without administration of lidocaine, 
Cmax of free platinum decreased with concomitant administration of lidocaine in our 
study group. 
Based on our results we cannot explain the difference in Cmax of oxaliplatin with and 
without lidocaine. Most likely, the difference in Cmax cannot be explained by a phar-
macokinetic interaction. Lidocaine is metabolized in the liver by CYP3A4 (16, 17), and 
oxaliplatin undergoes rapid nonenzymatic biotransformation and is not metabolized 
(17). Also, an in vitro interaction, using ICP-MS for analysis, can be ruled out. Lidocaine, 
after heating to 2600˚C, is broken down to carbon-, nitrogen- and hydrogen atoms, 
which have no interaction with the matrix (17). Since oxaliplatin has a short initial 
half-life time of 0.28h of oxaliplatin (17), timing of sample taking could potentially be a 
contributing factor for the difference in Cmax. However, when reviewing the study log, 
Figure 3. Concentration versus time after dose curve of oxaliplatin in ultra-filtered 
plasma with and without lidocaine (n=3)
Pt = Unbound platinum; PUF = Plasma ultra-filtrate
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timing of plasma sampling was performed strictly conform schedule. Thus potentially, 
an unknown pharmacodynamic interaction takes place, which lowers Cmax or affects 
the time of Cmax.
 Research on the correlation between the Cmax of oxaliplatin and survival in patients 
with colorectal or pancreatic carcinoma has not been reported. Dose reduction of 
oxaliplatin has not been reported to influence overall survival (25-27).
 The interaction of other antineoplastic drugs within the regimen with lidocaine 
as well as with oxaliplatin is worth consideration, as well as (changes in) comedication. 
None of the other drugs act as a CYP3A4 inhibitor, so pharmacokinetic reactions with 
lidocaine are unlikely. The different antineoplastic drugs within the regimen have a 
varied metabolism. Irinotecan is a DNA-topo-isomerase-I-inhibitor metabolized by 
carboxylesterase to SN-38 (active) and UDP glucuronosyltransferase 1A1 to SN38G 
(inactive), only partly by CYP3A4, with unchanged elimination. 5-fluorouracil (5-FU) 
and its oral prodrug capecitabine are metabolized in different tissues to 5-fluoro-deox-
uridinemono- and triphosphate (active) and dihydropyriminidine-dehydrogenase 
(inactive) with non-specific inhibition of thymidylatesynthetasis causing DNA-frag-
mentation and cell death, and has unchanged renal excretion. Bevacizumab is a 
monoclonal antibody (IgG1) binding to vascular endothelial growth factor (VEGF), 
obstructing its binding to VEGFR-1 (Flt-1) and VEGFR-2 (KDR) on the surface of 
endothelial cells. It is metabolized as endogenous IgG through proteolytic catabolism 
in multiple organs, and has non-liver or -kidney dependent elimination. Folinic acid 
diminishes the toxicity of folinic acid antagonists by competing for an influx membrane 
carrier and supplying the diminished folate pool, enhancing the therapeutic and toxic 
effect of fluoropyrimidines, with metabolization in liver and bowel to active 5-meth-
yltetrahydrofolic acid and mainly renal elimination (up to 90%). Important for the 
results, is the fact that for these drugs dose was not changed between cycles, whereby 
an influence on the differences in oxaliplatin plasma concentrations is unlikely. Also 
for nadroparin, the only comedication added (and thus changed) in between the 
cycles in one subject, pharmacokinetic interactions are unlikely. Other than pharmaco-
kinetic reactions with these drugs, as proposed with oxaliplatin, are theoretically 
possible, but were not measured (and thus addressed) within the current study. 
Within the evidently small sample size, a consistent course of plasma concentrations 
of oxaliplatin was seen, forcing critical appraisal of these results in relation to the 
clinical implications. An effect of lidocaine on the Cmax of oxaliplatin may influence 
patient safety and can bias future research on lidocaine as a promising strategy to 
treat OIN. A possible effect of lidocaine on the incidence or severity of OIN may 
actually be an effect of a reduction in the Cmax of oxaliplatin. Also, because of the 
steep drop in free platinum concentrations in our results, some uncertainty remains 
regarding the concentration (and Cmax)  from the start of oxaliplatin infusion up to the 
second sample (3 hours and 10 minutes later). 
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 Therefore, we opted for both publication of the current results, as well as 
preparing an additional and extended clinical research protocol to gain insight in the 
possible effect of lidocaine on the Cmax of oxaliplatin (mainly in the first hours of the 
administration of lidocaine with oxaliplatin) as well as the therapeutic effect of 
lidocaine on OIN. This might provide more information on these clinical implications 
and mechanisms responsible for the findings. 
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General discussion and 
recommendations for future research
The current focus of cancer treatment is on prolonging survival combined with 
maintaining a good quality of life in both the short and long term (1, 2). Pain is one of 
the most commonly reported problems in cancer survivors; it can be caused by either 
the disease process itself or its treatment (3). In this thesis, we set out to generate 
fundamental knowledge on how to improve the quality of cancer survivors’ lives, and 
to provide advice for future research and clinical explorations. 
 The treatment of chronic pain is challenging, and the prevention of the transition 
from acute to chronic pain would be a preferred option, however it is relatively 
unexplored. One of the possible mechanisms to prevent acute pain transitioning to 
chronic pain is to interfere in the inflammatory responses and/or increased hyperex-
citability phenomena. We explored options for modulating  this inflammatory 
response and hyperexcitability after surgery and chemotherapy.
The following research questions were formulated in chapter 1: 
1. Is a sodium channel blocker a treatment option for patients with chronic pain 
resulting from chemotherapy?
2. What is the current state of knowledge concerning the in vitro and in vivo 
mechanisms of iv lidocaine on the neuroinflammatory response in acute and 
chronic pain?
3. What is the role of the inflammatory response and nerve injury on the development 
of neuropathic pain: development of a two-hit murine surgical model and the 
effect of a sodium channel blocker.
4. What is the relation of the early inflammatory response with acute pain and 
postoperative complications in breast cancer surgery; and what is the effect of 
two anti-inflammatory drugs on the early inflammatory response?
5. Can surface EMG recording be used as a noninvasive screening method for the 
detection of acute oxaliplatin-induced neuropathy? 
6. What is the effect of iv lidocaine on the pharmacokinetics of oxaliplatin? 
Part I: Chronic cancer related pain and the rediscovery of an old-school drug 
Iv lidocaine can relieve pain in patients with CIPN, who are unresponsive  
to standard treatment algorithms.
In chapter 2, we published data of a pilot study with nine patients, who received 
lidocaine for intractable pain as a result of CIPN. We evaluated the analgesic efficacy 
and the effect on pressure pain thresholds and the extent of the stocking and glove 
distribution of sensory abnormalities during a simple bedside examination. Iv lidocaine 
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had a significant direct analgesic effect (pain intensity difference of > 30%, P = 0.01) in 
8 of the 9 patients. The long-term analgesic effect of iv lidocaine is moderate (average 
23 days), and was comparable to patients with diabetic polyneuropathy (chapter 3). 
In our patient group the cold (Aδ- and C-fibers) detection level was more distal than 
for pinprick (Aδ-fiber) detection. Small and large nerve sensory fibers can be affected 
after chemotherapy, and eventually motor fibers (Aα-fibers) can also be affected as 
the disease progresses (4). Importantly, we observed that lidocaine had a variable 
influence on thermal and mechanical stocking and glove distribution of the sensory 
symptoms. Although these sensory changes varied, it is interesting to note that 
a pharmacological agent can influence and even decrease sensory abnormalities. 
The drawbacks of this study are its small sample size and lack of control group, 
however it does provide a direction for further investigations.
IV lidocaine attenuates the neuroinflammatory response in perioperative 
pain and chronic neuropathic pain.
Since the neuroinflammatory response plays a key role in acute and chronic pain 
syndromes, in chapter 3 we categorized the current literature of lidocaine accordingly. 
The in vitro publications describing lidocaine’s target mechanisms in pain transmission 
show that low dose lidocaine inhibits voltage gated sodium channels, the glycinergic 
system, some potassium channels and Gαq-coupled protein receptors. Higher lidocaine 
concentrations block potassium and calcium channels, and NMDA receptors. The specimens 
and methodologies used to test of ion-channels or receptor function vary in these 
in vitro studies.  
 In vivo publications describing the effects of iv lidocaine are divided into animal 
and clinical studies. Animal studies show that lidocaine reduces peripheral and central 
nociceptive transmission without affecting normal nerve conduction suppression. 
This effect on excitability symptoms depends on the type of nerve injury, testing 
method and lidocaine dosages. Lidocaine shows anti-inflammatory effects during 
the first phase of a hyperinflammatory response. Clinical studies demonstrate that 
lidocaine reduces pain scores, opioid consumption, length of hospital stay, and pro-
inflammatory cytokines in abdominal surgery. Lidocaine’s analgesic effect in other 
types of surgery varies or is minimal, and the effect on the early inflammatory response 
has mostly not been evaluated. Lidocaine reduces neuropathic pain caused by diabetes, 
trauma or cerebrovascular disease, and has varying effects on hyperexcitability phenomena 
like brush evoked pain, cold allodynia or pinprick hyperalgesia. In these studies long- 
term analgesic effects in neuropathic pain syndromes were not always measured, 
the study groups were heterogenous and lidocaine dosages varied (5). 
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Future perspectives
Iv lidocaine followed by oral sodium channel blockers in ‘short term responders’ is a 
potential treatment option for patients with CIPN. Many trials evaluating analgesics in 
CIPN have been performed, and currently only duloxetin has been reported as having 
modest analgesic efficacy (6). A possible explanation for this is that neuropathic pain 
has been treated on the basis of the underlying etiology, but within a certain etiology 
patients can experience different negative and positive sensory symptoms caused by 
other mechanisms (e.g. heat hyperalgesia can be related to peripheral sensitization 
and pinprick hyperalgesia to central sensitization) (7). The specific sensory profile in an 
individual might cause a different treatment response (8). Several trials indicate that 
sensory phenotyping in neuropathic pain can predict drug responsiveness (7, 9). Thus, 
we advise setting up a larger and more detailed study to untangle the different patho-
phenotypes of CIPN and their responsiveness to treatment with sodium channel 
blockers (8), as is supported by recent European Medicines Agency guidelines (10). 
 We need a greater understanding of the mechanisms of action and to identify 
gaps in knowledge of specific analgesic drugs. We therefore reviewed the current 
literature on lidocaine. We conclude that to further elucidate the effect of iv lidocaine 
on the neuroinflammatory response in acute and chronic pain, the following should 
be investigated: (1) lidocaine’s effects on specific sodium, calcium and potassium 
channels, and receptors, and their interrelation; (2) the effects on aberrant electrical 
activity should be linked to specific types of nerve injury and/or ion-channel activity; 
(3) lidocaines effects on a ‘hyper-inflammatory’ response during several types of 
surgery; (4) the optimal dosing regimen of iv lidocaine and the effects of the lidocaine’s 
metabolites. 
 Although it was outside the scope of this thesis, it is important to note that a 
caveat in a mechanistic based view is the lack of the multidimensional aspects of 
chronic pain management. As noted in the thesis introduction, WHO-guidelines 
advice to prolong survival combined with maintaining a good QOL in patients 
diagnosed with cancer (1). Thus, a mechanistic approach needs to be incorporated in a 
multidimensional approach (11). 
 Another important note is that CIPN is just one example of chronic cancer-related 
pain, which has several other causes. Patients should be informed about the 
consequences of specific cancer treatments. A multidisciplinary clinical and research 
approach including oncologists, pain specialists and other physicians is needed to 
improve ‘survivorship care’. At an educational level, the incorporation of QOL 
programs in curricula will help achieve the WHO-goal.
 One of the options to reduce chronic cancer-related pain is to prevent the 
transition from acute to chronic pain by intervening in the inflammatory response or 
neuronal hyperexcitability; this is described in part II and III.  
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Part II: Perioperative inflammatory response 
Nerve injury seems mandatory for the development of neuropathic pain in  
a ‘two-hit’ murine model. Intraperitoneally administered lidocaine attenuates 
cold allodynia.
In chapter 4 we report on a prospective animal neuropathic pain model study in which 
mice (n=56) received mechanical ventilation (MV) only, sham-surgery (MV-sham), 
chronic constriction injury without lidocaine (MV-CCI) or with lidocaine (MV-CCI-lido). 
Plasma IL-1β, IL-6, IL-10, KC and TNF-α were determined on day 0 and 16. Sensory testing 
was performed on day 0, 3, 7 and 16 by cold plate test and von Frey test. The effect of 
lidocaine on cytokines and sensory testing was analyzed. 
 We found that MV (hit one) induces a rise in cytokine levels, and surgery (hit two) 
had an additive effect on the inflammatory response. No difference in cytokine levels 
was observed on day 16. A disbalance in the inflammatory response can play a role in the 
development of postoperative pain (12, 13). In most murine CCI models, animals are 
not mechanically ventilated during surgery and MV induces an inflammatory response 
(14). Lidocaine has been shown to reduce levels of TNF-α, IL-1β, IL-6 and IL-8 in animal 
endotoxemia models (15-17). Potential explanations for not finding the most prominent 
increase of proinflammatory cytokines in MV-CCI, and not finding an anti-inflamma-
tory effect of lidocaine are: (1) the postoperative inflammatory response was minimal; 
(2) not all measured cytokines could reach peak concentrations in this short 2-hour 
procedure; (3) one mouse died in MV, MV-CCI-lido and MV-CCI, which can account for 
statistical drawbacks.
 In our model, nerve injury and not the systemic inflammatory response contributed 
to the development of neuropathic pain, as thermal and mechanical allodynia was 
revealed in CCI-animals, but not after sham surgery. CCI is a common model for neuro - 
pathic pain research in animals (18), leading to spontaneous pain and an increased 
thermal and mechanical sensitivity (19). 
 Lidocaine reduced thermal allodynia significantly in CCI-animals on day 16 and 
had no effect on mechanical allodynia. As shown in chapter 3, the effect of lidocaine 
on excitability symptoms seems to vary depending on the type of nerve injury, testing 
method, and lidocaine dosages. In a rat spinal ligature model, sustained mechanical 
allodynia suppression was seen in animals receiving high dosages of lidocaine (20). 
In a crossover study in patients with peripheral nerve injury, lidocaine relieved 
mechanical allodynia and hyperalgesia, but had no effect on thermal allodynia (21). 
In another study in patients with peripheral nerve injury, lidocaine reduced repetitive 
pinprick- evoked pain, but had no effect on evoked pain to mechanical or thermal 
allodynia (22); in patients with CRPS, lidocaine exerted more effect on cool stimuli than 
on mechanical pain (23). 
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Dexamethasone modulates cytokines into an anti-inflammatory direction in 
patients undergoing a lumpectomy for breast cancer. Higher pain scores are 
linked to potential immune-related complications. There was no relationship 
between cytokine levels and pain scores or complications.
In chapter 5 we performed an explorative randomized study in 48 patients undergoing 
a lumpectomy. Patients were assigned to placebo or lidocaine supplemented by 
dexamethasone zero, 4 or 8 mg, yielding six groups of eight patients. IL-1β, IL-1Ra, IL-6, 
IL-10 levels and pain scores were measured at baseline and 4 hours postoperatively. 
Postoperative complications occurring within 30 days were assessed. Persistent pain 
and infections were noted as potential immune-related complications (PIRC). 
 Although lidocaine is known to reduce a hyperinflammatory response and to 
decrease proinflammatory cytokines in abdominal surgery, we did not find an effect 
on cytokine levels. As lumpectomy is a surgical procedure with less inflammatory 
stimuli, lidocaine may have little effect. Dexamethasone 8 mg increased IL-10 (b = 12.70, 
95%CI = 8.06 – 17.34; P < 0.001); dexamethasone 4 mg (b =  -2.60, 95%CI = -3.93 – -1.26; 
P < 0.001) and 8 mg (b = -3.59, 95%CI = -5.04 – -2.13; P < 0.001) decreased the IL-6/IL-10 
ratio. Dexamethasone’s anti-inflammatory effects depend on its dosage in relation 
to the extent of tissue trauma. Earlier reports in major abdominal or thoracic surgery 
demonstrate that a high dose of dexamethasone shifted cytokines towards an anti- 
inflammatory balance characterized by suppressed IL-6 and increased IL-10 levels, 
while effects on IL-1 and IL-1Ra levels were absent or showed a decrease (24-26).
 High pain scores were linked to the occurrence of PIRC’s (OR = 2.028, 95%CI = 
1.134—3.628; P = 0.017). Previous research in a cohort of patients undergoing a broad 
spectrum of surgeries from different specialities also demonstrated that higher pain 
scores after surgery were associated with an increased 30-day complication rate (27). 
Given the significant association between pain scores and PIRC, a common immune 
underlying mechanism would be expected. However, no relation with cytokine levels 
and pain scores or complications was found. In major abdominal or oncologic surgery, 
increased IL-6 levels on day 1 and thereafter were related with infectious complications 
(28-30); earlier reports show that following surgery and acute noxious stimuli, increased 
IL-6 levels were associated with higher pain levels (31, 32). Potential explanations are: 
(1) the postoperative cytokine response was influenced by dexamethasone; (2) the 
postoperative inflammatory response was minimal; (3) the time of measurement was 
not well chosen; (4) the range of pain scores was too narrow.
Future perspectives
As shown in chapter 4, nerve injury contributes to the development of postsurgical 
pain. Thus, current preventive strategies for chronic surgical pain should be continued 
and optimized: (1) blocking or limiting persistent pain sensitization; (2) reducing 
remedial risk factors like refining surgical technique to be less nerve damaging, 
stringent perioperative pain control, and preoperative psychological intervention (33). 
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Lidocaine relieves neuropathic symptoms as described in chapters 2 and 3, which 
supports the above-mentioned future perspectives.
 In chapters 4 and 5, the inflammatory response was minimal after minor surgery 
and did not significantly contribute to the development of pain or complications. 
However, we identified the following subjects for future large scale studies: 
(1) investigate the relation between the preoperative IL-6/IL-10 ratio or other patient 
specific immune factors and 30-day complications; (2) further explore an underlying 
immune-mediated mechanism for the relation between acute pain and complications; 
(3) if the above mechanisms are clarified, we need to evaluate mechanism-based 
interventions and their effect on short- and long-term outcomes.
Animal models may be used when humans studies are unethical or unfeasible when 
seeking knowledge about human biology or the human response to interventions 
(34). Well-designed animal models have contributed to the understanding of the 
pathophysiological mechanisms of chronic pain and have helped to identify potential 
drug targets (19). However, in recent years, there has been a growing concern about 
the clinical validity of translational pain models (35): new therapies or interventions 
shown to be effective in animal studies were often less effective or ineffective in 
clinical trials, or were even harmful to humans. Several challenges exist to successfully 
translate these studies’ outcomes from ‘bench to bedside’, and future pain research 
should address the following points: (1) preclinical side: behavioral assessment of pain 
in animals, biological differences between species and strains, age and gender effects, 
how to interpret acute versus chronic conditions, relevance of pain models; (2) clinical 
side: lack of phenotyping in pain conditions; (3) methodological: differences in design 
of animal and clinical trials, methodological quality, and publication bias (19, 35). 
 General initiatives for improving the value of animal studies are the following: (1) 
implementation of the Animals in Research: Reporting in Vivo Experiments (ARRIVE) 
guidelines which have been published with the aim of improving standards or 
reporting in bioscience; (2) conducting systematic reviews of animal studies as they 
can disclose inadequacies in former individual study methodologies; this can help 
future study design and reduce the failure rate of new studies; (3) data-sharing and 
study registration of animal studies to reduce publication bias and efficiency; (4) 
lastly, importantly, the backtranslation of clinical data in preclinical models (34, 36). 
Part III: Hyperexcitability after chemotherapy
sEMG recording is a simple objective screenings tool to detect nerve 
hyperexcitability in patients after oxaliplatin administration.  
Chapter 6 presents a feasibility study which evaluates whether sEMG is able to detect 
nerve hyperexcitability in patients with acute oxaliplatin induced neuropathy (OIN). 
Physical examination, a questionnaire, and sEMG were assessed after the second 
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(n=14) and fourth oxaliplatin cycles (n=8). All patients reported a variable degree of 
OIN symptoms: sensitivity to touching cold or swallowing cold items were reported as 
being the most severe which is in line with previous reports (37-39). Signs of nerve 
hyperexcitability could be detected with physical examination in 55%, which was less 
sensitive than the sEMG (82% detection). Although nEMG corroborated our sEMG 
results in 2 participants, sEMG recordings may have missed spontaneous discharges 
from motor units lying deep in the muscle, which hampers a 100% detection rate. 
Pharmacokinetic interferences of lidocaine and oxaliplatin 
In chapter 7 we report on a unique clinical observation which explores the effect of 
lidocaine on the pharmacokinetics of oxaliplatin. In a prospective cross-over trial, 
3 patients received oxaliplatin with and without lidocaine. Plasma levels of unbound 
free platinum were determined hourly until 6 hours after cessation of oxaliplatin, and 
the mean percentual difference in the AUC and Cmax of unbound free platinum was 
calculated. We found no difference in the mean percentual AUC with and without 
administration of lidocaine (P = 0.641) and the mean percentual Cmax (P = 0.014) was 
lower with concomitant administration of lidocaine. No research on the correlation 
between the Cmax of oxaliplatin and survival in patients with colorectal or pancreatic 
carcinoma has been reported. The AUC of oxaliplatin is the most important parameter 
in drug interaction studies and for oxaliplatin treatment effect (40). 
 We hypothesize that the difference in Cmax cannot be explained by a pharmacokinetic 
interaction. Lidocaine is metabolized in the liver by CYP3A4 (41), and oxaliplatin 
undergoes rapid nonenzymatic biotransformation and is therefore not metabolized 
(42). Thus potentially, an unknown pharmacodynamic interaction takes place, which 
either lowers Cmax or affects the time of Cmax.
Future perspectives
The severity of the acute OIN has been shown to be one of the risk factors for 
developing high grade chronic OIN (43). Accessible and objective monitoring that 
evaluates the course of the acute hyperexcitability induced by oxaliplatin and the 
effect of potential treatments is warranted. sEMG to detect OIN needs further 
validation and future studies should focus on (1) evaluating the optimal muscle sample 
size to detect hyperexcitability; (2) performing serial measurements on consecutive 
days after oxaliplatin administration, investigating if repeated measurements could 
improve the detection rate further and how the hyperexcitability evolves over time; 
(3) the correlation with chronic OIN and sEMG findings. 
 Considering lidocaine’s mechanism of action, it is possibly an interesting treatment 
for acute OIN and the prevention of chronic OIN; this needs to be evaluated in a larger 
scale study. However, additional plasma sampling before cessation and in the first 
hour after cessation of oxaliplatin is needed to investigate the effect of lidocaine on 
the Cmax of oxaliplatin. 
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Oxaliplatin induces a clear acute neuropathy, which has a relation with chronic OIN. 
However, other types of chemotherapy induce a gradual dose-dependent sensory 
length-dependent neuropathy with symptoms including numbness, paresthesias, 
loss of proprioception and hyperalgesia (44). In 1979, the WHO already recommended 
recording patients’ baseline data, tumor characteristics, responsiveness and treat-
ment-related toxicity (45). Though CIPN is a common side effect of several chemother-
apeutic agents, currently it is still an underestimated and under-diagnosed clinical 
entity (46), and there is no standardized approach to CIPN screening. A number of 
CIPN assessment tools exists; they are either patient-reported, clinician-reported, or 
objective outcome scales (47). All have their shortcomings, and no best tool can yet be 
nominated. Patients underreport because they are worried that effective treatment 
could be modified. Conversely, health-care providers are ineffectively trained and 
educated to apply these tools and recognize the earliest evidence of CIPN (46). 
Additionally, there is no advice in current cancer guidelines about how often and for 
how long these tools should be applied. Greater awareness among physicians is 
warranted and patients need to receive better information from their specialists 
about any unwanted side effects of chemotherapy, so that the QOL of cancer survivors 
can be optimized. In order to achieve this goal, CIPN needs to be recognized earlier, and 
efforts should be made to develop a standardized approach in patients who undergo 
therapy with chemotherapeutic agents.
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General conclusions
and recommendations for future research
In this thesis, we set out to add fundamental knowledge and provide advice for future 
research and clinical explorations on how to reduce cancer-related pain as a result 
of chemotherapy or surgery, and to improve cancer patients’ QOL. We report on the 
following: 
Lidocaine can be a treatment option for intractable pain caused by chronic CIPN. 
Nerve injury and not the systemic cytokine response leads to neuropathic pain in a 
murine model mimicking clinical surgical conditions; lidocaine reduced hyperexcit-
ability but had no effect on the cytokine response. Acute pain after lumpectomy for 
breast cancer is related to 30-day complications, early cytokine levels were not related 
to acute pain or 30-day outcomes. Dexamethasone modulates cytokines into an an-
ti-inflammatory direction, and lidocaine had no effect on cytokine levels in patients 
undergoing a lumpectomy. Oxaliplatin induces an acute hyperexcitability which can 
be measured with sEMG recording. Lidocaine reduces maximum plasma levels of 
oxaliplatin. 
Recommendations for research 
1. Studies unraveling the different sensory phenotypes in CIPN (and other causes of 
cancer related chronic pain) and their responsiveness to specific treatments, like 
sodium channel blockers, should be performed. 
2. Further exploration of the effects of lidocaine on the neuroinflammatory 
response.
3. Development of clinically relevant translational research models for elucidating 
pathophysiological mechanisms which contribute to the transition from acute to 
chronic pain.  
4. Research on preoperative patient-specific immune factors, the dysregulation of 
the postoperative immune balance, and the impact on short and long term 
outcome parameters should be performed. 
5. Further research on the development of objective diagnostic tools to recognize 
early evidence of CIPN, like sEMG. A gold standard for screening and diagnosing 
CIPN is required. 
Recommendations for clinical practice 
1. Implementation of WHO-guidelines to prolong survival combined with maintaining 
a good QOL in patients diagnosed with cancer. 
2. A multidisciplinary and interdisciplinary approach is needed in pain management; 
this should include oncologists, neurologists, pain specialists, and other physicians. 
3. Timely and adequate diagnosis of CIPN; the use of surveys or clinical tools e.g. 
sEMG.  
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4. Preventing the transition from acute to chronic pain in several cancer treatments; 
identifying patients at risk of developing chronic pain.
5. Informing patients about the consequences of specific cancer treatments; shared 
decision making about QOL.
Recommendations for further education 
1. Training healthcare providers to recognize cancer treatment-related pain and to 
discuss the implications of pain on QOL with their patients.
2. Incorporation of standardized screening questionnaires for pain and CIPN.
3. Incorporation of QOL programs in medical education. 
4. Involvement of patient groups/societies, use of web-based educational programs.
Recommendations for societal impact
1. The Ministry of Health should pay greater attention to QOL programs and patient 
participation models to improve cancer care in the Netherlands
2. Support of international research program big data projects should connect 
research institutes. International research meetings with scientific societies for 
improvement of preclinical and clinical studies. 
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 179
179
GENERAL DISCUSSION AND RECOMMENDATIONS FOR FUTURE RESEARCH
8
References
1. Cancer Diagnosis and Treatment [Internet].
2. McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, et al. American Society of Clinical 
Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31(5):631-40.
3. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update 
on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom 
Manage. 2016;51(6):1070-90 e9.
4. Kroigard T, Schroder HD, Qvortrup C, Eckhoff L, Pfeiffer P, Gaist D, et al. Characterization and diagnostic 
evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to 
quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21(4):623-9.
5. Tremont-Lukats IW, Challapalli V, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetics 
to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg. 2005;101(6):1738-49.
6. Prevention and treatment of chemotherapy-induced peripheral neuropathy [Internet]. UpToDate. Aug 2019.
7. Baron R, Forster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related 
sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol. 2012;11(11):999-1005.
8. Vollert J, Maier C, Attal N, Bennett DLH, Bouhassira D, Enax-Krumova EK, et al. Stratifying patients with 
peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain. 
2017;158(8):1446-55.
9. Helfert SM, Reimer M, Hoper J, Baron R. Individualized pharmacological treatment of neuropathic pain. 
Clin Pharmacol Ther. 2015;97(2):135-42.
10. Agency. EM. EMA/CHMP/970057/2011: guideline on the clinical development of medicinal products 
intended for the treatment of pain. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_ 
guideline/2016/12/WC500219131.pdf. Accessed December 15, 2016.
11. Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a 
systematic review of interventions and outcomes. Rheumatology (Oxford). 2008;47(5):670-8.
12. Hsing CH, Wang JJ. Clinical implication of perioperative inflammatory cytokine alteration. Acta 
Anaesthesiol Taiwan. 2015;53(1):23-8.
13. Shavit Y, Fridel K, Beilin B. Postoperative pain management and proinflammatory cytokines: animal and 
human studies. J Neuroimmune Pharmacol. 2006;1(4):443-51.
14. Vaneker M, Halbertsma FJ, van Egmond J, Netea MG, Dijkman HB, Snijdelaar DG, et al. Mechanical ventilation 
in healthy mice induces reversible pulmonary and systemic cytokine elevation with preserved alveolar 
integrity: an in vivo model using clinical relevant ventilation settings. Anesthesiology. 2007;107(3):419-26.
15. Peiro JR, Barnabe PA, Cadioli FA, Cunha FQ, Lima VM, Mendonca VH, et al. Effects of lidocaine infusion 
during experimental endotoxemia in horses. J Vet Intern Med. 2010;24(4):940-8.
16. Flondor M, Listle H, Kemming GI, Zwissler B, Hofstetter C. Effect of inhaled and intravenous lidocaine on 
inflammatory reaction in endotoxaemic rats. Eur J Anaesthesiol. 2010;27(1):53-60.
17. Taniguchi T, Shibata K, Yamamoto K, Mizukoshi Y, Kobayashi T. Effects of lidocaine administration on 
hemodynamics and cytokine responses to endotoxemia in rabbits. Crit Care Med. 2000;28(3):755-9.
18. Robinson I, Meert TF. Stability of neuropathic pain symptoms in partial sciatic nerve ligation in rats is 
affected by suture material. Neurosci Lett. 2005;373(2):125-9.
19. Berge OG. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol. 2011;164(4): 
1195-206.
20. Chaplan SR, Bach FW, Shafer SL, Yaksh TL. Prolonged alleviation of tactile allodynia by intravenous 
lidocaine in neuropathic rats. Anesthesiology. 1995;83(4):775-85.
21. Attal N, Rouaud J, Brasseur L, Chauvin M, Bouhassira D. Systemic lidocaine in pain due to peripheral nerve 
injury and predictors of response. Neurology. 2004;62(2):218-25.
22. Gottrup H, Bach FW, Juhl G, Jensen TS. Differential effect of ketamine and lidocaine on spontaneous and 
mechanical evoked pain in patients with nerve injury pain. Anesthesiology. 2006;104(3):527-36.
23. Wallace MS, Ridgeway BM, Leung AY, Gerayli A, Yaksh TL. Concentration-effect relationship of intravenous 
lidocaine on the allodynia of complex regional pain syndrome types I and II. Anesthesiology. 2000;92(1):75-83.
24. El Azab SR, Rosseel PM, de Lange JJ, Groeneveld AB, van Strik R, van Wijk EM, et al. Dexamethasone decreases 
the pro- to anti-inflammatory cytokine ratio during cardiac surgery. Br J Anaesth. 2002;88(4):496-501.
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 180
180
CHAPTER 8
25. Sato N, Koeda K, Ikeda K, Kimura Y, Aoki K, Iwaya T, et al. Randomized study of the benefits of preoperative 
corticosteroid administration on the postoperative morbidity and cytokine response in patients 
undergoing surgery for esophageal cancer. Ann Surg. 2002;236(2):184-90.
26. Holte K, Kehlet H. Perioperative single-dose glucocorticoid administration: pathophysiologic effects and 
clinical implications. J Am Coll Surg. 2002;195(5):694-712.
27. van Boekel RLM, Warle MC, Nielen RGC, Vissers KCP, van der Sande R, Bronkhorst EM, et al. Relationship 
Between Postoperative Pain and Overall 30-Day Complications in a Broad Surgical Population: An 
Observational Study. Ann Surg. 2019;269(5):856-65.
28. Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, et al. Procalcitonin, interleukin 6 and 
systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major 
surgery. Br J Anaesth. 2005;94(6):767-73.
29. Oka Y, Murata A, Nishijima J, Yasuda T, Hiraoka N, Ohmachi Y, et al. Circulating interleukin 6 as a useful 
marker for predicting postoperative complications. Cytokine. 1992;4(4):298-304.
30. Rettig TC, Verwijmeren L, Dijkstra IM, Boerma D, van de Garde EM, Noordzij PG. Postoperative Interleukin-6 
Level and Early Detection of Complications After Elective Major Abdominal Surgery. Ann Surg. 2016; 
263(6):1207-12.
31. Lisowska B, Maldyk P, Kontny E, Michalak C, Jung L, Cwiek R. Postoperative evaluation of plasma interleukin-6 
concentration in patients after total hip arthroplasty. Ortop Traumatol Rehabil. 2006;8(5):547-54.
32. Edwards RR, Kronfli T, Haythornthwaite JA, Smith MT, McGuire L, Page GG. Association of catastrophizing 
with interleukin-6 responses to acute pain. Pain. 2008;140(1):135-44.
33. Thapa P, Euasobhon P. Chronic postsurgical pain: current evidence for prevention and management. 
Korean J Pain. 2018;31(3):155-73.
34. Hooijmans CR, Ritskes-Hoitinga M. Progress in using systematic reviews of animal studies to improve 
translational research. PLoS Med. 2013;10(7):e1001482.
35. Yezierski RP, Hansson P. Inflammatory and Neuropathic Pain From Bench to Bedside: What Went Wrong? 
J Pain. 2018;19(6):571-88.
36. T. Denayer TS, M. van Roy. Animal models intranslational medicine: Validation and prediction. New 
horizons in translational medicine 2014;2:5-11.
37. Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S. Predicting acute and persistent neuropathy 
associated with oxaliplatin. Am J Clin Oncol. 2013;36(4):331-7.
38. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. Clinical Course of Oxaliplatin-Induced 
Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416-22.
39. Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC. Dose effects of oxaliplatin on 
persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One. 
2011;6(4):e18469.
40. Claudia Burz IB-N, Ovidiu Balacescu, Claudiu Tanaselia, Monica Ursu, Adriana Gog, Laurian Vlase, Mircea 
Chintoanu, Loredana Balacescu, Sorin E Leucuta, Alexandru Irimie, Victor Cristea. Clinical and Pharmaco-
kinetics Study of Oxaliplatin in Colon Cancer Patients. J Gastrointestin Liver Dis. 2008;18(1):39-45.
41. Laurence Weinberg BP, Chong Tan, Mehrdad Nikfarjam. Pharmacokinetics and pharmacodynamics of 
lignocaine: A review. World J Anesthesiology. 2015;4:17-29.
42. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of 
oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205-18.
43. Velasco R, Bruna J, Briani C, Argyriou AA, Cavaletti G, Alberti P, et al. Early predictors of oxaliplatin-induced 
cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014;85(4):392-8.
44. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): 
an update. Crit Rev Oncol Hematol. 2012;82(1):51-77.
45. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207-14.
46. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: 
an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book. 2015:e553-60.
47. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced 
peripheral neuropathy outcome measures standardization study: from consensus to the first validity and 
reliability findings. Ann Oncol. 2013;24(2):454-62.
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 181
181
GENERAL DISCUSSION AND RECOMMENDATIONS FOR FUTURE RESEARCH
8
549977-L-bw-Heuvel
Processed on: 29-10-2020 PDF page: 182
9
549977-L-bw-Heuvel











Processed on: 29-10-2020 PDF page: 184
549977-L-bw-Heuvel





In this thesis, we set out to add fundamental knowledge and provide advice for future 
research and clinical explorations on how to reduce cancer-related pain as a result of 
chemotherapy or surgery, and subsequently improve quality of life of cancer patients.
 In chapter 1, the introduction to this thesis, we report the increasing number of 
cancer survivors world-wide. According to WHO-guidelines, the goal of cancer treatment 
is to prolong survival combined with maintaining a good quality of life (QOL) in both 
the short and long term, i.e. survivorship care. Cancer-related pain is highly prevalent 
among cancer survivors; it reduces their QOL, is still unrecognized by health care 
providers, and it has a huge socio-economic impact. Two common causes of 
cancer-related pain are then described: chronic postsurgical pain and chemotherapy 
induced peripheral neuropathy (CIPN). Chronic pain is difficult to treat and the 
prevention of the transition from acute to chronic pain is desirable. Common 
mechanisms in the transition from acute to chronic pain are a disbalance in the 
inflammatory response and hyperexcitability phenomena. 
 In chapter 2, we publish data on a case series of nine patients with intractable 
pain caused by CIPN. We evaluated  the effect of an infusion of lidocaine on pain and 
sensory symptoms. Iv lidocaine had a significant analgesic effect during lidocaine 
administration in 8 of 9 patients with CIPN. The long-term effect was moderate: 
in 3 patients the analgesic effect disappeared almost immediately after discontinuation 
of the infusion, and in 5 patients the analgesic effect varied from 3 days up to 56 days. 
Noteworthy is that we observed that lidocaine had a variable influence on thermal 
and mechanical stocking and glove distribution of the sensory symptoms. 
 In chapter 3, we present a review delineating the current literature of in vitro 
publications describing lidocaine’s target mechanisms in pain transmission, and the 
in vivo publications describing the effects of iv lidocaine in acute and chronic pain 
conditions. Lidocaine has analgesic, anti-hyperalgesic, and anti-inflammatory properties 
in perioperative and neuropathic pain. 
 Chapter 4 describes a ‘two-hit’ murine model of nerve injury, and the effects of 
intraperitoneally administered lidocaine. Nerve injury and not the systemic inflammatory 
response resulted in neuropathic pain. Lidocaine attenuated thermal allodynia, indicating 
a modulatory role for lidocaine in the development of pain. 
 In chapter 5, we performed an explorative (blinded) randomized study in 48 patients 
undergoing a lumpectomy for breast cancer. We evaluated the effect of iv lidocaine 
and dexamethasone on the early cytokine response, and studied the relation between 
cytokine levels, pain scores and 30-day complications. Dexamethasone, but not 
iv lidocaine, modulated cytokines into an anti-inflammatory direction. Higher pain 
scores, but not raw cytokine levels, were linked to potential immune-related 
complications. There was no relationship between cytokine levels and pain scores. 
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The relation with acute pain and 30-day complications suggest a common underlying 
mechanism; this needs further exploration.
 Chapter 6 presents a feasibility study which evaluates whether sEMG was able 
to detect nerve hyperexcitability in 14 patients after oxaliplatin administration. 
All patients reported a variable degree of acute oxaliplatin induced neuropathy 
symptoms, and sEMG detected signs of hyperexcitability in 82% of the patients. These 
results suggest that sEMG is an accessible and objective tool, which after further 
validation, can be used to evaluate the course of oxaliplatin induced neuropathy and 
the effect of potential treatments. 
 In chapter 7 we report on a unique clinical observation which explores the effect 
of concomitant administration of lidocaine on the pharmacokinetics of oxaliplatin. 
We demonstrate that the area under the curve, the most important parameter for 
drug interaction studies, was not affected. However, peak plasma levels were lower in 
patients receiving lidocaine. These results indicate that in future studies evaluating 
lidocaine’s effect in oxaliplatin induced neuropathy, the pharmacokinetics of oxaliplatin 
should be monitored. 
 In chapter 8, we discuss the results of this thesis in a scientific context, and 
provide recommendations for future research directions.  
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Dit proefschrift heeft als doel wetenschappelijke kennis bij te dragen, die advies geeft 
over verdere klinische verdieping en toekomstig onderzoek om kanker-gerelateerde 
pijn als gevolg van chemotherapie of chirurgie te verminderen, en daardoor de kwaliteit 
van leven van patiënten te verbeteren.
 In hoofdstuk 1 wordt de achtergrond van dit proefschrift beschreven. Wereldwijd 
is er een toenemend aantal patiënten die kanker hebben of hebben gehad. Volgens de 
huidige WHO-richtlijnen is het doel van de behandeling van kanker het verlengen van 
de overleving in combinatie met het behoud van een goede kwaliteit van leven op de 
korte en lange termijn, de zogenaamde ‘survivorship care’. Pijnklachten als gevolg van 
kanker of de behandeling ervan komen frequent voor, hebben een negatieve invloed 
op de kwaliteit van leven, worden te weinig erkend door zorgverleners en hebben een 
forse sociaaleconomische impact. Chronische post-chirurgische pijn en chemotherapie 
geïnduceerde perifere neuropathie (CIPN) zijn twee vaak voorkomende oorzaken van 
kanker gerelateerde pijn. Chronische pijn is moeilijk te behandelen, daardoor is het 
voorkomen van de overgang van acute naar chronische pijn het meest wenselijk. 
Bijdragende pathofysiologische mechanismen in de overgang van acute naar chronische 
pijn zijn een disbalans in de inflammatoire respons en neuronale hyperexcitabiliteit.
 In hoofdstuk 2 presenteren we negen patiënten met moeizaam te behandelen 
chronische pijnklachten door CIPN. Het effect van iv lidocaïne op hun pijn en de 
sensorische symptomen werd beoordeeld. Acht van de 9 patiënten ervaarden tijdens 
lidocaïne toediening een duidelijke pijnreductie. De duur van pijnreductie was echter 
matig: 3 patiënten ervaarden vrijwel onmiddellijk na stopzetten van lidocaïne geen 
pijnstilling meer; bij de andere 5 patiënten varieerde de pijnreductie 3 tot 56 dagen. 
Een opmerkelijke bevinding in deze studie was dat lidocaïne de koude en pin-prik 
sensorische afwijkingen in de handen en voeten kon beïnvloeden.
 In hoofdstuk 3 wordt een literatuur overzicht gegeven van de in vitro publicaties 
die de effecten van lidocaïne op de mechanismen betrokken bij nociceptie beschrijven, 
en van de in vivo publicaties die het effect van lidocaïne op de neuro-inflammatoire 
respons in acute en chronische pijn beschrijven. Wij concludeerden dat lidocaïne 
analgetische, anti-hyperalgetische en anti-inflammatoire eigenschappen heeft, en dat 
het de neuro-inflammatoire reactie bij peri-operatieve en chronische neuropathische 
pijn dempt.
 In hoofdstuk 4 wordt een ‘two-hit’ muizenmodel van chirurgisch zenuwletsel 
beschreven en wordt het effect van perioperatief intraperitoneaal toegediend 
lidocaïne in dit model onderzocht. In dit model resulteerde zenuwletsel in latere 
neuropathische pijn, en de inflammatoire respons lijkt geen relatie te hebben met het 
ontwikkelen van pijn.
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 In hoofdstuk 5 beschrijven we een gerandomiseerd onderzoek bij 48 patiënten 
die een lumpectomie in verband met borstkanker ondergingen. Het effect van iv lidocaïne 
en dexamethason op de vroege cytokine-respons en de relatie tussen cytokines, 
pijnscores en complicaties bij 30 dagen werd onderzocht. Dexamethason had een 
 anti-inflammatoir effect, lidocaïne had geen effect op de cytokines. Hogere pijnscores, 
maar niet cytokine-levels, waren gerelateerd aan immuun-gerelateerde complicaties. 
Er was tevens geen verband tussen cytokine-levels en pijnscores. De relatie met acute 
pijn en 30-daagse complicaties suggereert dat er een gemeenschappelijk onderliggend 
mechanisme is, wat verder moet worden onderzocht.
 In hoofdstuk 6 onderzoeken we in 14 patiënten of sEMG neuronale hyperexcitabiliteit 
na toediening van oxaliplatin kan detecteren. Alle patiënten hadden symptomen van 
acute oxaliplatin geïnduceerde neuropathie. sEMG detecteerde bij 82% van de patiënten 
tekenen van hyperexcitabiliteit. Onze resultaten suggereren dat sEMG een bruikbare 
en objectieve tool is, welke na verdere validatie kan worden toegepast bij het evalueren 
van het verloop van oxaliplatin geïnduceerde neuropathie en het effect van mogelijke 
behandelingen.
 In hoofdstuk 7 beschrijven we het effect van iv lidocaïne op de farmacokinetiek 
van oxaliplatin. De ‘area-under-the-curve’ van oxaliplatin, welke de belangrijkste parameter 
is in geneesmiddeleninteractiestudies, werd niet beïnvloed door lidocaïne; echter 
de piekplasmaconcentratie was lager bij patiënten die lidocaïne toegediend kregen. 
Hieruit volgt dat bij toekomstige studies, die het effect van lidocaïne op oxaliplatin 
geïnduceerde neuropathie onderzoeken, tevens de farmacokinetische parameters van 
oxaliplatin moeten worden gecontroleerd.
 In hoofdstuk 8 bespreken we de resultaten van dit proefschrift in een weten-
schappelijke context en geven we aanbevelingen voor toekomstig onderzoek
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The data in this thesis are collected and stored according to Findable, Accessible, 
Interoperable and Reusable (FAIR) principles. The results of chapters 2, 5, 6 and 7 were 
based on human studies conducted in accordance with the principles of the 
Declaration of Helsinki. The medical and ethical review board Committee on Research 
involving Human Subjects Region Arnhem Nijmegen, the Netherlands approved these 
studies. All patients were well informed about the study and gave written informed 
consent prior to participation.
 The results presented in chapter 4 are based on data of an animal study, approved 
by the Radboud University Animal Experiment Committee. The study was conducted in 
accordance to the regulations stipulated in the Wet op de Dierproeven and in the Dier-
proevenbesluit.
 Locking of and access to informed consents and study data is compliant with 
Good Clinical Practice. The privacy of subjects is guaranteed due to anonymization of 
data using an anonymized subject code. The encryption code is only available to the 
research team. All study data were monitored by two researchers. For the studies in 
chapters 2 and 7, data were filled in on a paper Case Report Form and stored at 
Radboudumc, room M333.04.424, closet number 5, colour code white; the digital 
versions were stored on the departments’ H-drive, which is backed-up daily to prevent 
data loss (Chapter 2 = H:\ANES\ResearchPipa\CIPN-15 HEU, Chapter 7 = H:\ANES\
ResearchPipa\LION-15 STE). Paper CRF data were converted to Excel (Microsoft Office, 
Redmond, Washington, USA) and then to Statistical Package for Social Sciences, 
Version 22.0 (IBM Corporation, Armonk, NY, USA) and Graphpad Prism (Graphpad 
Software, La Jolla, USA).
 For the studies in chapters 5 and 6, in addition to a paper CRF, we used the Castor 
Electronic Data Capture (Castor EDC 2019, available at: https://castoredc.com) data- 
management system. In Castor EDC, an audit trail is used to provide documentary 
evidence of activities that can affect the original data. The Castor EDC data were 
converted to SPSS and Graphpad Prism and stored on the department’s H-drive 
(Chapter 6 = H:\ANES\ResearchPipa\SUR EMG-15 HEU; chapter 5 = H:\ANES\
ResearchPipa\Lido PIL-14 VS).
 For the study in chapter 4, data are stored in the bunker (Radboudumc, M333.02.229, 
room 2.16, closet number A), and collected in an Excel file on the department’s H-drive 
(H:\ANES\ResearchRLAPP\Analisten\Afgeronde DEC aanvragen\2013), and converted 
to Graphpad Prism. 
 All data will be stored for 15 years after termination of the studies. Using these 
data for future research is only possible after renewed permission is received from the 
patient, as recorded in the informed consent. The datasets analysed in these studies 
are available from the corresponding author on a reasonable request. 
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En opeens is er ‘het boekje’…. Het was een bijzondere periode in vele opzichten, en ja… 
ik zou het weer doen. Vele lieve collegae, vrienden en familie hebben direct of indirect 
een bijdrage geleverd aan dit proefschrift. Graag dank ik een aantal mensen voor hun 
bijdrage, daarbij wetende dat dit niet volledig is. 
Dankzij de fijne begeleiding van mijn promotoren en copromotoren is dit proefschrift tot 
stand gekomen. Ik waardeer jullie enorm en kijk uit naar toekomstige projecten. 
Beste Kris, dank voor de vaste PhD-structuur, en voor de vele malen dat ik zonder 
afspraak bij je binnen kon lopen. Door je creatieve geest en mij te bevragen, was ik 
soms na een PhD-overleg even de draad kwijt, om later mijn juiste weg en ‘onder-
zoeks’-visie te vinden. Als facilitator zorg je dat iemand zijn talent kan ontwikkelen en 
zichzelf ‘op de kaart kan zetten’. Dit mede dankzij je uitgebreide (inter)-nationale 
netwerk, visie op pijngeneeskunde, en oog voor de mens achter de medewerker. 
Beste Monique, jij hebt mij het vertrouwen gegeven dat ik een onderzoeker ben en 
hebt me geleerd mijn ‘onderzoeks’-gevoel te ontwikkelen/volgen. Jij bent een 
inspirerend voorbeeld, integere en empathische ‘talenten-duizendpoot’, die de patiënt 
en haar team voorop zet. We hebben heel wat uurtjes achter de boks-zak doorgebracht 
om te ‘resetten’; maar ook veel gelachen en gepraat en dit het liefst vanuit een 
hangmatje. 
Beste Selina, ik heb jouw ingeslagen ‘onderzoeks’-pad kunnen opvolgen en daardoor kon ik 
een vliegende start maken met dit proefschrift. Jij geniet van brainstormsessies en 
hebt talent voor het vinden van een goede visualisatie en bewoording van artikelen of 
presentaties. Als academicus, vind je het belangrijk om de menselijke kant niet uit het 
oog te verliezen, en kun je bij jou altijd je verhaal kwijt. 
Beste Nens, door je originele, nuchtere en pragmatische benadering, heb je de kunde 
om structuur aan te brengen in mijn gedachten wat mede heeft geholpen een ‘onder-
zoeks’-brein te ontwikkelen. Ondanks je drukke agenda, kreeg ik snel feedback met veel 
aandacht voor een consequente spelling, interpunctie en het tot de kern brengen van 
een boodschap in een manuscript.  
Leden van de manuscriptcommissie, Prof. Dr. Carla van Herpen, Prof. Dr. Baziel van 
Engelen en Prof. Dr. André Wolff, hartelijk dank voor het beoordelen van dit proefschrift 
en de spoedige goedkeuring hiervan. 
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Zonder de deelname van patiënten en muizen, en de ondersteuning van verpleegkun-
digen, onderzoekers en artsen had dit proefschrift nooit voltooid kunnen worden. 
Door de specifieke kennis van mijn medeauteurs, zijn de artikelen naar een hoger 
niveau getild. Graag werk ik in de toekomst nog veel met jullie samen. Dr. Jos Lerou, 
ik heb tijdens de bezoekjes aan uw historische studie-kamer genoten van uw hartelijkheid 
en kritische doch enthousiaste ‘onderzoeks’-houding. Ewald, statistiek wordt leuk en 
begrijpelijk door jou. Michiel, je helikoperview en inzicht in wetenschap zijn een verrijking.
Prof. Dr. Leo Booij, ondanks dat u al geruime tijd met emiraat bent, bent u telkens zeer 
meedenkend geweest met mijn onderzoek. Veel dank voor uw persoonlijke bijdrage 
aan dit proefschrift. 
Prof. Dr. Gert-Jan Scheffer, gestart als wat onzekere AIOS in 2006, voelde ik me met 
weinig woorden telkens gesteund door u en heb ik onder uw hoede kunnen groeien op 
persoonlijk en professioneel vlak. 
Jacky, Ilona en Tijn, jullie benaderbaarheid en ‘onderzoeks’-enthousiasme maakt dat ik 
veel geleerd heb over de praktische uitvoering van de Good Clinical Practice. Yvonne, 
Hans, Rianne en Marianne, dank voor de handige ‘tips and tricks’ als ik weer met een 
vraag bij jullie kwam binnenvallen. 
Geneeskunde studenten, Hielke, Lotte, Chris, Jens, Merwin, Iris, Karlijn, Elisa, Marlous, 
Annabel en Suvarna, dank voor al het werk wat jullie hebben gedaan. Dit heeft 
geresulteerd in mooie onderzoeksverslagen met bruikbare data, tabellen en grafieken, 
welke verwerkt zijn in dit proefschrift.
Collega-promovendi van onze afdeling, dank voor de momenten dat we even bij elkaar 
terecht konden of even konden brainstormen. Mooi dat wetenschap zo leeft onder 
ons!
Chef-De-Clinique’s, Bert en Xandra dank voor jullie flexibiliteit en het regelen van 
 ‘onderzoeks’-tijd, zeker tijdens de final-run van dit proefschrift, wetende dat dit niet 
altijd makkelijk was om te organiseren.
Mijn lieve talentvolle PiPa-(oud)-collega’s, Kees, Robert, Heinrich, Steven, Lieven, Ban, 
Evelien, Marieke, Ellen, Simone, Remko, Edwin, Carel, Bart-Jorrit, Mark, Frank en 
pijn-fellows. Eigenlijk verdient ieder van jullie een apart woordje voor jullie bijdrage 
aan dit proefschrift: vanwege het doorsturen van patiënten voor onderzoek, het 
meedenken of een wetenschappelijk idee klinisch uitvoerbaar is, overnemen poli’s, 
studieprotocollen in EPIC ‘bouwen’, leuke congressen samen, samen shoppen in NY, 
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voorbereidingen voor cabaret, persoonlijke gesprekken, en het creëren van een sfeer 
waarin het doen van onderzoek gestimuleerd wordt. Kees, jij bent een icoon, ik ben 
vereerd door jou opgeleid te zijn. Frank, jouw efficiëntie en heerlijk nuchtere blik zorgt 
voor een prettige samenwerking in verder CIPN-onderzoek. Remko al lang in het VU, 
maar jouw positieve energie en oprechtheid maakt je een pijn-maatje voor altijd.   
 Daarnaast een heel team wat betrokken is bij de zorg voor onze patiënten, 
waaronder verpleegkundigen, PA’ers, secretariële ondersteuning, psychologen, fysio-
therapeuten, radiologie-laboranten, OK-assistenten, verkoevermedewerkers, chirurgen, 
revalidatieartsen, en neurologie, die allen bijdragen aan dat ik me thuis voel in Dekkerswald 
en Boxmeer, en ik trots ben op mijn werkplek. Kees en Thea, jullie luisterend oor en 
zorg maakte dat patiënten graag komen voor een lidocaïne infuus. Petra, dank voor je 
nauwkeurigheid en de begeleiding van patiënten met CIPN. Beppie, mijn Dekkers-
wald-moedertje, ik word blij als ik met je mag werken; Bianca vervult deze taak in 
Boxmeer. Wietske, jij zorgt ervoor dat eigenlijk alles mogelijk is. Nicole, een engel, dank 
voor je belangeloze inzet en zorg voor een feilloze pijn-planning.
Anesthesiologen, velen hebben bijgedragen aan mijn opleiding tot anesthesioloog, en 
door als groep achter wetenschappelijke verdieping te staan, heb ik dit kunnen doen. 
Mijn anesthesie-moeder Dominique, een AIOS kan geen betere mentor wensen. Mijn 
kamergenoten, heerlijk dat we bij elkaar terecht kunnen. Marc Snoek, met jou heb ik 
mijn eerste onderzoeks-stapjes gezet. Michiel, dankzij jouw tomeloze enthousiasme 
en de inspanningen van Twan wordt er ook bij de PA-groep wetenschap bedreven. 
 Arts-assistenten anesthesiologie, omdat ik ‘even wat af moest schrijven’, was ik soms 
wat kort in mijn uitleg, dank voor jullie begrip en goede onderlinge sfeer op en buiten 
het werk. 
 Lieve collegae van de OK, anesthesie- en verkoever medewerkers, PA-ers, OK-
assistenten, chirurgen en logistiek dank voor de samenwerking en persoonlijke interesse. 
 Alle ZUT-collega’s, dienst hebben voor de ZUT voelt echt als van je hobby je werk 
maken. We zijn een goed voorbeeld van een prettige intercollegiale samenwerking. 
De jaarlijkse ZUT-weekenden…. blieb.
Dankzij het samenwerkingsverband met het KCMC ben ik een betere anesthesio-
loog-pijnarts en onderzoeker geworden; leren relativeren, inventief zijn en mede 
opzetten van een internationale samenwerking. Hierbij heb ik van diverse mensen 
hulp gehad, Gert Jan, Monique, Irma, Laurens, Marjolein, Rob en Geert. Luc, jij bent een 
wereldburger en kan als geen ander uren enthousiast onderwijs geven. Marieke, jouw 
grondige en praktische benadering met daarbij een liefde voor de Afrikaanse klei is 
zeer waardevol. Maartje, ik hoop dat het voor jou ook een 2e thuis wordt. Quirijn, 
Niels, Esther en Mieke, ondanks een verassende Tanzaniaanse wending hier-en-daar, 
is er geleidelijke verbetering in onderwijs, kliniek en wetenschap. Andre dank voor je 
vertrouwen in me!
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All Tanzanian residents, nurses, AMO, and external collaborators (UK, USA, Dutch), 
you are an inspiring group of people, and made working and discussing projects/research 
over there a light-weighted task. Kaino, my friend, we had a very effective collaboration 
thanks to your international networking capacity, visionary, humor and your heart to 
improve health care in Tanzania. Sweetbert, my ‘brother from another mother’, I am 
impressed by your social skills, practical point of view and hardworking attitude.
Mijn lieve dieren, jullie hebben zeker bijgedragen aan mijn boekje. Mijn poes, die pas 
bij me komt zitten als ik even rust neem. Iris en Cassanova, tijdens de uurtjes op stal of 
al rijdend kon ik mijn hoofd leeg maken. Jullie waren de ‘opposites – attracts’ onder de 
paarden. Cassanova de sensibele, speelse en expressieve ruin (ja, dieren kunnen 
praten). Iris de nuchtere, lieve, hardwerkende, zorgzame merrie, ik heb genoten van de 
21 jaar die je bij me bent geweest.  
 Via jullie heb ik diverse lieve mensen leren kennen. Jeroen, ik waardeer je enorm. 
Met me meedenkend en met veel humor gaf je me les, waarbij ik een van de eerste 
keren nog de bak uit galoppeerde en we uiteindelijk ZZL hebben bereikt. Bettina, 
mooi dat jij het belang ziet van zo veel mogelijk te genieten, op naar nog meer ‘uitjes’. 
Annemarie, een positieve, inspirerende vrouw en kundige teacher. Tamara, Silvester, 
Chris, Lonneke, clubgenoten dank voor jullie interesse, nuchterheid en gezelligheid.
 Naast mijn dieren, heeft sporten de nodige ontspanning gegeven. Boksen en luisteren 
naar de goede grappen van Roy. Hardlopen en uiteindelijk trainen voor halve marathon 
in Berlijn, toch nog een keer doen Laura, Monique, Selina en Bart-Jorit! Yoga op diverse 
mooie locaties, waarbij de Himalaya de meest indrukwekkende/onvergetelijke was.
Bollekes/Nachtbrakers/Bestelclub/.., Floor, Stan, Wim, Marit, Marloes, Dirk, Vanessa 
en Ruben, fijn om jullie als vrienden te hebben. Onze avondjes, uitstapjes en de 
regelmatige WhatsApp-berichten hebben bijgedragen aan de nodige ontspanning, 
lachbuien en bijspijkeren van mijn culinaire kennis. Creatieve en lieve Christa, Daan en 
Erik, dadelijk heb ik weer tijd om samen een kerfstokje vol te maken. Chrissie, mijn 
‘daughter form another mother’, lief, ontwapenend en knap hoe goed jij een connectie 
met mensen kan maken. Manon en Marieke, jullie kennen elkaar niet, maar volgens 
mij zijn jullie familie (delen o.a. de volgende kenmerken: energiek, sociaal, grappig en 
getrouwd met een rustige man). Lotte, jij wist al vroeg dat je je eigen weg moet 
volgen, met je gastvrije familie ben je ook aan de andere kant van de wereld dichtbij. 
Ricardo, vanaf dat we bij elkaar in de klas zaten zijn we aan het praten en hebben 
mooie avonturen beleefd. Binnenkort weer een filmpje pakken! Kim, al weer 25 jaar 
geleden leerden wij elkaar tijdens de Oetel-bezoekjes kennen. Je hebt heerlijke 
woordgrapjes, bent behulpzaam en weet altijd de juiste toon/benadering te vinden.  
Lieve tantes, ooms, neven, nichten en buren we zien elkaar niet veel, maar door in een 
warme familie / omgeving te kunnen opgroeien kan ik zijn wie ik ben. 
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Bart, jij kan met een boom nog een gezellig gesprek voeren; ‘Forever Young met een 
Rainbow in the Sky’, een tikkeltje drammerig, doch altijd attent, ben ik blij met jouw 
als schoonbroer. Ilse, je bent belangstellend en enthousiast over mijn bezigheden, 
fijn dat je heerlijk no-nonsens mijn broertje steunt. Estelle, Daantje, Laurens, Jules en 
Jarno, jullie zijn prachtige en waardige opvolgers van onze familie.
Lieve Albert, als kind was je koning treiteren, maar we konden ook gemoedelijk samen 
in de modder rollen en hebben legendarische stapavondjes beleefd. Ondertussen een 
hardwerkende man, maar sta je voor me klaar als het nodig is. Naar jou kijkende kan ik 
‘het druk hebben’ gelijk relativeren.  
Lieve Susan, paranimf, vanaf de eerste keer dat we aan de toog in Leuven hebben 
gezeten was onze vriendschap ‘aan’. Iedereen is altijd welkom en kan zichzelf zijn bij 
jou. We hebben veel geouwehoert, soms gehuild, maar vooral veel plezier gehad; laten 
we daar mee doorgaan. 
Lieve Jolanda, paranimf, toen we klein waren was jij de baas van ons drieën. 
Nu vooral een begane, ontzettend lieve zus, en ben je op zijn best als iedereen bij 
elkaar is. Een echte ‘fierce lady’, door jouw onfeilbare vertrouwen in dat alles goed 
komt, komt het ook goed. 
Lieve mama, eigenlijk is er een extra boekje nodig om jou te bedanken. Zonder enige 
twijfel kan ik stellen dat ik hier sta dankzij jou lieve onvoorwaardelijke zorg. Ik kan elk 
moment bij je binnenvallen, en word compleet verzorgd als ik bij je ben. Je bent een 
enorm sterke vrouw en ik heb veel bewondering voor je. 
Lieve papa, jij hebt mogelijk gemaakt dat ik kan bereiken wat ik wil. Ik hoor je nog 
regelmatig door mijn hoofd: “goed kijken en luisteren”, “alles nog eens nakijken”, “ je moet 
ook achter de kruiwagen kunnen lopen”. Dit heeft zeker bijgedragen aan dit boekje. 
We hebben menig discussie gehad, maar konden om dezelfde grapjes lachen en mooi 
als we op dezelfde manier ergens de weg aan het zoeken waren. Ik kan me levendig 
voorstellen hoe trots je was geweest op de weg die ik nu gevonden heb. N’oubliez 
jamais , J. Cocker, 1997.
Lieve Bent, jij bent recht in mijn hart binnengekomen en nu al een enorme motivator. 
Ik heb nog niet eerder zo moeiteloos en vlot geschreven als tijdens de normaliter 
laatste zware loodjes van een proefschrift. Ik voel me zeer vereerd dat je er bent en kijk 
enorm uit naar de toekomst samen! ॐ मणि पदम् े ह ू ँ
En nu…
  
The dock of the bay , O. Redding, 1968.
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Sandra van den Heuvel werd geboren op 6 oktober 1980 in ’s-Hertogenbosch. Na het 
behalen van haar VWO diploma aan het Stedelijk Gymnasium te ’s-Hertogenbosch, 
studeerde ze geneeskunde aan de Katholieke Universiteit van Leuven, België. Tijdens 
het laatste jaar coschap anesthesiologie, wist zij dat ze zich hier verder in wilde 
specialiseren. Na 6 maanden te hebben gewerkt op de Intensive Care van het Amphia 
Ziekenhuis in Breda, begon ze in 2006 met opleiding anesthesiologie in het Radboudumc 
te Nijmegen bij Prof. Dr. G.J. Scheffer. De wetenschappelijke verdieping tijdens de opleiding 
zorgde ervoor dat zij zich ging interesseren voor onderzoek. Na het afronden van de 
opleiding anesthesiologie in 2012, begon ze met een fellowship pijngeneeskunde, en is 
ze sedert 2013 staflid op de afdeling anesthesiologie, pijn en palliatieve geneeskunde 
van het Radboudumc. 
 Doordat ze diverse patiënten op de polikliniek met chronische pijn ná kanker zag, 
welke onderkend werd en een grote invloed had op hun kwaliteit van leven, ging zij 
zich hierin verdiepen op klinisch en wetenschappelijk gebied. In 2015 is zij onder 
begeleiding van Prof. Dr. K.C.P. Vissers gestart met een PhD-traject. In 2018 ontving ze 
in samenwerking met de afdeling oncologie een subsidie van het Radboud Oncologie 
Fonds voor onderzoek naar de behandeling van CIPN. De resultaten van de studies in 
dit proefschrift zijn gepresenteerd op internationale congressen.  
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“After trying several analgesics, I was one of the first patients to receive iv lidocaine for 
CIPN. During the infusion I experienced a heavenly relief of the pain, which unfortunately 
lasted only for a short time in my case. Psychologically this was disappointing, although 
I realized that it’s impossible to receive lidocaine infusions for a longer period due to 
 the increasing risk of cardiac and neurologic side-effects. As a result of my experience, 
the study investigating the effects of iv lidocaine in patients with intractable pain caused 
by CIPN was started, which is a part of this thesis. 
 Additionally, it led to the idea  that lidocaine infusion during chemotherapy could 
maybe block the injury of the nerve endings.
 I decided to accept the situation and continued treatment with daily dosages of 
amitriptyline, although its effect was marginal as it didn’t make much difference to the 
severity of the pain when I stopped using it for a while.
 It shows that it’s really important to find a method for prevention and or treatment 
of pain caused by CIPN. The continuous pain still limits my activities, and that makes me 
a strong supporter of further studies on the mechanism and treatment of CIPN and 
other causes of pain after cancer treatment. Despite the pain, I still enjoy life and I’m 
happy that I was given the additive chemotherapy in addition to surgery. If I had to make 
the choice again, I’d accept it without any doubt.”
Prof. Dr. L.H.D.J. Booij
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